-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K9/bMgwkY2BpMVAgF/tWOsPHH7zgjNmVp63due1GbjZI/kyKed9AOxVtY8URL+JS t7uiyGhyYHiEmto2eEE6cQ== 0000892569-98-001298.txt : 19980508 0000892569-98-001298.hdr.sgml : 19980508 ACCESSION NUMBER: 0000892569-98-001298 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 19980507 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: COMBICHEM INC CENTRAL INDEX KEY: 0001002276 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 330617379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: SEC FILE NUMBER: 333-37981 FILM NUMBER: 98612102 BUSINESS ADDRESS: STREET 1: 9050 CAMINO STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195300484 MAIL ADDRESS: STREET 1: 9050 CAMINO SANTA FE CITY: SAN DIEGO STATE: CA ZIP: 92121 S-1/A 1 AMENDMENT NO. 9 TO FORM S-1 1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 7, 1998 REGISTRATION NO. 333-37981 ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ AMENDMENT NO. 9 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ COMBICHEM, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 8731 33-0617379 (STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER INCORPORATION OR ORGANIZATION) CLASSIFICATION CODE NUMBER) IDENTIFICATION NUMBER)
9050 CAMINO SANTA FE, SAN DIEGO, CALIFORNIA 92121 (619) 530-0484 (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) DR. VICENTE ANIDO, JR. PRESIDENT AND CHIEF EXECUTIVE OFFICER 9050 CAMINO SANTA FE SAN DIEGO, CALIFORNIA 92121 (619) 530-0484 (NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE) ------------------------ COPIES TO: FAYE H. RUSSELL, ESQ. FREDERICK T. MUTO, ESQ. THOMAS E. HORNISH, ESQ. ERIC J. LOUMEAU, ESQ. LANCE S. KURATA, ESQ. CHRISTOPHER W. KRUEGER, ESQ. BROBECK, PHLEGER & HARRISON LLP COOLEY GODWARD LLP 550 WEST "C" STREET, SUITE 1300 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO, CALIFORNIA 92101 SAN DIEGO, CA 92121 (619) 234-1966 (619) 550-6000
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as practicable after the effective date of this Registration Statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. [ ] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] - ------------ If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] - ------------ If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SUCH SECTION 8(a), MAY DETERMINE. ================================================================================ 2 INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. SUBJECT TO COMPLETION, DATED MAY 7, 1998 [COMBICHEM LOGO] 2,250,000 SHARES COMMON STOCK All of the 2,250,000 shares of Common Stock offered hereby are being sold by CombiChem, Inc. ("CombiChem" or the "Company"). Prior to this offering, there has been no public market for the Common Stock of the Company. It is currently estimated that the initial public offering price will be between $8.00 and $10.00 per share. See "Underwriting" for information relating to the method of determining the initial public offering price. The Company has applied for quotation of the Common Stock on the Nasdaq National Market under the symbol "CCHM." Elan International Services Ltd., a stockholder of CombiChem, and a wholly owned subsidiary of Elan Corporation, plc (whose wholly owned subsidiary, Athena Neurosciences, Inc. is a collaborative partner of CombiChem), has expressed an interest in acquiring approximately $2 million of the shares of Common Stock offered hereby at the initial public offering price. -------------------------------------------------------- THE COMMON STOCK OFFERED HEREBY INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" BEGINNING ON PAGE 6. -------------------------------------------------------- THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. ============================================================================================================ UNDERWRITING PRICE TO DISCOUNTS AND PROCEEDS TO PUBLIC COMMISSIONS(1) COMPANY(2) - ------------------------------------------------------------------------------------------------------------ Per Share................................. $ $ $ Total(3).................................. $ $ $ ============================================================================================================
(1) The Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. See "Underwriting." (2) Before deducting expenses payable by the Company estimated at $1,000,000. (3) The Company has granted the Underwriters a 30-day option to purchase up to an additional 337,500 shares of Common Stock, solely to cover over-allotments if any. See "Underwriting." If such option is exercised in full, the total Price to Public, Underwriting Discounts and Commissions and Proceeds to Company will be $ , $ and $ , respectively. -------------------------------------------------------- The Common Stock is offered by the Underwriters as stated herein, subject to receipt and acceptance by them and subject to their right to reject any order in whole or in part. It is expected that delivery of such shares will be made through the offices of BancAmerica Robertson Stephens, San Francisco, California on or about , 1998. BANCAMERICA ROBERTSON STEPHENS DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION SALOMON SMITH BARNEY THE DATE OF THIS PROSPECTUS IS , 1998. 3 [DEPICTIONS OF COMBICHEM'S DISCOVERY PROCESS] IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OF THE COMPANY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. 2 4 NO DEALER, SALES REPRESENTATIVE OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES OTHER THAN THE REGISTERED SECURITIES TO WHICH IT RELATES OR AN OFFER TO, OR A SOLICITATION OF, ANY PERSON IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION WOULD BE UNLAWFUL. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF OR THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF. UNTIL , 1998 (25 DAYS AFTER THE DATE OF THIS PROSPECTUS), ALL DEALERS EFFECTING TRANSACTIONS IN THE REGISTERED SECURITIES, WHETHER OR NOT PARTICIPATING IN THIS DISTRIBUTION, MAY BE REQUIRED TO DELIVER A PROSPECTUS. THIS DELIVERY REQUIREMENT IS IN ADDITION TO THE OBLIGATION OF DEALERS TO DELIVER A PROSPECTUS WHEN ACTING AS UNDERWRITERS AND WITH RESPECT TO THEIR UNSOLD ALLOTMENTS OR SUBSCRIPTIONS. ------------------------ TABLE OF CONTENTS
PAGE ---- Summary..................................................... 4 Risk Factors................................................ 6 Use of Proceeds............................................. 16 Dividend Policy............................................. 16 Capitalization.............................................. 17 Dilution.................................................... 18 Selected Financial Data..................................... 19 Management's Discussion and Analysis of Financial Condition and Results of Operations................................. 20 Business.................................................... 26 Management.................................................. 43 Certain Transactions........................................ 56 Principal Stockholders...................................... 59 Description of Capital Stock................................ 61 Shares Eligible for Future Sale............................. 64 Underwriting................................................ 66 Legal Matters............................................... 68 Experts..................................................... 68 Additional Information...................................... 68 Index to Financial Statements............................... F-1
------------------------ CombiChem was incorporated in California in May 1994 and subsequently reincorporated in Delaware in October 1997. The Company's executive offices are located at 9050 Camino Santa Fe, San Diego, California 92121, and its telephone number is (619) 530-0484. The Company intends to furnish to its stockholders annual reports containing audited financial statements certified by an independent public accounting firm and quarterly reports containing unaudited interim financial information for each of the first three fiscal quarters of each fiscal year of the Company. The Company has filed, or plans to file, for trademark protection for the following: Discovery Engine(TM), Universal Informer Library(TM) and Cascader(TM). All other trademarks or service marks appearing in this Prospectus are the property of their respective holders. 3 5 SUMMARY The following summary is qualified in its entirety by the more detailed information, including "Risk Factors," and the Financial Statements and Notes thereto, appearing elsewhere in this Prospectus. This Prospectus may contain forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under "Risk Factors" and elsewhere in this Prospectus. THE COMPANY CombiChem, Inc. is a computational drug discovery company that is applying its proprietary design technology and rapid synthesis capabilities to accelerate the discovery process for new drugs. The Company believes its approach offers pharmaceutical and biotechnology companies the opportunity to conduct their drug discovery efforts in a more productive and cost-effective manner. Using its proprietary Discovery Engine(TM) process, the Company focuses on the generation, evolution and optimization of potential new lead candidates for its collaborative partners, who will then develop, manufacture, market and sell any resulting drugs. CombiChem believes that its process is widely applicable to a variety of disease targets and therapeutic indications. To date, the Company has established collaborative agreements with Teijin Limited ("Teijin"), Roche Bioscience, a division of Syntex (U.S.A.) Inc. ("Roche Bioscience"), Sumitomo Pharmaceuticals Co., Ltd. ("Sumitomo"), ImClone Systems Incorporated ("ImClone"), Athena Neurosciences, Inc., a wholly owned subsidiary of Elan Corporation, plc ("Elan/Athena") and ICOS Corporation ("ICOS"). In addition, the Company intends to use its approach on internal programs to discover new lead candidates and then to outlicense them to third parties, retaining a larger economic interest. During March 1998 there were several developments which further validate the Company's technology and business strategy: (i) The achievement of a research milestone in CombiChem's collaboration with Roche Bioscience triggering a cash milestone payment. This stems from the identification, in less than one year, of novel drug development candidates for a potential new treatment for respiratory disease. (ii) The expansion of its existing collaboration with Elan/Athena whereby Elan/Athena authorized an additional project and purchased an option for an additional target not previously covered by the agreement. In addition, Elan International Services Ltd., a stockholder of CombiChem, and a wholly owned subsidiary of Elan Corporation, plc (whose wholly owned subsidiary, Athena Neurosciences, Inc. is a collaborative partner of CombiChem), has expressed an interest in acquiring approximately $2 million of the shares of Common Stock offered hereby at the initial public offering price. (iii) The establishment of a new agreement on an identified, undisclosed target with ICOS, bringing the number of its collaborative partners to a total of six. The Company's proprietary Discovery Engine is a convergent, iterative process for drug discovery based on libraries (collections of compounds) designed for information rather than merely diversity. The design of such libraries requires the use of various computational and combinatorial chemistry technologies to select molecules that collectively probe the biological target in a systematic way to determine the chemical characteristics required for binding to such target. By identifying features that discriminate between active and inactive compounds, the computer constructs predictive models, called hypotheses, and then uses those models to select a more focused library of compounds. The computer selects compounds from the Company's proprietary Virtual Library, a computational representation of more than 1 trillion drug-like molecules chosen for ease of laboratory synthesis. CombiChem believes that, by repeating this process of selecting, synthesizing and screening informative compounds and analyzing the resulting data, the Discovery Engine quickly converges on the most predictive hypothesis. This hypothesis describes the characteristics a compound must possess to be active against the target and, thus, is used to select a variety of potent lead candidates. CombiChem is applying its drug discovery approach to three important types of programs: (i) lead generation, where the goal is to find lead candidates against new biological targets; (ii) lead evolution, where the goal is to develop alternative structural series with the same biological activity profile; and (iii) lead optimization, where the goal is to modify a specific drug template to improve its biological activity. For novel targets where little or no information is available as well as those targets for which no suitable leads have been identified, the Company initiates the Discovery Engine process by making available for screening its Universal Informer Library(TM), which consists of a computer-designed, proprietary collection of approximately 10,000 physical compounds. CombiChem believes that its Discovery Engine has the following advantages: (i) generating lead candidates from multiple structural series that exhibit the same biological activity; (ii) generating lead structures against a wide range of targets including those for which little or no information is available; (iii) achieving rapid generation, evolution and optimization of lead candidates; and (iv) reducing synthesis and screening costs. The Company's design technology facilitates the use of small, informative libraries. The efficiency provided by the use of such informative libraries is expected to shorten the time required for the identification of lead candidates to less than two years. The Company's objective is to be the industry leader in the generation, evolution and optimization of novel lead candidates. The Company intends to utilize its scientific and technology assets in the discovery process through a mix of collaborative and internal programs by applying the following business strategies: (i) to establish multiple collaborations with large pharmaceutical and biotechnology companies focused on biological targets chosen by the collaborators; (ii) to partner with companies to apply discovery technologies to jointly agreed-upon biological targets; (iii) to conduct internal discovery efforts aimed at selected biological targets, retaining a larger economic interest in the subsequently outlicensed lead candidates; (iv) to expand collaborative opportunities in alternative industries such as the agrochemical field; and (v) to maintain technology leadership in both software development and rapid synthesis capabilities. 4 6 THE OFFERING Common Stock Offered by the Company....... 2,250,000 shares Common Stock Outstanding after the Offering................................ 13,231,938 shares(1) Use of Proceeds........................... To fund research and development, expansion of laboratory and office facilities, potential technology acquisitions and general corporate purposes. See "Use of Proceeds." Proposed Nasdaq National Market Symbol.... CCHM
SUMMARY FINANCIAL DATA (in thousands, except per share data)
PERIOD FROM MAY 23, 1994 THREE MONTHS ENDED (INCEPTION) TO YEAR ENDED DECEMBER 31, MARCH 31, DECEMBER 31, ------------------------------ ------------------ 1994 1995 1996 1997 1997 1998 --------------- ------- ------- -------- ------- ------- (unaudited) STATEMENT OF OPERATIONS DATA: Total revenue.......... $ -- $ 50 $ 2,967 $ 7,471 $ 491 $ 2,622 Total operating expenses............ 711 6,763 8,085 12,004 2,247 4,130 ----- ------- ------- -------- ------- ------- Loss from operations... (711) (6,713) (5,118) (4,533) (1,756) (1,508) Net loss............... $(706) $(6,675) $(5,118) $ (4,322) $(1,627) $(1,424) ===== ======= ======= ======== ======= ======= Pro forma basic net loss per share(2)... $ (0.49) $ (0.14) ======== ======= Shares used in computing pro forma basic net loss per share(2)............ 8,804 10,202 ======== =======
MARCH 31, 1998 ------------------------------------------ PRO FORMA AS ACTUAL PRO FORMA(3) ADJUSTED(3)(4) -------- ------------ -------------- (unaudited) BALANCE SHEET DATA: Cash and cash equivalents.......................... $ 3,914 $ 3,914 $ 21,747 Short-term investments............................. 10,575 10,575 10,575 Working capital.................................... 10,567 10,567 28,399 Total assets....................................... 25,926 25,926 43,759 Long-term obligations, including current portion... 5,441 5,441 5,441 Redeemable convertible preferred stock............. 23,130 -- -- Accumulated deficit................................ (18,244) (18,244) (18,244) Total stockholders' equity (deficit)............... (7,612) 15,518 33,350
- --------------- (1) Based on the number of shares outstanding as of March 31, 1998. Includes: (i) 7,754,933 shares of Common Stock to be issued upon conversion of redeemable convertible preferred stock, par value $0.001 per share (the "Preferred Stock"), of the Company; and (ii) 779,625 shares of Common Stock which are currently subject to repurchase by the Company. Excludes: (i) 535,596 shares of Common Stock issuable upon the exercise of stock options outstanding as of March 31, 1998, with a weighted average exercise price of $3.95 per share, all of which are exercisable and 49,415 of which are vested; (ii) 139,478 shares of Common Stock issuable upon the exercise of outstanding warrants, with a weighted average exercise price of $2.27 per share; and (iii) 58,125 shares of Common Stock issuable upon the exercise and conversion of Series J convertible preferred stock options, all of which are exercisable and vested with an exercise price of $0.40 per share. See "Capitalization." (2) Computed on the basis described for pro forma basic net loss per share in Note 1 of Notes to Financial Statements. (3) Gives effect to the conversion of the Preferred Stock into Common Stock effective upon the closing of this offering. (4) Adjusted to reflect the sale of 2,250,000 shares of Common Stock offered hereby, assuming a public offering price of $9.00 per share (the mid-point of the range set forth on the front cover) less estimated underwriting discounts and commissions and other expenses of this offering, resulting in net proceeds to the Company of $17.8 million. See "Use of Proceeds." Except as otherwise indicated herein, all information contained in this Prospectus (i) gives effect to a one-for-four reverse split of the Common Stock, (ii) reflects the conversion of all outstanding shares of Preferred Stock into an aggregate of 7,754,933 shares of Common Stock, effective upon the closing of this offering, and (iii) assumes no exercise of the Underwriters' over-allotment option. 5 7 RISK FACTORS In addition to the other information in this Prospectus, the following risk factors should be considered carefully in evaluating the Company and its business before purchasing shares of the Common Stock offered hereby. The Prospectus may contain forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth in the following risk factors and elsewhere in this Prospectus. NEW AND UNCERTAIN TECHNOLOGY AND BUSINESS The Company's Discovery Engine process is novel and has not yet been shown to be successful in the discovery of lead candidates that have been subsequently developed into commercialized drugs. Furthermore, the Company's drug discovery efforts are focused on some targets the functions of which are not yet known. Development of new pharmaceutical products is highly uncertain, and no assurance can be given that the Company's drug discovery process will result in lead candidates that will be safe or efficacious or commercially successful as products. Failure to validate the Company's technology through the successful discovery of lead candidates would have a material adverse effect on the Company's business, financial condition and results of operations. The Company's strategy, which is unproven, is to use its proprietary design technology for the purpose of rapidly identifying, optimizing and obtaining proprietary rights to as many lead candidates and development candidates as possible. The Company's ability to achieve profitability in the near term depends entirely on its ability to enter into additional collaborative agreements with third parties and to maintain the agreements it currently has in place. The pricing and nature of the Company's collaborative relationships is such that there may only be a limited number of pharmaceutical, biotechnology and agrochemical companies that will be its potential customers. The Company's ability to succeed is also dependent upon the acceptance by potential customers of its Discovery Engine process as an effective tool in new drug discovery. Historically, pharmaceutical, biotechnology and agrochemical companies have conducted lead candidate identification and optimization within their own research departments, due to the highly proprietary nature of the activities being conducted, the central importance of these activities to their drug discovery and development efforts and the desire to obtain maximum patent and other proprietary protection on the results of their internal programs. In order to achieve its business objectives, the Company must convince these companies that its technology and capabilities justify the outsourcing of their programs to the Company. There can be no assurance that the Company will be able to attract any future customers on acceptable terms for its products and services or develop a sustainable, profitable business. Failure to do so will have a material adverse effect on the Company's business, financial condition and results of operations. The Company's collaborative agreements are structured in a way that provides the Company with payments for (i) initiating the collaboration, (ii) providing research for a specified period, typically over a one- to two-year period for each project undertaken under the collaboration, (iii) attaining specifically negotiated milestones, and (iv) royalties from the sale of any drug successfully developed under each collaborative agreement. Whereas a significant portion of the Company's revenue to date has been related to the research phase of each of its collaborative agreements which is for a specified period and is generally offset by corresponding research costs, the Company expects any profit to result primarily from project initiation fees, milestone payments and royalties. Following the completion of the research phase of each collaborative agreement, the Company may receive additional revenue under each respective collaborative agreement only from milestones and royalties. As of March 31, 1998, the Company had completed the research phase of its collaborative agreement with Teijin. There can be no assurance that the Company will receive any additional milestone or royalty payments from any of its collaborative agreements. Failure to do so could have a material adverse effect on the Company's business, financial condition and results of operation. See "-- Dependence of Company's Strategy on Third Parties" and "Business." 6 8 LIMITED OPERATING HISTORY; HISTORY OF OPERATING LOSSES; UNCERTAINTY OF FUTURE PROFITABILITY The Company has had a limited operating history. For the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1998, the Company had net losses of approximately $6.7 million, $5.1 million, $4.3 million and $1.4 million, respectively. As of March 31, 1998, the Company had an accumulated deficit of approximately $18.2 million. The Company's expansion of its operations and enhancements to its Discovery Engine and related drug discovery technology will result in significant expenses over the next several years that may not be offset by significant revenue. The Company's ability to achieve profitability in the near term depends entirely on its ability to enter into additional collaborative agreements with third parties and to maintain the agreements it currently has in place. To date, substantially all revenue received by the Company has been from project initiation fees and research funding paid pursuant to existing collaborative agreements with third parties. The Company has not yet received any revenue from royalties for the sale of a commercial drug by a customer, and there can be no assurance when the Company will receive such revenue, if at all. An element of the Company's commercialization strategy is the potential development and licensing to others of lead compounds or drug development candidates identified by the Company through its internal programs, at its own expense, for potential pharmaceutical development. To date, no such license has been entered into, and there can be no assurance that any such license will be entered into on acceptable terms in the future, if at all. The Company is unable to predict when, or if, it will become profitable. See "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." DEPENDENCE OF COMPANY'S STRATEGY ON THIRD PARTIES The Company's strategy depends upon the formation of multiple collaborative arrangements with third parties on a regular basis. To date, the Company has entered into six such arrangements, and substantially all of its revenue has been from its collaborative arrangements. There can be no assurance that the Company will be able to continue to establish additional collaborative arrangements, that any such arrangements will be on terms favorable to the Company, or that current or any future collaborative arrangements will ultimately be successful. Failure to enter into additional collaborative agreements on favorable terms would have a material adverse effect on the Company's business, financial condition and results of operations. Whereas a significant portion of the Company's revenue to date has been related to the research phase of each of its collaborative agreements, which is for a specified period and is generally offset by corresponding research costs, the Company expects any profit to result primarily from project initiation fees, milestone payments and royalties. Following the completion of the research phase of each collaborative agreement, the Company may receive additional revenue under each respective collaborative agreement only from milestones and royalties, which may not be paid, if at all, until some time well into the future. Further, CombiChem's receipt of revenue from collaborative arrangements is affected by the timing of efforts expended by the Company and its collaborators and the timing of lead compound identification by the Company. Milestone payments may be earned for different events or achievements from agreement to agreement and, for certain collaborations, such fees may not be earned until the collaborator has advanced products into clinical testing, until some time well into the future. The Company's products and services will only result in commercialized pharmaceutical products generating milestone payments and royalties upon the successful outcome of significant preclinical and clinical development, the procurement of requisite regulatory approvals, the establishment of manufacturing, sales and marketing capabilities and the achievement of successful marketing. The Company does not currently intend to perform any of these activities. Therefore, the Company will be dependent upon the expertise and dedication of sufficient resources by third parties to develop and commercialize products based on library compounds produced and lead compounds discovered or optimized by the Company. In addition, there can be no assurance that any such development or commercialization efforts by third parties would be successful. Should a collaborative partner fail to develop or commercialize a compound or product to which it has rights from the Company, the Company may not receive any future milestone payments and will not receive any royalties associated with such compound or product. In addition, the 7 9 Company's collaborative arrangements with its partners do not obligate the partners to develop or commercialize lead compounds discovered or optimized by the Company. Each collaborative partner may independently move forward with a competing lead candidate developed either by such partner internally or in collaboration with others, including the Company's competitors. The potential drugs developed by a collaborative partner may be derivatives of the lead compounds provided to the customer by the Company. While the Company's existing collaborative agreements provide that the Company retain milestone and royalty payment rights with respect to drugs developed from certain derivative compounds, there can be no assurance that disputes will not arise over the application of payment provisions to such drugs. There can be no assurance that current or future collaborative partners, if any, will not pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including the Company's competitors, as a means for developing treatments for the diseases targeted by collaborative arrangements with the Company. Furthermore, there can be no assurance that conflicts will not arise between collaborative partners as to proprietary rights to particular compounds. The amount and timing of resources that current and future collaborators, if any, devote to collaborations with the Company are not within the control of the Company. There can be no assurance that such collaborators will perform their obligations as expected. Further, the Company's collaborations generally may be terminated by its collaborators upon short notice and following an uncured material breach, which terminations would result in a loss of anticipated revenue. Termination of the Company's existing or future collaborative agreements, if any, could have a material adverse effect on the Company's business, financial condition and results of operations. The Company's strategy also involves conducting its own internally funded discovery programs by choosing biological targets of current scientific interest and working in collaboration with screening companies. There can be no assurance that the Company will continue to have access to such targets, novel or otherwise, on an ongoing basis. Furthermore, despite the Company's installation of independent teams to conduct each collaborative project, there can be no assurance that conflicts will not arise among collaborators as to the rights to overlapping lead candidate compounds developed independently as a result of being identified through the use of the Company's technologies. Failure to manage multiple existing and future collaborator relationships successfully, maintain confidentiality among such relationships or prevent the occurrence of such conflicts could lead to disputes that result in, among other things, a significant strain on management resources, legal claims involving significant time and expense and loss of reputation, a loss of capital or a loss of current or future collaborators, any of which could have a material adverse effect on the Company's business, financial condition and results of operations. See "Business -- Strategy" and "Business -- CombiChem's Collaborative Arrangements." SIGNIFICANT FLUCTUATIONS IN QUARTERLY RESULTS To date, substantially all revenue received by the Company has been from the receipt of project initiation fees, research funding and a milestone fee paid pursuant to collaborative agreements. The Company expects that a significant portion of its revenue for the foreseeable future will be comprised of such payments. The timing of certain revenue in the future will depend upon the completion of certain milestones as provided for in the Company's collaborative agreements. In any one fiscal quarter the Company may receive multiple or no payments from its several collaborators. Operating results may therefore vary substantially from quarter to quarter and will not necessarily be indicative of results in subsequent periods. There can be no assurance that such quarterly fluctuations in revenue or financial results will not have a material impact on the Company's stock price. COMPANY'S SUCCESS DEPENDENT ON INTELLECTUAL PROPERTY RIGHTS The Company's success will depend in large part on its own, its licensees' and its licensors' ability to obtain and defend patents for each party's respective technologies and the compounds and other products, if any, resulting from the application of such technologies, maintain trade secrets and operate without infringing upon the proprietary rights of others, both in the United States and in foreign countries. The patent positions of pharmaceutical and biotechnology companies, including the 8 10 Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. The Company has pending United States and foreign patent applications relating to various aspects of its technology, certain systems, materials and methods used in screening compounds and the libraries or compounds contained therein. These patent applications are either owned or co-owned by the Company or rights under them are licensed to the Company. To date, one foreign patent owned by the Company has issued and notices of allowance for two United States patent applications owned by the Company have been received. To the extent that any foreign patent application filed in the European Patent Office or the Japanese Patent Office issues as a patent, a challenge to the validity of such patent may be presented in an opposition proceeding. There can be no assurance that patents will issue as a result of any such pending applications or that, if issued, such patents will be sufficiently broad to afford protection against competitors with similar technologies. The Company is aware of three United States patents issued to a third party that claim proprietary rights; two of the three patents are entitled "System and method for automatically generating chemical compounds with desired properties" and the third is entitled "System, method, and computer program for at least partially automatically generating chemical compounds having desired properties." Although the Company believes that its current activities do not infringe these patents, there can be no assurance that the Company's belief would be affirmed in any litigation over the patents or that the Company's future technological developments would be outside the scope of these patents. Further, there can be no assurance that the third party will not seek to assert such patent rights against the Company, which would result in significant legal costs and require substantial management resources, and there can be no assurance that the Company would be able to obtain a license from the third party, if required, on commercially reasonable terms, if at all. The inability of the Company either to demonstrate non-infringement of these and other current and future patents, whether issued in the United States or overseas, or to obtain the appropriate licenses, would have a material adverse effect on the Company's business, financial condition and operations. Moreover, there can be no assurance that the Company or its customers will be able to obtain patent protection for lead compounds or pharmaceutical products based upon the Company's or such customers' technologies. There can be no assurance that any patents issued to the Company or its collaborative partners, or for which the Company has license rights, will not be challenged, invalidated or circumvented, or that the rights granted thereunder will provide competitive advantages to the Company. To the extent that the Company or its consultants or collaborators use intellectual property owned by others in their work for the Company, disputes may also arise as to the rights in related or resulting know-how and inventions. Litigation may be necessary to enforce the Company's patent and license rights or to determine the scope and validity of others' proprietary rights. Any such litigation whether or not the outcome thereof is favorable to the Company, could result in substantial cost to and diversion of effort by the Company. Further, United States patents do not provide any remedies for infringement that occurred before the patent is issued. The commercial success of the Company will also depend upon successfully avoiding the infringement of current and future patents issued to competitors and upon maintaining the technology licenses upon which certain of the Company's current products are, or any future products under development might be, based. If competitors of the Company prepare and file patent applications in the United States that claim inventions also claimed by the Company or its collaborators, the Company or its collaborators may have to participate in interference proceedings declared by the United States Patent and Trademark Office ("PTO") to determine the priority of invention, which could result in substantial cost to the Company, even if the outcome is favorable to the Company. An adverse outcome could subject the Company to significant liabilities to third parties and require the Company to license disputed rights from third parties or cease using the technology. From time to time the Company receives invitations from third parties to license patents owned or controlled by third parties. The Company evaluates these requests and intends to obtain licenses that are compatible with its business objectives. There can be no assurance, however, that the Company will be able to obtain any licenses on acceptable terms, if at all. The Company's inability to obtain or maintain patent protection or necessary licenses could have a material adverse effect on the business, financial condition and results of operations of the Company. 9 11 A United States patent application is maintained under conditions of confidentiality while the application is pending in the PTO, so that the Company cannot determine the inventions being claimed in pending patent applications filed by its competitors in the PTO. A number of pharmaceutical and biotechnology companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to the Company's business. Some of these technologies, applications or patents may conflict with the Company's technologies or patent applications. Such conflict could limit the scope of the patents, if any, that the Company may be able to obtain, or result in the denial of the Company's patent applications. In addition, there can be no assurance that the Company would be able to obtain licenses to patents held by third parties that may cover the Company's activities at a reasonable cost, if at all, or that the Company would be able to develop or obtain any alternative technologies. The Company currently has certain licenses from third parties and in the future may require additional licenses from other parties in order to refine its Discovery Engine further and to allow its collaborators to develop, manufacture and market commercially viable products effectively. There can be no assurance that (i) such licenses will be obtainable on commercially reasonable terms, if at all, (ii) any patents underlying such licenses will be valid and enforceable or (iii) the proprietary nature of any patented technology underlying such licenses will remain proprietary. The Company relies substantially on certain technologies that are not patentable or proprietary and are therefore available to the Company's competitors. The Company also relies on certain proprietary trade secrets and know-how that are not patentable. Although the Company has taken steps to protect its unpatented trade secrets and know-how, in part through the use of confidentiality agreements with its employees, consultants and certain of its contractors, there can be no assurance that (i) these agreements will not be breached, (ii) the Company would have adequate remedies for any breach or (iii) the Company's trade secrets will not otherwise become known or be independently developed or discovered by competitors. Failure by the Company to protect all or part of its patents, trade secrets and know-how could have a material adverse effect on the Company's business, financial condition and results of operations. See "Business -- Patents and Proprietary Information." COMPETITIVE NATURE OF COMPANY'S INDUSTRY AND RISKS OF OBSOLESCENCE OF TECHNOLOGY Many organizations are actively attempting to identify, optimize and generate lead compounds for potential pharmaceutical development. The Company competes with the research departments of pharmaceutical companies, biotechnology companies, combinatorial chemistry companies and research and academic institutions as well as other computationally based drug discovery companies. Many of these competitors have greater financial and human resources and more experience in research and development than the Company. Historically, large pharmaceutical companies have maintained close control over their research activities, including the synthesis, screening and optimization of chemical compounds. Many of these companies, which represent one of the largest potential markets for CombiChem's products and services, are internally developing combinatorial and computational approaches and other methodologies to improve productivity, including major investments in robotics technology to permit the automated parallel synthesis of compounds. In addition, these companies may already have large collections of compounds previously synthesized or ordered from chemical supply catalogs or other sources against which they may screen new targets. Other sources of compounds include compounds extracted from natural products, such as plants and microorganisms, and compounds created using rational drug design. Academic institutions, governmental agencies and other research organizations are also conducting research in areas in which the Company is working, either on their own or through collaborative efforts. The Company anticipates that it will face increased competition in the future as new companies enter the market and advanced technologies become available. The Company's processes may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of the Company's competitors. The existing approaches of the Company's competitors or new approaches or technology developed by the Company's competitors may be more effective than those developed by the Company. See "Business -- Competition." 10 12 SUCCESS OF COMPANY DEPENDENT ON SCALE-UP AND MANAGEMENT OF GROWTH The Company's success will depend on the expansion of its operations to service additional collaborative arrangements and the management of these expanded operations. To be cost-effective in its delivery of services and products, the Company must enhance productivity through further automation of its processes and improvements to its technology generally. In addition, the Company must successfully structure and manage multiple additional collaborative relationships, including maintaining the confidentiality of the research being provided to multiple customers. There can be no assurance that the Company will be successful in adding technical personnel as needed to meet the staffing requirements of any additional collaborative relationship. In addition, there can be no assurance that the Company will be successful in its engineering efforts to automate its processes further or in its initiatives to improve its technology. Failure to achieve any of these goals could have a material adverse effect on the Company's business, financial condition or results of operations. See "Business -- CombiChem's Collaborative Arrangements" and "Business -- Employees." DEPENDENCE OF COMPANY ON KEY EMPLOYEES The Company is highly dependent on the principal members of its scientific and management staff. The loss of one or more key members of the Company's scientific or management staff could have a material adverse effect on the Company's business, financial condition and results of operations. The Company's future success will also depend in part on the continued service of its key design engineering, scientific, software and management personnel and on its ability to identify, hire and retain any additional personnel. There is intense competition for such qualified personnel in the areas of the Company's activities, and there can be no assurance that the Company will be able to continue to attract and retain such personnel necessary for the development of the Company's business. Failure to attract and retain key personnel could have a material adverse effect on the Company's business, financial condition and results of operations. See "Business -- Employees" and "Management." GOVERNMENT REGULATION Regulation by governmental entities in the United States and other countries will be a significant factor in the production and marketing of any pharmaceutical products that may be developed by a customer or collaborator of the Company or, in the event the Company decides to develop a drug beyond the preclinical phase, by the Company. The nature and the extent to which such regulation may apply to the Company's customers will vary depending on the nature of any such pharmaceutical products. Virtually all pharmaceutical products developed by the Company's customers will require regulatory approval by governmental agencies prior to commercialization. In particular, human pharmaceutical therapeutic products are subject to rigorous preclinical and clinical testing and other approval procedures established by the United States Food and Drug Administration (the "FDA") and by foreign regulatory authorities. Various federal and, in some cases, state statutes and regulations also govern or influence, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of such products. Non-compliance with applicable requirements can result in fines, warning letters, recall or seizure of products, clinical study holds or delays, total or partial suspension of production, refusal of the government to grant approvals, and civil and criminal penalties. The process of obtaining these approvals and the subsequent compliance with appropriate federal and foreign statutes and regulations are time-consuming and require the expenditure of substantial resources. Generally, in order to gain FDA approval, a company first must conduct preclinical studies in the laboratory and in animal models to gain preliminary information on a compound's efficacy and to identify any safety problems. Preclinical studies must be conducted by laboratories that comply with FDA regulations regarding Good Laboratory Practices. The results of these studies are submitted as a part of an Investigational New Drug application (an "IND") that the FDA must review before human clinical trials of an investigational drug can begin. In order to commercialize any products, the Company or its customer will be required to sponsor and file an IND and will be responsible for initiating and overseeing the clinical studies to demonstrate the safety and efficacy that are necessary to obtain FDA and foreign regulatory authority approval of any such 11 13 products. Clinical trials are normally done in three phases and generally take two to five years but may take longer to complete. After completion of clinical trials of a new product, FDA and foreign regulatory authority marketing approval must be obtained. If the product is classified as a new drug, the Company or its customer will be required to file a New Drug Application (an "NDA") and receive approval before commercial marketing of the drug. The testing and approval processes require substantial time and effort, and there can be no assurance that any approval will be granted on a timely basis, if at all. NDAs submitted to the FDA can take, on average, two to five years to obtain approval. If questions arise during the FDA review process, approval can take more than five years. Even if FDA regulatory clearances are obtained, a marketed product is still subject to continual review, and later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market, as well as possible civil or criminal sanctions. Domestic manufacturing facilities of the Company or its customers are subject to biannual inspections by the FDA and must comply with the FDA's current Good Manufacturing Practices regulations. To comply with such regulations, a manufacturer must spend funds, time and effort in the areas of production and quality control to ensure full technical compliance. The FDA stringently applies regulatory standards for manufacturing. For marketing outside the United States, the Company or its customer will also be subject to foreign regulatory requirements governing human clinical trials and marketing approval for pharmaceutical products. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country. FUTURE CAPITAL NEEDS; UNCERTAINTY OF ADDITIONAL FUNDING Although the Company anticipates that its existing capital resources, including the net proceeds from this offering, will be adequate to fund the Company's operations at least through the next 12 months, there can be no assurance that changes will not occur that would consume available capital resources before such time. The Company may be required to raise additional capital over a period of several years in order to continue to conduct its operations. Such capital may be raised through additional public or private financings, as well as collaborative arrangements, borrowings and other available sources. There can be no assurance that the Company's collaborative arrangements will produce revenue adequate to fund the Company's operating expenses. The Company's capital requirements depend on numerous factors, including the ability of the Company to enter into additional collaborative arrangements, competing technological and market developments, changes in the Company's existing collaborative relationships, the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, the purchase of additional capital equipment, the progress of the Company's drug discovery programs and the progress of the commercialization of milestone- and royalty-bearing compounds by the Company's customers. The Company does not currently plan independently to develop, manufacture or market any drugs it discovers. To the extent that additional capital is needed, it may be raised through the sale of equity or convertible debt securities, and the issuance of such securities could result in dilution to the Company's existing stockholders. There can be no assurance that additional funding, if necessary, will be available on favorable terms, if at all. If adequate funds are not available, the Company may be required to curtail operations significantly or to obtain funds through entering into arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates, products or potential markets that the Company would not otherwise relinquish. The failure to receive additional funding would have a material adverse effect on the Company's business, financial condition and results of operations. See "Management's Discussion and Analysis of Financial Condition and Results of Operations." UNCERTAINTY OF PHARMACEUTICAL PRICING AND HEALTH CARE REFORM The Company expects that substantially all of its revenue in the foreseeable future will be derived from products and services provided to the pharmaceutical and biotechnology industries. Accordingly, the Company's success in the foreseeable future is directly dependent upon the success of the 12 14 companies within those industries and their continued demand for the Company's products and services. The level of revenue and profitability of pharmaceutical companies may be affected by the continuing efforts of governmental and third-party payors to contain or reduce the costs of health care through various means and the initiatives of third-party payors with respect to the availability of reimbursement. For example, in certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to governmental control. In the United States, there have been, and the Company expects that there will continue to be, a number of federal and state proposals to implement similar governmental control. It is uncertain what legislative proposals may be adopted or what actions federal, state or private payors for health care goods and services may take in response to any health care reform proposals or legislation. To the extent that such proposals or reforms have a material adverse effect on the business, financial condition and profitability of pharmaceutical and biotechnology companies that are actual or prospective collaborators for certain of the Company's products and services, the Company's business, financial condition and results of operations may be adversely affected. COMPANY'S USE OF HAZARDOUS MATERIALS The research and development processes of the Company involve the controlled use of hazardous materials. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although the Company believes that its activities currently comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any damages that result, and any such liability could exceed the resources of the Company. In addition, there can be no assurance that the Company will not be required to incur significant costs to comply with environmental laws and regulations in the future. The occurrence of any such event could have a material adverse effect on the Company's business, financial condition and results of operations. SHARES ELIGIBLE FOR FUTURE SALE Future sales of Common Stock in the public market following this offering could adversely affect the market price of the Common Stock. Based on the number of shares outstanding as of March 31, 1998, upon completion of this offering, the Company will have 13,231,938 shares of Common Stock outstanding, assuming no exercise of currently outstanding options. Of these shares, the 2,250,000 shares sold in this offering (plus any additional shares sold if the Underwriters exercise their over-allotment option) will be freely transferable without restriction under the Securities Act of 1933, as amended (the "Securities Act"), unless they are held by "affiliates" of the Company as that term is used under the Securities Act and the regulations promulgated thereunder. Each holder who signed a lock-up agreement has agreed, subject to certain limited exceptions, not to sell or otherwise dispose of any of the shares held by them as of the date of this Prospectus for a period of 180 days after the date of this Prospectus without the prior written consent of BancAmerica Robertson Stephens. At the end of such 180-day period, approximately 8,980,000 shares of Common Stock (including approximately 121,000 shares issuable upon exercise of vested options) will be eligible for immediate resale, subject to compliance with Rule 144 and Rule 701. The remainder of the approximately 4,252,000 shares of Common Stock outstanding or issuable upon exercise of options held by existing stockholders or option holders will become eligible for sale at various times over a period of less than two years and could be sold earlier if the holders exercise any available registration rights or upon vesting pursuant to the Company's standard four year vesting schedule. The holders of 7,754,933 shares of Common Stock have the right in certain circumstances to require the Company to register their shares under the Securities Act for resale to the public. If such holders, by exercising their demand registration rights, cause a large number of shares to be registered and sold in the public market, such sales could have an adverse effect on the market price for the Company's Common Stock. If the Company were required to include in a Company-initiated registration shares held by such holders pursuant to the exercise of their piggyback registration rights, such sales may have an adverse effect on the Company's ability to 13 15 raise needed capital. In addition, the Company expects to file immediately upon the effective date of this registration statement, a registration statement on Form S-8 registering a total of approximately 1,222,170 shares of Common Stock including those outstanding shares which may be repurchased by the Company and shares issuable upon exercise of outstanding stock options or reserved for issuance under the Company's stock incentive plan and employee stock purchase plan. See "Management -- Benefit Plans," "Description of Capital Stock -- Registration Rights," "Shares Eligible for Future Sale" and "Underwriting." CONTROL BY MANAGEMENT AND EXISTING STOCKHOLDERS Upon completion of this offering, the Company's executive officers, directors and affiliated entities together will beneficially own approximately 30.8% of the outstanding shares of Common Stock (approximately 30.0% if the Underwriters' overallotment option is exercised in full). As a result, these stockholders will be able to exercise control over matters requiring stockholder approval, including the election of directors and mergers, consolidations and sales of all or substantially all of the assets of the Company. This may prevent or discourage tender offers for Common Stock unless the terms are approved by such stockholders. See "Principal Stockholders." NO PRIOR PUBLIC MARKET FOR COMMON STOCK; POSSIBLE VOLATILITY OF STOCK PRICE Prior to this offering, there has been no public market for the Common Stock, and there can be no assurance that an active public market for the Common Stock will develop or be sustained after the offering. The initial offering price will be determined by negotiations between the Company and the Underwriters and is not necessarily indicative of the market price at which the Common Stock of the Company will trade after this offering. The market prices for securities of life sciences companies have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Announcements of technological innovations or new commercial products by the Company or its competitors, developments concerning proprietary rights, including patents and litigation matters, publicity regarding actual or potential results with respect to products or compounds under development by the Company or its strategic partners, regulatory developments in both the United States and foreign countries, public concern as to the efficacy of new technologies, general market conditions, as well as quarterly fluctuations in the Company's revenue and financial results among other factors, may have a significant impact on the market price of the Common Stock. In particular, the realization of any of the risks described in these "Risk Factors" could have a dramatic and adverse impact on such market price. See "Underwriting." ANTI-TAKEOVER EFFECT OF CERTAIN CHARTER AND BY-LAW PROVISIONS AND DELAWARE LAW The Company's Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") authorizes the Board of Directors to issue, without stockholder approval, 5,000,000 shares of Preferred Stock with voting, conversion and other rights and preferences that could adversely affect the voting power or other rights of the holders of Common Stock. Although the Company has no current plans to issue any shares of Preferred Stock, the issuance of Preferred Stock or of rights to purchase Preferred Stock could be used to discourage an unsolicited acquisition proposal. In addition, the possible issuance of Preferred Stock could discourage a proxy contest, make more difficult the acquisition of a substantial block of the Company's Common Stock or limit the price that investors might be willing to pay in the future for shares of the Company's Common Stock. The Company's Certificate of Incorporation provides for staggered terms for the members of the Board of Directors. A staggered Board of Directors and certain provisions of the Company's by-laws and of Delaware law applicable to the Company could delay or make more difficult a merger, tender offer or proxy contest involving the Company. Further, the Company's stock option plans generally provide for the acceleration of vesting of options granted under such plans in the event of certain transactions which result in a change of control of the Company. In addition, the Company is subject to Section 203 of the General Corporate Law of Delaware which, subject to certain exceptions, restricts certain transactions 14 16 and business combinations between a corporation and a stockholder owning 15% or more of the corporation's outstanding voting stock (an "interested stockholder") for a period of three years from the date the stockholder becomes an interested stockholder. These provisions may have the effect of delaying or preventing a change of control of the Company without action by the stockholders and, therefore, could adversely affect the price of the Company's Common Stock. See "Management," "Description of Capital Stock -- Preferred Stock" and "Description of Capital Stock -- Possible Anti-Takeover Effect of Certain Charter Provisions -- Delaware Anti-Takeover Statute." BROAD MANAGEMENT DISCRETION IN USE OF PROCEEDS The Company's management will have broad discretion to allocate proceeds of this offering to uses that it believes are appropriate. There can be no assurance that the proceeds of this offering can or will be invested to yield a positive return. See "Use of Proceeds." RISK OF IMMEDIATE AND SUBSTANTIAL DILUTION Purchasers of the shares of Common Stock offered hereby will experience immediate and substantial dilution estimated at $6.48 per share in the net tangible book value of their investment from the initial offering price. Additional dilution will occur upon exercise of outstanding options and warrants. See "Dilution" and "Shares Eligible for Future Sale." 15 17 USE OF PROCEEDS The net proceeds to the Company from the sale of the 2,250,000 shares of Common Stock offered hereby are estimated to be approximately $17.8 million ($20.7 million if the Underwriters' over-allotment option is exercised in full), assuming a public offering price of $9.00 per share (the mid-point of the range set forth on the front cover) and after deducting the estimated underwriting discounts and commissions and other estimated offering expenses. The principal purposes of this offering are to increase the Company's equity capital and to create a public market for the Company's Common Stock in order to facilitate future access by the Company to public equity markets as well as to create liquidity for its existing stockholders. The Company intends to use the net proceeds of this offering, together with its existing cash and cash equivalents and short-term investments, to fund research and development (approximately $10.0 million), expansion of laboratory and office facilities (approximately $5.0 million) and the remainder for general corporate purposes. The Company may also use a portion of the net proceeds for the acquisition of businesses, technologies or products complementary to those of the Company. There are no present arrangements or agreements for any such acquisitions. The amounts actually expended for each purpose may vary significantly depending upon numerous factors, including the amount and timing of additional collaborative agreements, the progress of the Company's development, technological advances, the commercial potential of the Company's services and the status of the Company's competitors. The Company believes that its existing cash, cash equivalents and short-term investments, combined with the net proceeds of this offering, projected funding from equipment leases and interest income will be adequate to satisfy its capital requirements and fund operations at least through the next 12 months. Pending application of the net proceeds as described above, the Company intends to invest the net proceeds of this offering in short-term investment-grade securities. DIVIDEND POLICY The Company has never declared or paid dividends on its capital stock. The Company does not anticipate paying any cash dividends in the foreseeable future. Payments of future dividends, if any, will be at the discretion of the Company's Board of Directors after taking into account various factors, including the Company's financial condition, operating results, current and anticipated cash needs and plans for expansion. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Liquidity and Capital Resources." 16 18 CAPITALIZATION The following table sets forth as of March 31, 1998 (i) the actual capitalization of the Company, (ii) the pro forma capitalization of the Company, after giving effect to the conversion of all outstanding shares of Preferred Stock into Common Stock effective upon the closing of this offering, and (iii) pro forma as adjusted to give effect to the sale by the Company of 2,250,000 shares of Common Stock offered hereby, assuming a public offering price of $9.00 per share (the mid-point of the range set forth on the front cover) less estimated underwriting discounts and commissions and other expenses of this offering.
MARCH 31, 1998 ------------------------------------------ PRO FORMA AS ACTUAL PRO FORMA(2) ADJUSTED(2)(3) -------- ------------ -------------- (in thousands) Long-term obligations, including current portion..... $ 5,441 $ 5,441 $ 5,441 Redeemable convertible preferred stock: Preferred Stock, $0.001 par value; 63,196,296 shares authorized and 31,019,635 shares issued and outstanding actual; 5,000,000 shares authorized and no shares issued and outstanding pro forma and pro forma as adjusted............. 23,130 -- -- Stockholders' equity (deficit): Common Stock, $0.001 par value; 80,000,000 shares authorized actual; 3,227,005 shares issued and outstanding actual; 40,000,000 shares authorized pro forma and pro forma as adjusted; 10,981,938 shares issued and outstanding pro forma; and 13,231,938 shares issued and outstanding pro forma as adjusted(1)............................ 3 11 13 Additional paid-in capital......................... 12,520 35,642 53,472 Notes receivable from stockholders................. (419) (419) (419) Deferred compensation.............................. (1,472) (1,472) (1,472) Accumulated deficit................................ (18,244) (18,244) (18,244) -------- -------- -------- Total stockholders' equity (deficit)............ (7,612) 15,518 33,350 -------- -------- -------- Total capitalization....................... $ 20,959 $ 20,959 $ 38,791 ======== ======== ========
- --------------- (1) Includes 779,625 shares of Common Stock which are currently subject to repurchase by the Company. Excludes: (i) 535,596 shares of Common Stock issuable upon the exercise of stock options outstanding as of March 31, 1998, with a weighted average exercise price of $3.95 per share, all of which are exercisable and 49,415 of which are vested; (ii) 139,478 shares of Common Stock issuable upon the exercise of outstanding warrants, with a weighted average exercise price of $2.27 per share and (iii) 58,125 shares of Common Stock issuable upon the exercise and conversion of Series J convertible preferred stock options, all of which are exercisable and vested with an exercise price of $0.40 per share. (2) Gives effect to the conversion of the Preferred Stock into 7,754,933 shares of Common Stock effective upon the closing of this offering. (3) Adjusted to reflect the sale of 2,250,000 shares of Common Stock offered hereby, assuming a public offering price of $9.00 per share (the mid-point of the range set forth on the front cover) less estimated underwriting discounts and commissions and other expenses of this offering, resulting in net proceeds to the Company of $17.8 million. See "Use of Proceeds." 17 19 DILUTION The pro forma net tangible book value of the Company at March 31, 1998 was $15,518,000 or $1.41 per share of Common Stock. Pro forma net tangible book value per share of Common Stock represents the amount of total tangible assets of the Company less total liabilities divided by the number of shares of the Common Stock outstanding after giving effect to the conversion of all outstanding shares of Preferred Stock into 7,754,933 shares of Common Stock upon the completion of this offering. After giving effect to the sale of the 2,250,000 shares of Common Stock offered hereby assuming a public offering price of $9.00 per share, the mid-point of the range set forth on the front cover, less estimated underwriting discounts and commissions and other expenses of this offering, the Company's net tangible book value as of March 31, 1998 would have been $33,350,000 or $2.52 per share of Common Stock. This represents an immediate increase in pro forma net tangible book value per share of Common Stock of $1.11 to existing stockholders and immediate dilution in pro forma net tangible book value of $6.48 per share to new investors purchasing Common Stock in this offering. The following table illustrates the per share dilution: Assumed initial public offering price....................... $ 9.00 Pro forma net tangible book value of Common Stock as of March 31, 1998....................................... $1.41 Increase attributable to new investors................. 1.11 Pro forma net tangible book value of Common Stock after this offering.................................................. 2.52 ------ Dilution to new investors(1)................................ $ 6.48 ======
- --------------- (1) If the Underwriters' over-allotment option is exercised in full, dilution per share to new investors would be $6.33. The following table summarizes, on a pro forma basis as of March 31, 1998, the number of shares of Common Stock purchased from the Company, the total consideration paid (based on value received by the Company at the time of issuance) and the average price per share paid by the existing stockholders and by new investors purchasing shares in this offering (before deduction of estimated underwriting discounts and commissions and other expenses of this offering):
SHARES PURCHASED TOTAL CONSIDERATION AVERAGE --------------------- ---------------------- PRICE PER NUMBER PERCENT AMOUNT PERCENT SHARE ---------- ------- ----------- ------- --------- Existing stockholders....... 10,981,938 83.0% $34,005,799 62.7% $ 3.10 New investors............... 2,250,000 17.0 20,250,000 37.3 9.00 ---------- ------ ----------- ----- Total..................... 13,231,938 100.0% $54,255,799 100.0% ========== ====== =========== =====
All of the above computations assume no exercise of outstanding options or warrants to purchase Common Stock. The shares purchased and total consideration paid by existing shareholders does not include costs incurred by the Company to issue Common and Preferred Stock. As of March 31, 1998, options to purchase 535,596 shares of Common Stock were outstanding at a weighted average exercise price of approximately $3.95 per share under the Company's stock option plan, warrants to purchase 139,478 shares of Common Stock were outstanding at a weighted average exercise price of approximately $2.27 per share and options to purchase 58,125 shares of Common Stock issuable upon the exercise and conversion of Series J convertible Preferred Stock, all of which are exercisable and vested with an exercise price of $0.40 per share. To the extent these options or warrants are exercised, there will be further dilution to new investors. 18 20 SELECTED FINANCIAL DATA The selected financial data set forth below with respect to the Company's statements of operations for the years ended December 31, 1995, 1996 and 1997, and with respect to the Company's balance sheets at December 31, 1996 and 1997, are derived from the financial statements of the Company that have been audited by Ernst & Young LLP, which are included elsewhere herein and are qualified by reference to such financial statements. The Company's statement of operations data for the period from May 23, 1994 (inception) to December 31, 1994 and the balance sheet data at December 31, 1994 and 1995 have been derived from the financial statements audited by Ernst & Young LLP, which are not included herein. The statement of operations data for the three months ended March 31, 1997 and 1998 and the balance sheet data at March 31, 1998 have been derived from unaudited financial statements also appearing herein which, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial position and results of operations for the unaudited interim periods. The operating results for the three months ended March 31, 1998 are not necessarily indicative of the results that may be expected for the full fiscal year ending December 31, 1998 or for any subsequent period. The selected financial data set forth below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Company's financial statements and notes thereto appearing elsewhere in this Prospectus.
PERIOD FROM MAY 23, 1994 YEAR ENDED THREE MONTHS (INCEPTION) TO DECEMBER 31, ENDED MARCH 31, DECEMBER 31, --------------------------- ----------------- 1994 1995 1996 1997 1997 1998 -------------- ------- ------- ------- ------- ------- (in thousands, except per share data) STATEMENT OF OPERATIONS DATA: Revenue: Project initiation fees and milestone payments.............................. $ -- $ -- $ 2,500 $ 3,333 $ -- $ 750 Research and development funding........ -- -- 420 4,138 491 1,872 Grant revenue........................... -- 50 47 -- -- -- ----- ------- ------- ------- ------- ------- -- 50 2,967 7,471 491 2,622 Expenses: Research and development: Collaborative......................... -- -- 420 4,317 138 1,923 Proprietary........................... 413 4,763 4,820 4,400 1,237 1,315 ----- ------- ------- ------- ------- ------- 413 4,763 5,240 8,717 1,375 3,238 General and administrative.............. 298 2,000 2,845 3,287 872 892 ----- ------- ------- ------- ------- ------- Total operating expenses.................. 711 6,763 8,085 12,004 2,247 4,130 Loss from operations...................... (711) (6,713) (5,118) (4,533) (1,756) (1,508) Interest income, net...................... 5 38 -- 411 129 114 Foreign tax expense....................... -- -- -- (200) -- (30) ----- ------- ------- ------- ------- ------- Net loss.................................. $(706) $(6,675) $(5,118) $(4,322) $(1,627) $(1,424) ===== ======= ======= ======= ======= ======= Pro forma basic net loss per share(1)..... $ (0.49) $ (0.14) ======= ======= Shares used in computing pro forma basic net loss per share(1)................... 8,804 10,202 ======= =======
DECEMBER 31, -------------------------------------------- MARCH 31, 1994 1995 1996 1997 1998 -------- -------- -------- -------- --------- (in thousands) BALANCE SHEET DATA: Cash and cash equivalents................... $ 1,622 $ 3,136 $ 367 $ 5,867 $ 3,914 Short-term investments...................... -- -- 12,166 11,055 10,575 Working capital............................. 1,420 1,990 8,946 12,896 10,567 Total assets................................ 1,796 4,150 16,658 25,526 25,926 Long-term obligations, including current portion................................... -- 584 2,541 4,944 5,441 Redeemable convertible preferred stock...... 2,250 9,650 23,107 23,130 23,130 Accumulated deficit......................... (706) (7,381) (12,499) (16,821) (18,244) Total stockholders' equity (deficit)........ (682) (7,261) (12,363) (6,299) (7,612)
- --------------- (1) See Note 1 of Notes to Financial Statements for information concerning the computation of pro forma net loss per share and shares used in computing pro forma basic net loss per share. 19 21 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management's Discussion and Analysis of Financial Condition and Results of Operations may contain forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under "Risk Factors" and elsewhere in this Prospectus. OVERVIEW CombiChem is a computational drug discovery company that is applying its proprietary design technology and rapid synthesis capabilities to accelerate the discovery process for new drugs. The Company believes its approach offers pharmaceutical and biotechnology companies the opportunity to conduct their drug discovery efforts in a more productive and cost-effective manner. Using its proprietary Discovery Engine process, the Company focuses on the generation, evolution and optimization of potential new lead candidates for its collaborative partners, who will then develop, manufacture, market and sell any resulting drugs. CombiChem believes that its process is widely applicable to a variety of disease targets and therapeutic indications. Through March 31, 1998, the Company has established collaborative agreements with Teijin, Roche Bioscience, Sumitomo, ImClone, Elan/Athena and ICOS. In addition, the Company intends to use its approach on internal programs to discover new lead candidates and then to outlicense them to third parties, while retaining a larger economic interest. Since inception in May 1994, the Company has raised $34.0 million through private sales of equity securities. The Company's revenue to date is primarily attributable to the receipt of project initiation fees and research funding. Project initiation fees are received from the Company's collaborators upon, or shortly following, execution of the collaborative agreement. Research funding is received by the Company in connection with the performance of research services under the collaborative agreement. Such funding typically will be received only during the life of the research program under the particular collaboration. In addition, the Company has received advance payments under certain of its collaborations and in connection with a feasibility study, which require the Company to complete certain performance obligations. Such payments have been recorded as deferred revenue and will be recognized as revenue when the Company's performance obligations have been met, as evidenced by the collaborator's written approval and acceptance. The collaborative activities under these agreements for which the Company receives revenue typically occur over a one- to three-year period, although the agreements provide for earlier termination in certain circumstances. See "Business -- CombiChem's Collaborative Arrangements." The Company expects that a significant portion of its revenue for the foreseeable future will be comprised of such payments, although the receipt of project initiation fees will be dependent on the Company's ability to enter into additional collaborative agreements which provide for such fees and the timing of such payments will be difficult to predict. In addition, the timing of certain revenue in the future will depend upon the completion of certain milestones as provided for in the Company's collaborative agreements, which are contingent and uncertain. Milestone fees may be earned for different events or achievements from agreement to agreement, and for certain collaborations, such fees may not be earned until the collaborator has advanced products into clinical testing. In any one fiscal quarter the Company may earn multiple or no payments from its several collaborators. Operating results may therefore vary substantially from period to period and will not necessarily be indicative of results in subsequent periods. Completion of the research phase of a single project collaboration or a single project within a broad multiple project collaboration is not expected to have a material adverse effect on the Company's financial condition and results of operations. However, the termination or conclusion of any collaborative agreement could have a material adverse effect on the Company's financial condition and results of operations, and the failure of the Company to enter into additional collaborative agreements on favorable terms would have a material adverse effect on the Company's financial condition and results of operations. 20 22 The research phase of the collaborative agreement with Teijin was completed as of March 31, 1998, and the research phase of three projects under the collaborative agreement with Roche Bioscience are scheduled to end in 1998. The Company expects that the completion of the research phases of the collaborative agreement with Teijin and three projects under the collaborative agreement with Roche Bioscience or any of its other collaborative agreements will not have a material adverse impact on its financial condition and results of operations, although the failure of the Company to enter into additional collaborative agreements on favorable terms would have a material adverse effect on the Company's financial condition and results of operations. The Company's revenue to date is primarily attributable to its corporate collaborations: Teijin, entered into in March 1996, Roche Bioscience, entered into in October 1996, Sumitomo, entered into in August 1997, ImClone, entered into in October 1997, and Elan/Athena, also entered into in October 1997. Under its collaborations, the Company has received aggregate payments, excluding equity purchases, of $14.2 million through March 31, 1998 and has recognized an aggregate of $13.1 million as revenue. Substantially all of the $2.9 million revenue recognized under collaborative agreements in 1996 was due to project initiation fees, and a significant portion of the $7.5 million revenue recognized in 1997 was due to project initiation fees. Revenue in the first quarter of 1998 includes $0.8 million in milestone revenue. The remaining portion of the Company's revenue during such periods was from ongoing research funding from collaborators which is generally offset by corresponding research costs. The Company is also entitled to receive royalty payments if any product is commercialized under the collaborations. Project initiation fees, milestone and royalty payments generally have no associated cost of services. Milestone and royalty payments under individual agreements may not be paid until sometime well into the future. As of March 31, 1998, the Company has earned revenue from project initiation fees, research funding and milestone payments, but has not earned any royalty revenue, and such revenue is not expected for the next few years, if at all. The Company has not been profitable since inception and has incurred a cumulative net loss of $18.2 million through March 31, 1998. Losses have resulted principally from costs incurred in research and development activities related to the Company's efforts to develop its technologies and from the associated administrative costs required to support these efforts. The Company's ability to achieve profitability is dependent on its ability to market its technology to pharmaceutical and biotechnology companies. RESULTS OF OPERATIONS Three Months Ended March 31, 1998 and 1997 Revenue The Company's revenue for the three months ended March 31, 1998 was $2.6 million compared to $0.5 million for the three months ended March 31, 1997. The first quarter 1998 revenue resulted from $1.9 million in research funding under the Company's various collaborative agreements, as well as a milestone fee of $0.8 million earned under the collaborative agreement with Roche. Revenues from collaborators exceeding 10% of total revenues for the three months ended March 31, 1998 was 57% from Roche, 24% from Sumitomo, and 10% from Elan/Athena. For the three months ended March 31, 1997, Roche was 68% of revenues, and Teijin was 32% of revenues. Operating Expenses Research and development expenses for the quarter ended March 31, 1998 totalled $3.2 million compared to $1.4 million for the same period in 1997. The $1.8 million increase was primarily attributable to research and development costs incurred on behalf of its collaborators ("collaborative research and development"). Cost of services under the Company's collaborative agreements approximated the research funding earned under the agreements. Research and development costs incurred on behalf of the Company's proprietary projects increased to $1.3 million in 1998 from $1.2 million in 1997 as the Company continued investing in its proprietary technologies. 21 23 Net Loss The Company's net loss for the three months ended March 31, 1998 decreased $0.2 million to $1.4 million from $1.6 million for the same period in 1997. The decrease is primarily attributable to increased revenue, of which $0.8 million was a milestone fee under the collaborative agreement with Roche. This increase in revenue was partially offset by increased collaborative research and development expenses. Years Ended December 31, 1997 and 1996 Revenue The Company's revenue for the year ended December 31, 1997 increased $4.5 million to $7.5 million from $3.0 million for the same period in 1996. The revenue for the year ended December 31, 1997 included $4.1 million in research support and $3.3 million in project initiation fees compared to $0.4 million in research support and $2.5 million in project initiation fees for 1996. Revenues from collaborators exceeding 10% of total revenues for the year ended December 31, 1997 was 39% from Sumitomo, 30% from Roche, and 18% from Elan/Athena. Operating Expenses The Company's research and development expenses for the year ended December 31, 1997 increased $3.5 million to $8.7 million from $5.2 million for the same period in 1996. This increase reflects increased research and development expenses incurred both on behalf of collaborators through the addition of chemists and software application staff for each project team and in support of the development of the Company's technology including the addition of software development and analytical staff, the depreciation of laboratory equipment and the establishment of an advanced technology group. The Company has the ability to direct its scientific personnel to work either on its collaborative agreements or on its internal research projects as needs arise. The Company expects research and development spending to increase over the next several years due to increased activities related to collaborations, internal programs and technology development. The Company's general and administrative expenses for the year ended December 31, 1997 increased $0.5 million to $3.3 million from $2.8 million for the same period in 1996. This increase reflects increased business development activities, including outside consulting fees and increased travel costs, and administrative support for the Company's expansion in 1997. These expenses will likely continue to increase in future periods to support the projected growth of the Company. Net Loss The Company's net loss for the year ended December 31, 1997 decreased $0.8 million to $4.3 million from $5.1 million for the same period in 1996. The decrease is primarily attributable to additional revenue generated from corporate collaborations during 1997. Years Ended December 31, 1996 and 1995 Revenue The Company's revenue for the year ended December 31, 1996 increased to $3.0 million from $50,000 for the same period in 1995. This increase was attributable to revenue related to the Company's collaborative agreements with Teijin and Roche Bioscience which were entered into during 1996. The revenue for the year ended December 31, 1996 included $0.4 million in research support and $2.5 million in project initiation fees. No revenue was received from the Company's collaborators for the year ended December 31, 1995. Revenues from collaborators exceeding 10% of revenues for the year ended December 31, 1996 was 67% from Roche and 31% from Teijin. 22 24 Operating Expenses The Company's research and development expenses for the year ended December 31, 1996 increased $0.4 million to $5.2 million from $4.8 million for the same period in 1995. This increase reflects increased research and development expenses on behalf of collaborators and for the development of the Company's technology, including investment in the Company's discontinued automated synthesis instruments. The Company discontinued development of its automated synthesis instruments in the second quarter of 1996, after incurring expenses of approximately $4.0 million from inception of the Company through discontinuance. The Company's general and administrative expenses for the year ended December 31, 1996 increased $0.8 million to $2.8 million from $2.0 million for the same period in 1995. This increase was primarily due to costs associated with increased business development activities and administrative support, which accompanied the Company's expansion during 1996. Net Loss The Company's net loss for the year ended December 31, 1996 decreased $1.6 million to $5.1 million from $6.7 million for the same period in 1995. The decrease was primarily attributable to the increase in revenue generated from the Teijin and Roche Bioscience collaborations. LIQUIDITY AND CAPITAL RESOURCES At March 31, 1998, the Company held cash and cash equivalents and short-term investments with a value of $14.5 million. The Company's working capital at March 31, 1998 was $10.6 million. The Company has funded operations to date with sales of preferred stock and common stock totaling $34.0 million, payments from corporate collaborators totaling $14.2 million, and the utilization of capital equipment lease financing totaling $7.2 million. The Company has maintained capital lease arrangements since 1994. Under these arrangements, the Company has funded certain capital expenditures with lease terms ranging from 36 to 48 months in duration. As of March 31, 1998, the Company had utilized $7.2 million of the available $7.9 million financing facility. The Company's accounts receivable balance increased from $0.5 million at December 31, 1997 to $1.9 million at March 31, 1998. The $1.9 million is comprised of $1.5 million due from customers and approximately $0.4 million due from a leasing company. The $1.4 million increase was primarily attributable to $0.8 million receivable from Roche for a milestone fee earned in March 1998, approximately $0.4 million receivable from ICOS as an advance payment under the collaboration agreement, and $0.3 million receivable from an unnamed pharmaceutical company for an advance payment related to a feasibility study. In April 1998, the Company collected all of the amounts due from customers and a portion of the amounts due from the leasing company. Prepaid expenses and other current assets increased $0.1 million to $0.9 million at March 31, 1998 from $0.8 million at December 31, 1997. The change is primarily attributable to increases in prepaid expenses and interest receivable. Deposits and other assets increased from $0.9 million at December 31, 1997 to $1.0 million at March 31, 1998 as a result of additional costs incurred directly related to the proposed offering. Net cash provided by financing activities for the three months ended March 31, 1998 and 1997 was $0.5 million and $0.1 million, respectively, due to advances under the Company's capital lease line. Net cash provided by financing activities for the year ended December 31, 1997 was $12.6 million, primarily reflecting the issuance of Common Stock to ImClone and Elan/Athena. Net cash provided by financing activities for the year ended December 31, 1996 was $14.5 million, largely due to the issuance of $13.0 million in Preferred Stock sold to various investors. Net cash provided by financing activities for the year ended December 31, 1995 was $8.0 million, resulting mainly from capital contributions and proceeds from bridge financing. Net cash used in operating activities for the three months ended March 31, 1998 and 1997 was $1.1 million and $2.4 million, respectively, reflecting the decreased net loss in the first quarter of 1998. 23 25 Net cash used in operating activities for the years ended December 31, 1997, 1996 and 1995 was $3.5 million, $2.4 million, and $5.7 million, respectively, primarily due to the Company's scale-up of research and development activities. Net cash used in investing activities during the year ended December 31, 1997 and the three months ended March 31, 1998 was $3.6 million and $1.3 million, respectively, resulting primarily from purchases of short-term investments and property and equipment. Net cash used in investing activities for the year ended December 31, 1996 was $14.9 million as compared to $0.8 million for the year ended December 31, 1995. This increase primarily reflects purchases of short-term investments and property and equipment. Net cash provided by investing activities for the three months ended March 31, 1997 was $4.0 million, due to maturities of short-term investments. Although the Company anticipates that its existing capital resources, including the net proceeds from this offering, will be adequate to fund the Company's operations at least through the next 12 months, there can be no assurance that changes will not occur that would consume available capital resources before such time. The Company may be required to raise additional capital over a period of several years in order to continue to conduct its operations. Such capital may be raised through additional public or private financings, as well as collaborative arrangements, borrowings and other available sources. The Company expects that a significant portion of its revenue for the foreseeable future will be comprised of project initiation fees and research funding paid pursuant to its collaborative agreements, although the receipt of project initiation fees will be dependent on the Company's ability to enter into additional collaborative agreements for which such fees are due. In addition, the Company may from time to time earn milestone fees under its collaborations. However, there can be no assurance that any such fees will be earned, and, in addition, milestone fees may be earned for different events or achievements from agreement to agreement. Furthermore, for certain collaborations, such fees may not be earned until the collaborator has advanced products into clinical testing. Such milestones may not be earned for several years, if at all. During such period, there can be no assurance that the Company's collaborative arrangements will produce revenue adequate to fund the Company's operating expenses. The Company's capital requirements depend on numerous factors, including the ability of the Company to enter into additional collaborative arrangements, competing technological and market developments, changes in the Company's existing collaborative relationships, the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, the purchase of additional capital equipment, the progress of the Company's drug discovery programs and the progress of the commercialization of milestone- and royalty-bearing compounds by the Company's customers. The Company does not currently plan independently to develop, manufacture or market any drugs it discovers. To the extent that additional capital is needed, it may be raised through the sale of equity or convertible debt securities, and the issuance of such securities could result in dilution to the Company's existing stockholders. There can be no assurance that additional funding, if necessary, will be available on favorable terms, if at all. If adequate funds are not available, the Company may be required to curtail operations significantly or to obtain funds through entering into arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, product candidates, products or potential markets that the Company would not otherwise relinquish. The failure to receive additional funding would have a material adverse effect on the Company's business, financial condition and results of operations. NET OPERATING LOSSES At December 31, 1997, the Company had federal and California income tax net operating loss carryforwards of approximately $15.4 million and $15.5 million, respectively. The federal and California tax loss carryforwards will begin to expire in 2009 and 2002, respectively, unless previously utilized. The Company also has federal and California research tax credit carryforwards of approximately $379,000 and $275,000, respectively, which will begin to expire in 2010 unless previously utilized. The Company also has a federal foreign tax credit carryforward of approximately $200,000, which will expire in 2002 unless previously utilized. 24 26 Pursuant to Sections 382 and 383 of the Internal Revenue Code, annual use of approximately $7 million and $200,000 of the Company's net operating loss and credit carryforwards, respectively, may be limited because of cumulative changes in ownership of more than 50% which occurred during 1995. However, the annual limitation will not prevent the entire amount of the net operating loss and credit carryforwards from being used during the carryforward period. Therefore, the Company does not believe such limitation will have a material effect upon the utilization of these carryforwards. YEAR 2000 The Company has determined that its proprietary drug discovery software is not affected by Year 2000 issues. However, the Company has determined that it will need to review, modify or replace portions of its or its vendors' standard operating systems, such as payroll, cash management and other financial systems, so they will function properly with respect to dates in the year 2000 and beyond. The Company has initiated discussions with its financial institutions to ensure that those parties have appropriate plans to remediate Year 2000 issues where their systems interface with the Company's systems or otherwise impact its operations. The Company is assessing the extent to which its operations are vulnerable should those organizations fail to remediate properly their computer systems. While the Company believes its planning efforts are adequate to address its Year 2000 concerns, there can be no guarantee that the systems of other companies on which the Company's systems and operations rely will be converted on a timely basis and will not have a material effect on the Company. The cost of the Year 2000 initiatives is not expected to be material to the Company's results of operations or financial position. 25 27 BUSINESS OVERVIEW CombiChem is a computational drug discovery company that is applying its proprietary design technology and rapid synthesis capabilities to accelerate the discovery process for new drugs. The Company believes its approach offers pharmaceutical and biotechnology companies the opportunity to conduct their drug discovery efforts in a more productive and cost-effective manner. Using its proprietary Discovery Engine process, the Company focuses on the generation, evolution and optimization of potential new lead candidates for its collaborative partners who will then develop, manufacture, market and sell any resulting drugs. CombiChem believes that its process is widely applicable to a variety of disease targets and therapeutic indications. To date, the Company has established collaborative agreements with Teijin, Roche Bioscience, Sumitomo, ImClone and Elan/Athena and ICOS. In addition, the Company intends to use its approach on internal programs to discover new lead candidates and then to outlicense them to third parties, retaining a larger economic interest in such candidates. In the recent months there have been several developments which further validate the Company's technology and business strategy: (i) The achievement of a research milestone in CombiChem's collaboration with Roche Bioscience triggering a cash milestone payment. This stems from the identification, in less than one year, of novel drug development candidates for a potential new treatment for respiratory disease. (ii) The expansion of its existing collaboration with Elan/Athena whereby Elan/Athena authorized an additional project and purchased an option for an additional target not previously covered by the agreement. In addition, Elan International Services Ltd., a stockholder of CombiChem, and a wholly owned subsidiary of Elan Corporation, plc (whose wholly owned subsidiary, Athena Neurosciences, Inc. is a collaborative partner of CombiChem), has expressed an interest in acquiring approximately $2 million of the shares of Common Stock offered hereby at the initial public offering price. (iii) The establishment of a new agreement on an identified, undisclosed target with ICOS, bringing the number of its collaborative partners to a total of six. INDUSTRY BACKGROUND During the past decade, significant advances in life sciences research and the increasing appreciation of the complexity of biological processes have highlighted the productivity limitations of traditional approaches to drug discovery. These limitations, together with increased competition in the pharmaceutical and biotechnology industries, have created intense pressure on companies involved with drug development to reconsider the allocation of their research budgets and to improve the cost-effectiveness of their drug discovery process. Between 1976 and 1996, the number of new chemical entities approved by the FDA remained relatively constant, ranging between 12 to 30 per year, despite a more than 10-fold increase in research and development spending by pharmaceutical and biotechnology companies. Furthermore, it typically takes 12 to 15 years from the original concept of modulating the activity of a particular biological target to the market introduction of a drug that performs such a function. The average cost of bringing a new drug to market has been estimated to be in excess of $300 million. Frustrated with the inefficiencies of traditional drug discovery approaches, pharmaceutical and biotechnology companies are beginning to embrace new enabling technologies, such as combinatorial chemistry, genomics, structure-based drug design, high-throughput screening and information technologies, in order to gain a competitive advantage by accelerating the time to develop and commercial- 26 28 ize new compounds. These technologies also have the potential to reduce significantly the cost associated with drug discovery. The Traditional Drug Discovery Process and its Limitations The traditional path to discovering a therapeutic drug compound typically begins with the identification of one or more biological targets that are believed to mediate a disease state. A biological test or assay based on a target is then developed, predicated on the scientific belief that a compound binding with this target may have a therapeutic benefit with respect to the disease under study. Such an assay facilitates the screening (testing to determine which of the compounds have the desired activity against the target) of a collection of hundreds to thousands of candidate compounds (a library) that have been synthesized in the laboratory. Compounds that bind to the target protein and modulate its activity are referred to as hits. Medicinal chemists optimize these hits until they have sufficient potency to become lead candidates and then improve their preclinical characteristics (such as potency, specificity and in vivo profile) further with the goal of producing drug development candidates. In summary, the traditional drug discovery process consists of the following steps: [CHART] The traditional drug discovery process shown above is extremely expensive, inefficient and unreliable. Failure at any point during this discovery process would typically force the scientist either to abandon the project or to return to the initial starting point and repeat the process. As a result, the discovery of a novel therapeutic agent for a specified target can take years or can fail entirely. In recent years, the advent of robotic high-throughput screening and automated synthesis technologies, such as combinatorial chemistry and parallel synthesis, has begun to relieve one apparent bottleneck involving screening, synthesis and purification of compounds in the library. While these technologies facilitate the mechanics of drug discovery, they address neither the unreliability of the process nor its principal inefficiency: the number of iterations required to find a lead candidate. To address these problems, a novel approach is needed that can provide information to improve the selection of each subsequent library of compounds to synthesize, potentially reducing the number of iterations. Only by improving the processes of data analysis and compound selection can a laborious, iterative procedure be forced to converge on the lead candidates with the most desirable pharmacological profiles. Current Combinatorial Chemistry and Computational Approaches and Their Limitations Combinatorial chemistry involves the rapid creation of large collections of chemical compounds for the purpose of identifying hits through random screening. Combinatorial chemistry has made possible the synthesis of thousands or even millions of molecules in a short period of time instead of the traditional approach of synthesizing only one molecule at a time. Over the last decade, the field of combinatorial chemistry has evolved from only companies that design and synthesize molecules to include those that develop software and automation to facilitate design and synthesis. These companies tend to use highly varied approaches, including: focusing on single, pure compounds versus making mixtures; building large versus small, focused libraries; automating part versus all of the process; and using or not using medicinal chemistry as a principal guiding force. 27 29 Computational methods are also employed in drug discovery. These methods involve the use of computer-based and information technologies to manage large chemical databases, to examine X-ray crystal structures of the target when available (structure-based drug design), to operate the assorted automated devices available for the synthesis of libraries, to determine how changes in the structure affect the activity of a molecule (SAR activity) and to generate "virtual libraries" using chemical building blocks from readily available sources. Currently, the dominant method of pursuing drug discovery focuses on screening large libraries to search for a lead candidate directly in the library, or at least a hit, which can then be optimized by the more traditional techniques of medicinal chemistry to generate a development candidate. The Company believes this brute-force, trial-and-error approach is flawed because limited or no information has been factored into the library design to force the iterative drug discovery process to converge. This limitation in current combinatorial chemistry approaches is underscored by the fact that most compound libraries used for screening have been constructed with the sole objective of isolating a development candidate with the highest binding affinity to a target. In order to achieve this objective against all possible targets, it is believed such libraries would have to contain in excess of 100 million compounds, which size is well beyond current synthesis capabilities. In addition, the challenge of drug discovery is not only to find a lead candidate that exhibits activity against a biological target. It is also important to ensure that the lead candidate will have characteristics that will enable it to overcome the more difficult in vivo hurdles of toxicity, metabolism or problems with oral administration, none of which will become evident until early preclinical testing. Unless information can be extracted about which characteristics are most necessary for binding, it is difficult to know how to modify a compound to maintain tight binding affinity while overcoming in vivo hurdles. Furthermore, if no hits are found after the screening of a traditional combinatorial library, a scientist has no starting point for the drug discovery process. While both combinatorial chemistry and computational approaches are useful in drug discovery to some degree, they are severely taxed by the complexity of properly using the information available for library design, as evidenced by the following drawbacks: (i) the inability to derive and integrate information both from compounds that are active and those that are inactive against the target; (ii) the inability to probe the target in order to compute ways of improving the predictive models or hypotheses; and (iii) the inability to handle the dual requirements of speed and quality when large data sets must be analyzed. The Company believes that these inabilities to use information efficiently constitute fundamental reasons that current discovery approaches have been only moderately successful in generating lead candidates and development candidates, despite the large number of initial hits. COMBICHEM'S SOLUTION AND ADVANTAGES The Company believes that it offers a solution to drug discovery by combining its proprietary design technology and rapid synthesis capabilities in a unique way. The Company's convergent, iterative process for drug discovery -- its Discovery Engine (see the following diagram) -- is based on libraries designed for information. The design of libraries for information involves the selection of compounds that collectively probe the biological target in a systematic way to determine the chemical characteristics required for binding to such target. By identifying features that discriminate between active and inactive compounds, the computer constructs predictive models, called hypotheses, and then uses those models to select a more focused library of compounds. The computer selects compounds from the Company's proprietary Virtual Library, a computational representation of more than 1 trillion drug-like molecules chosen for the ease of laboratory synthesis. CombiChem believes that by repeating this process of selecting, synthesizing and screening informative compounds and analyzing the resulting data, the Discovery Engine quickly converges on the most predictive hypothesis. This hypothesis describes the characteristics a compound must possess to be active against the target and, thus, is used to select a variety of potent lead candidates. 28 30 Each cycle of the Discovery Engine refines the computer's definition of the best hypothesis for the target in question. After several cycles, the resulting hypothesis can be used to design highly potent compounds from a broad range of chemical classes including those not readily amenable to combinatorial synthesis techniques. By facilitating the design of a variety of potent compounds for preclinical testing, the Discovery Engine has the potential to increase greatly the likelihood that at least one of these compounds passes the in vivo and other downstream hurdles and eventually becomes a commercial drug. [DIAGRAM] CombiChem believes that the advantages of its Discovery Engine include the following: Generating lead candidates from multiple structural series that exhibit the same biological activity. By using predictive hypotheses to search the more than 1 trillion-molecule Virtual Library, multiple structural series of compounds that have the same effect on the target can be identified. The availability of multiple structural series increases the likelihood that at least one of these molecules will overcome the in vivo hurdles in preclinical development. In addition, this provides an opportunity for the Company and its collaborators to enhance the intellectual property position that potentially can be developed around these compounds by having more than one patentable structural series. Generating lead structures against a wide range of targets including those for which little or no information is available. The Universal Informer Library consists of a computer-designed, proprietary collection of approximately 10,000 physical compounds that can be screened against targets where little or no information is available about the molecular structures that may be active against those targets. Once the Universal Informer Library has been screened, the information obtained can be used to start the Discovery Engine process. In addition, because the technology is not dependent on having prior knowledge about the target (e.g., an X-ray crystal structure representative of the target), it can 29 31 potentially be used to discover drugs against any target the activity of which could be modified through binding a small molecule. Achieving rapid generation, evolution and optimization of lead candidates. By combining flexible design technology and rapid synthesis, the Company's Discovery Engine can produce lead candidates for any of the three types of drug discovery programs -- lead generation, lead evolution or lead optimization -- with less than two years of effort. See "CombiChem's Discovery Programs." Reducing synthesis and screening costs. The Company's design technology facilitates the use of small, informative libraries. Use of these small libraries decreases the costs associated with synthesis and screening. In addition, the Virtual Library of drug-like molecules has been explicitly constructed for the ease of laboratory synthesis. STRATEGY The Company's objective is to be the industry leader in the generation, evolution and optimization of novel lead candidates. The Company intends to utilize its scientific and technology assets in the discovery process through a mix of collaborative and internal programs by applying the following business strategies: To establish multiple collaborations with large pharmaceutical and biotechnology companies focused on biological targets chosen by the collaborators. The Company intends to collaborate with large pharmaceutical and biotechnology companies on fully funded programs aimed at biological targets chosen by these collaborators. The Company's collaborative efforts are exclusively focused on the discovery process, with a particular emphasis on the discovery of novel compounds against biological targets. The Company believes its technology platform provides it with opportunities to establish multiple collaborations, which may be for the same disease state, thereby building a portfolio of opportunities that may include project initiation fees, research support, milestone payments and royalties. To partner with companies to apply discovery technologies to jointly agreed-upon biological targets. In addition to collaborations on designated biological targets, the Company intends to establish arrangements for jointly funded discovery programs aimed at jointly agreed-upon biological targets, typically with biotechnology companies. In these arrangements, the Company and its partner will choose an appropriate biological target, the Company will apply its discovery technologies to develop novel compounds against the specific target, and the partner will fully fund and complete the drug development process. The Company and its partner will share in the economic interest resulting from their efforts. To conduct internal discovery efforts aimed at selected biological targets, retaining a larger economic interest in the subsequently outlicensed lead candidates. The Company also intends to conduct its own internally funded discovery programs by choosing biological targets of current scientific interest and working in collaboration with genomics, biotechnology or screening companies. After identifying lead candidates that are ready for development, the Company intends to outlicense them, retaining a larger economic interest in such candidates as they are developed and commercialized by a third party. To expand collaborative opportunities in alternative industries such as the agrochemical field. The Company has initially targeted large pharmaceutical and biotechnology companies in its marketing efforts. The Company is considering additional opportunities in alternative industries, including the agrochemical field. To maintain technology leadership in both software development and rapid synthesis capabilities. The Company intends to continue to extend its technology leadership through enhancements of existing software, design of future generations of software and continued advancements of its synthesis capabilities. The Company believes that these developments will allow it to decrease the time required to discover lead candidates and to maintain its technology leadership and competitive advantage. 30 32 COMBICHEM'S PROCESS: THE DISCOVERY ENGINE The successful implementation of the Company's Discovery Engine process requires the direct involvement of and interaction between its chemists and its software applications team. This process consists of the following steps: Data analysis -- the compilation and analysis of screening data, literature information and available data about the target. The starting point for a drug discovery program varies depending on the amount of prior information that is available. The collaborator may have tested its corporate collection of compounds or some other chemical library and have information regarding structures of compounds that are initial hits (moderately active compounds), information regarding structures that are inactive against the particular target or prior information about the target structure itself. On the other hand, if little or no prior information or screening data is available on the initial hits or target, the Company will make available for screening its proprietary Universal Informer Library as a way of generating a relevant set of information with which to initiate the Discovery Engine. See "CombiChem's Proprietary Technologies -- Universal Informer Library." The analysis of the available information is a critical step in the process because it will determine what type of program will be undertaken -- lead generation, lead evolution or lead optimization -- and the resources that will be required. See "CombiChem's Discovery Programs." Hypothesis generation -- the software-based generation of models that predict the biological activity of molecular structures. Once the analysis of the available data is completed by the Company's chemists and software applications team, the information is used as input for hypothesis generation, the first step of which involves conformational analysis. - Conformational analysis. Conformational analysis is performed on each active and inactive molecule to determine which shapes or conformations such molecules can take. Because it is typically unknown which of these shapes a particular molecule will assume when it shows its greatest activity against a biological target, all reasonable conformations are computationally described and analyzed. The Company's proprietary technology allows for the analysis of large data sets and complex molecular structures to be completed with both quality and speed. - Hypothesis generator. Using the screening data and the results of conformational analysis, the hypothesis generation software produces computational models (called hypotheses) that attempt to explain the observed differences in biological activity between active and inactive molecules. In the early phases of a discovery program, the hypothesis generator will often generate many hypotheses that are consistent with the data, but the repeated application of the Discovery Engine systematically tests the hypotheses, eliminating some while strengthening others by providing supporting data. Repeating this procedure quickly results in predictive hypotheses. The Company believes that its proprietary design technology differs from others currently in use in that it (i) includes all of the screening data (including inactives) in generating hypotheses, (ii) takes into account a much broader characterization of molecule-target interaction and (iii) forces convergence to a predictive model of the important binding features by probing the target systematically using rapid synthesis and screening. Virtual Library search -- the computational search of the Virtual Library to find molecular structures that fit the hypotheses. Once the hypotheses have been generated, they are used to search the Company's proprietary Virtual Library to identify molecular structures that have the features represented in the hypotheses. The Virtual Library is a computational representation of more than 1 trillion drug-like molecules chosen for the ease of laboratory synthesis. For each hypothesis that is generated, a more focused library of tens to hundreds of molecules from the Virtual Library will be chosen by the computer for synthesis in the laboratory. The Virtual Library is generated and searched by proprietary design technology, which can exploit much larger libraries than is possible with commercially available tools. See "CombiChem's Proprietary Technologies -- Virtual Library." 31 33 Library synthesis -- the laboratory synthesis of molecular structures that are selected from the Virtual Library using a wide range of chemistries. Once the more focused library of compounds is designed, using molecules chosen from the Virtual Library, the Company's chemists are responsible for synthesizing the compounds in the laboratory. Unlike many combinatorial chemistry groups, the chemists are not restricted to particular chemical reactions or a limited list of structural templates, thus providing maximum flexibility to synthesize the libraries quickly. See "CombiChem's Proprietary Technologies -- Synthesis and Analytical Chemistry Technology." The above four steps in the Discovery Engine process are completed by project teams within the Company. Once the molecules are synthesized, those libraries are then sent to the partner (or a contract group) for screening. Data from these assays will be available to the Company for the next iteration of the cycle. With each such iteration, the Discovery Engine provides more information, improving the hypotheses and increasing the likelihood of discovering active molecules with desirable pharmacological characteristics. Eventually, the hypotheses will converge to provide lead compounds that warrant further testing as development candidates. It currently takes the Company's scientists approximately three months to advance through the steps in one Discovery Engine cycle. Depending upon the information available to start a project, it may take two to four iterations of the cycle to generate strongly predictive hypotheses that may eventually yield novel and highly active lead candidates. The Company's Discovery Engine process is being validated by both its active collaborative programs and retrospective analysis of drug discovery examples taken from the recent scientific literature. In one such example, the Company applied its design technology to a project where the data provided was a compilation of third-party research into the design of HIV protease inhibitors. The objective was to determine whether CombiChem's process could be used to discover novel inhibitors for the enzyme given a collection of only weakly active hits from screening. The Company generated hypotheses with distinct features by collecting information on eight weakly active HIV protease inhibitors and 500 randomly selected inactive molecules with the same drug-like characteristics as the weakly active compounds. Each of these weakly active compounds was found by either an academic or commercial team in the early phases of trying to discover an HIV protease drug. To assess whether the generated hypotheses are, in fact, able to predict the activities of new molecules, several highly potent HIV protease inhibitors, including currently marketed drugs, were added to a virtual library of several hundred inactive compounds. Using the hypotheses, the computer searched the Virtual Library, and the search produced a list of highly ranked protease inhibitors with a variety of chemical structures, including some of the highly potent HIV protease inhibitors currently under development or marketed by major pharmaceutical companies. The structures selected from the Virtual Library differ significantly from those used to develop the hypotheses, validating the Company's capabilities in lead evolution. The Company has similarly validated its technology on over a dozen other literature data sets and on several programs with collaborators. In one lead evolution program with a collaborator, for example, the Company has already been successful in evolving from one structural series to multiple, novel structural series while improving the biological activity. These results and a variety of equally successful applications of the Discovery Engine demonstrate the viability of the Company's computational drug discovery methods and the strength of its proprietary technology. COMBICHEM'S PROPRIETARY TECHNOLOGIES To implement its Discovery Engine process, CombiChem has developed and assembled an integrated set of proprietary technologies. These include the following: Universal Informer Library The use of many traditional drug discovery approaches presupposes the existence of prior information to start the process. However, recent efforts such as the Human Genome Project and others are producing a number of novel targets about which there is limited prior information. In addition, there are many known targets for which no suitable leads have been identified. To address 32 34 these situations, CombiChem completed development of a Universal Informer Library ("UIL") in mid-1997. The UIL consists of a computer-designed, proprietary collection of approximately 10,000 physical compounds. Unlike other libraries that are used to identify lead structures directly after screening, the UIL is used to gather information concerning the relevant binding features that are important to the target. The compounds in the UIL are highly promiscuous molecules, which are molecules with the potential to bind to many different targets. Screening against the UIL is therefore intended to provide a few, weakly active compounds against the background of many, varied inactive compounds. Using this data, hypotheses may be extracted, which allow the Discovery Engine to be initiated. The UIL was designed to provide hits for virtually all possible targets, but if there is some reason to expect certain structural features to be relevant to a particular target, the UIL can be augmented with compounds that contain those features. In this way, information gained from prior experience can be incorporated into the UIL; this may improve the hypotheses and therefore reduce the number of cycles required to converge. The Company completed validation of its UIL approach by screening a subset of the UIL against a wide range of targets and achieving an outcome comparable to that typically seen in the pharmaceutical industry with libraries containing hundreds of thousands of compounds. Virtual Library CombiChem's Virtual Library is a computational representation of more than 1 trillion drug-like molecules chosen for the ease with which they can be synthesized in the laboratory. To maximize the likelihood that the Virtual Library will contain potent, patentable compounds active against most targets, the Company has populated it with hundreds of novel structural templates, each of which has two to four sites at which a wide variety of structural changes can be made synthetically using available chemicals. This chemistry can also be scaled up to give ready access to quantities of each lead candidate sufficient to perform early preclinical testing. The Virtual Library is generated and searched by two components of the Company's proprietary software: Virtual Library Cascader(TM) software and Virtual Library Search software. See "-- Design Technology." Synthesis and Analytical Chemistry Technology Once the Virtual Library is searched for collections of molecules that match the hypotheses, the Company's chemists initiate synthesis of these molecules in the laboratory. The challenge for CombiChem's chemists is to select the technique that will most quickly achieve the synthesis of the library. While there is considerable debate throughout the industry about the relative merits of various methods of chemical synthesis (solid versus solution phase, for example), CombiChem's chemists have the flexibility to use the appropriate approach for each specific synthesis task. The Company believes it has expertise in most or all of the readily used techniques and, in addition, has access to a number of new proprietary methods. As long as relatively straightforward chemistry is applied to library production, synthesis is generally not the rate-limiting step. The challenge lies in the isolation and purification of the library compounds. The Company applies several approaches, including a number of proprietary semi-automated techniques, to facilitate these procedures in order to achieve its purity standards of greater than 85%. Design Technology The Company relies on its proprietary design technology in order to complete several of the key steps in its Discovery Engine. The proprietary design technology includes: Conformational analysis software -- a computer program for identifying the distinct three-dimensional shapes of a molecule. Conformational analysis is performed on each active and inactive molecule to determine which shapes or conformations such molecules can take. Because it is typically unknown 33 35 which of these shapes a particular molecule will assume when it shows its greatest activity against a biological target, all reasonable conformations are computationally described and analyzed. The Company has developed proprietary conformational analysis software, which rapidly determines all the distinct, reasonable shapes each molecule can assume. Both the speed and the thoroughness of the conformational analysis software distinguish it from commercial chemistry software and permit the Discovery Engine to handle large data sets. Hypothesis generation software -- a computer program for analyzing screening data to identify the requirements a potential drug must satisfy to bind to this target. Once conformational analysis has been applied to each of the screened molecules, the Company's proprietary hypothesis generation software produces computational models that can estimate the biological activity of chemical structures. These models, called hypotheses, are generated by applying methods from statistics, information theory, physical chemistry and computer science to the screening data in order to identify the differences between active compounds and inactive compounds. The predictive capabilities of the computational models and the novel algorithms used to produce them distinguish the Company's hypothesis generator from commercial chemistry software. Virtual Library Cascader software -- a computer program for conveniently describing virtual libraries. The Cascader software facilitates the rapid specification of virtual libraries to the computer. By providing databases of reagents and descriptions of reactions to the Cascader, a chemist can quickly describe large libraries of compounds to the computer. The Cascader can use the resulting description to construct explicit subsets of the large virtual library and to present the structures to the chemist and to the Virtual Library Search software. Virtual Library Search software -- a computer program for selecting molecules from the Virtual Library that, when synthesized and screened, will provide the most information about additional binding requirements. The Virtual Library search software uses hypotheses to estimate computationally the potency of prospective compounds in order to increase the likelihood that the chemists devote their synthesis efforts to compounds that fit the hypotheses and are thus most likely to bind to the target. By using the computer to test the compounds in the Virtual Library against the hypotheses, the Discovery Engine can rapidly identify both putatively active compounds (which satisfy several different hypotheses) and informative ones (which discriminate among hypotheses). Searching virtual libraries with billions of compounds has generally not been possible with commercial chemistry software. Each cycle of the Discovery Engine refines the computer's assessment of the best hypothesis for the target in question. After several cycles, the resulting hypothesis can be used to design highly potent compounds from a broad range of chemical classes including those not readily amenable to combinatorial synthesis techniques. By facilitating the design of a variety of potent compounds for preclinical testing, the Discovery Engine has the potential to increase greatly the likelihood that at least one of these compounds passes the in vivo and other downstream hurdles and eventually becomes a commercial drug. COMBICHEM'S DISCOVERY PROGRAMS The Company has applied, and intends to continue to apply, its technology to discover lead compounds for biological targets chosen by its collaborators. In addition, the Company will select, either jointly with a partner (most likely a biotechnology company) or on its own, a biological target of interest. In the first instance, where the Company is working on a target chosen by a collaborator, the commercial terms are negotiated based on a number of factors, including the number of targets to be included in the collaboration and the type of program -- lead generation, lead evolution or lead optimization. Depending upon the type of program, CombiChem will work on the program for a period of one to two years. A dedicated project team, funded by the collaborator, consisting of applications scientists and synthetic, medicinal and analytical chemists will be assigned. The team composition and size is dependent upon the type of program and its objectives. To ensure confidential- 34 36 ity, the Company provides target exclusivity to each of its collaborators, and each team works in a dedicated laboratory. At the conclusion of the program, assuming its objectives have been met, the program team will transfer the lead structure(s) to the collaborator. At this point, the work at CombiChem will be completed, but the partner will continue to develop the lead candidate. As the collaborator develops the lead candidate and reaches certain agreed-to objectives, the Company will receive milestone payments. Eventually, when the lead candidate becomes a marketed drug, the Company will receive royalties on the sales of the drug. In the jointly funded programs or the internal programs, the Company will pay for all or part of the work to be completed and, either jointly or on its own, will outlicense the lead structures to a partner for the development and commercialization phases. Depending upon the data available, the Discovery Engine can be applied to three types of discovery programs undertaken by the Company: lead generation, lead evolution and lead optimization. Lead generation uses the UIL to generate information for the Discovery Engine in situations where little or no prior information is known about the target. Lead evolution begins with existing information (either from the collaborator or from the scientific literature) regarding a lead candidate with the objective of identifying different structural series that can provide either other development options or an enhanced patent position. The evolution path may be chosen either as an outgrowth of a lead optimization program or directly from a collaborator's established lead candidate series. Lead optimization involves a lead candidate provided by a collaborator that requires improvement prior to being identified as a drug development candidate. Using CombiChem's computational drug discovery approach, initial libraries are constructed around a given template. Using a convergent, iterative process, subsequent libraries are increasingly focused as increased activity (e.g., affinity, selectivity) is achieved. Current Collaborative Discovery Programs The Company's current collaborative discovery programs are as follows:
- ---------------------------------------------------------------------------------------------- COMPANY NAME TARGET OR THERAPEUTIC AREA OF FOCUS TYPE OF PROGRAM - ---------------------------------------------------------------------------------------------- Teijin G-protein coupled receptor Lead evolution(1) Roche Bioscience Protein-Protein interaction Lead optimization Enzyme Lead evolution Receptor Lead optimization Sumitomo Target implicated in osteoarthritis Lead evolution and rheumatoid arthritis ImClone Multiple targets in oncology Lead generation, lead evolution Elan/Athena Multiple targets in central nervous Lead generation, lead evolution, system conditions lead optimization ICOS Identified, undisclosed target Lead evolution - ----------------------------------------------------------------------------------------------
(1) Started as a lead optimization program. Internal Discovery Programs The Company intends to conduct its own internally funded discovery programs by choosing biological targets of current scientific interest and working in collaboration with genomics, biotechnology or screening companies. After identifying lead candidates that are ready for development, the Company intends to outlicense them, retaining a larger economic interest in such candidates as they are developed and commercialized by a third party. 35 37 COMBICHEM'S COLLABORATIVE ARRANGEMENTS The Company's business model is to enter into collaborative arrangements focused on drug discovery efforts to improve the Company's chances of achieving profitability and to minimize its financing requirements. Commercial terms of a collaborative arrangement are driven by the number and nature of the targets. The key components of the commercial terms typically contained in the Company's collaborations include project initiation fees, research funding, milestone payments and royalties. The Company has the following completed or active collaborative arrangements: Teijin Limited In March 1996, the Company entered into a collaborative agreement with Teijin providing for a one-year research program on a G-protein coupled receptor target. In March 1997, the Company and Teijin amended their agreement to extend the research phase of the collaborative agreement for an additional year. While the initial focus of the collaboration was lead optimization, the effort was redirected to lead evolution during the course of the research. Under the agreement, Teijin paid a project initiation fee to CombiChem and agreed to provide research funding and milestone payments upon the achievement of certain preclinical and clinical milestones. Teijin also committed internal resources to the discovery effort. Teijin will make royalty payments on products resulting from the collaboration. CombiChem retains the rights to the compounds arising under this collaboration in North and South America; Teijin has rights to these compounds in Asia and Europe with a right of first negotiation to acquire CombiChem's rights. Under the original agreement, either party may terminate the agreement in the event of a material breach remaining uncured for 60 days. As of March 31, 1998, the Company has successfully concluded its research phase and delivered lead candidates to Teijin for further development. As this development process continues, Teijin will make additional payments if certain milestones are met. Roche Bioscience, a division of Syntex (U.S.A.) Inc. In October 1996, the Company entered into a collaborative agreement with Roche Bioscience providing for a broad two-year research program to perform research against three initial targets, including a protein-protein interaction, an enzyme and a receptor, with an option to add additional targets. Roche Bioscience can elect one of the approaches -- lead generation, lead evolution or lead optimization -- for each research program against each collaboration target. A program may be initiated at any time during the term of the collaboration, thereby extending the term to allow for completion of each program. Under the agreement, Roche Bioscience paid a project initiation fee to CombiChem and agreed to provide research funding and to make milestone payments upon the achievement of certain preclinical and clinical milestones. Roche Bioscience will make royalty payments on worldwide sales of products resulting from the collaboration. Upon completion of the first year of the agreement, Roche Bioscience may terminate the collaboration at any time upon six months' prior written notice. Certain special conditions could also allow Roche Bioscience to terminate with 45 days' prior written notice. In March 1998, the Company achieved a research milestone in its collaboration with Roche Bioscience triggering a cash milestone payment. This stems from the identification, in less than one year, of novel drug development candidates for a potential new treatment for respiratory disease. Sumitomo Pharmaceuticals Co., Ltd. In August 1997, the Company entered into a collaborative agreement with Sumitomo providing for a two-year lead evolution program on a target that is believed to play a fundamental role in osteoarthritis and rheumatoid arthritis. Under the agreement, Sumitomo paid a project initiation fee and agreed to provide research funding and milestone payments upon the achievement of certain preclinical and clinical milestones. Sumitomo will make royalty payments on worldwide sales of products resulting from the collaboration. Sumitomo may extend the research period for up to four 36 38 successive six-month periods upon mutual agreement. The agreement may be terminated by either party 90 days following an uncured material breach. ImClone Systems Incorporated In October 1997, the Company entered into a collaborative agreement with ImClone providing for a two-year research program to identify and characterize novel small molecule inhibitors to multiple targets for development in oncology. The agreement provides for ImClone's access to the Company's Universal Informer Library and Virtual Library under the supervision of the research management committee composed of representatives of the Company and ImClone. Under the terms of the agreement, ImClone will provide the Company with research support payments, milestone payments upon the achievement of certain program objectives and royalties on worldwide product sales of therapeutic products that may arise out of the collaboration. The agreement may be terminated by either party 90 days following an uncured material breach or by ImClone within 30 days prior to the one-year anniversary by providing 90 days' prior written notice. In connection with the collaborative agreement, ImClone purchased 250,000 shares of Common Stock for $2.0 million. Athena Neurosciences, Inc., a wholly owned subsidiary of Elan Corporation, plc In October 1997, the Company entered into a multiple project collaborative agreement with Athena Neurosciences, Inc., a wholly owned subsidiary of Elan Corporation, plc providing for a three-year research program to discover novel therapeutic compounds for treatment of central nervous system conditions. The first project was initiated upon signing of this collaboration agreement, with a second project authorized in March 1998, for which Elan/Athena has agreed to provide additional research funding. The agreement provides for Elan/Athena's access to the Universal Informer Library as deemed necessary by the research management committee composed of Elan/Athena and CombiChem representatives. Under the agreement, Elan/Athena paid a project initiation fee and agreed to provide research funding and milestone payments upon the achievement of pre-determined objectives. Elan/Athena will also make royalty payments on worldwide sales of products resulting from the collaboration. The agreement may be terminated by either party 90 days following an uncured material breach or by Elan/Athena after the one-year anniversary upon 90 days prior written notice. Additionally, in March 1998, Elan/Athena purchased an option for an undisclosed fee creditable against future project initiation fees, if any, covering an additional target (for a potential future project) not previously covered by the initial collaborative agreement. In connection with the initial collaborative agreement, Elan International Services Ltd., an affiliate of Elan/Athena, purchased 1,000,000 shares of Common Stock for $8.0 million. In addition, Elan International Services Ltd., a stockholder of CombiChem, and a wholly owned subsidiary of Elan Corporation, plc (whose wholly owned subsidiary, Athena Neurosciences, Inc. is a collaborative partner of CombiChem), has expressed an interest in acquiring approximately $2 million of the shares of Common Stock offered hereby at the initial public offering price. ICOS Corporation In March 1998, the Company entered into a collaborative agreement with ICOS providing for a lead evolution project on an identified, undisclosed target. Under the agreement, ICOS receives exclusive global rights to develop and market any products resulting from the collaboration. ICOS agreed to pay CombiChem an advance payment of approximately $0.4 million due in April 1998, research funding, payments upon achievement of certain clinical milestones and royalty payments on any product sales. The advance payment has been recorded as deferred revenue and will be recognized when the Company's performance obligations have been met. The lead evolution project terminates on August 31, 2000. The agreement may be terminated by either party 90 days following an uncured material breach. RESEARCH AND DEVELOPMENT The Company's expenses for Company-sponsored research and development activities for the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1998 and 1997 were 37 39 $4.8 million, $4.8 million, $4.4 million, $1.3 million and $1.2 million, respectively. The Company's expenses for collaborator-sponsored research and development activities for the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1998 and 1997 were $0, $0.4 million, $4.3 million, $1.9 million and $0.1 million, respectively. COMPETITION Many organizations are actively attempting to identify, optimize and generate lead compounds for potential pharmaceutical development. The Company competes with the research departments of pharmaceutical companies, biotechnology companies, combinatorial chemistry companies and research and academic institutions as well as other computationally based drug discovery companies. Many of these competitors have greater financial and human resources and more experience in research and development than the Company. Historically, large pharmaceutical companies have maintained close control over their research activities, including the synthesis, screening and optimization of chemical compounds. Many of these companies, which represent one of the largest potential markets for CombiChem's products and services, are internally developing combinatorial and computational approaches and other methodologies to improve productivity, including major investments in robotics technology to permit the automated parallel synthesis of compounds. In addition, these companies may already have large collections of compounds previously synthesized or ordered from chemical supply catalogs or other sources against which they may screen new targets. Other sources of compounds include compounds extracted from natural products, such as plants and microorganisms, and compounds created using rational drug design. Academic institutions, governmental agencies and other research organizations are also conducting research in areas in which the Company is working, either on their own or through collaborative efforts. The Company anticipates that it will face increased competition in the future as new companies enter the market and advanced technologies become available. The Company's processes may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of the Company's competitors. The existing approaches of the Company's competitors or new approaches or technology developed by the Company's competitors may be more effective than those developed by the Company. PATENTS AND PROPRIETARY INFORMATION The Company's success will depend in large part on its own, its licensees' and its licensors' ability to obtain and defend patents for each party's respective technologies and the compounds and other products, if any, resulting from the application of such technologies, maintain trade secrets and operate without infringing upon the proprietary rights of others, both in the United States and in foreign countries. The patent positions of pharmaceutical and biotechnology companies, including the Company, are uncertain and involve complex legal and factual questions for which important legal principles are largely unresolved. The Company has pending United States and foreign patent applications relating to various aspects of its technology, certain systems, materials and methods used in screening compounds and the libraries or compounds contained therein. These patent applications are either owned or co-owned by the Company or rights under them are licensed to the Company. To date, one foreign patent owned by the Company has issued and notices of allowance for two United States patent applications owned by the Company have been received. To the extent that any foreign patent application filed in the European Patent Office or the Japanese Patent Office issues as a patent, a challenge to the validity of such patent may be presented in an opposition proceeding. There can be no assurance that patents will issue as a result of any such pending applications or that, if issued, such patents will be sufficiently broad to afford protection against competitors with similar technologies. The Company is aware of three United States patents issued to a third party that claim proprietary rights; two of the three patents are entitled "System and method for automatically generating chemical compounds with desired properties" and the third is entitled "System, method, and computer program for at least partially automatically generating chemical compounds having desired properties." Although the Company believes that its current activities do not infringe these patents, there can be 38 40 no assurance that the Company's belief would be affirmed in any litigation over the patents or that the Company's future technological developments would be outside the scope of these patents. Further, there can be no assurance that the third party will not seek to assert such patent rights against the Company, which would result in significant legal costs and require substantial management resources, and there can be no assurance that the Company would be able to obtain a license from the third party, if required, on commercially reasonable terms, if at all. The inability of the Company either to demonstrate non-infringement of these and other current and future patents, whether issued in the United States or overseas, or to obtain the appropriate licenses, would have a material adverse effect on the Company's business, financial condition and operations. Moreover, there can be no assurance that the Company or its customers will be able to obtain patent protection for lead compounds or pharmaceutical products based upon the Company's or such customers' technologies. There can be no assurance that any patents issued to the Company or its collaborative partners, or for which the Company has license rights, will not be challenged, invalidated or circumvented, or that the rights granted thereunder will provide competitive advantages to the Company. To the extent that the Company or its consultants or collaborators use intellectual property owned by others in their work for the Company, disputes may also arise as to the rights in related or resulting know-how and inventions. Litigation may be necessary to enforce the Company's patent and license rights or to determine the scope and validity of others' proprietary rights. Any such litigation, whether or not the outcome thereof is favorable to the Company, could result in substantial cost to and diversion of effort by the Company. Further, United States patents do not provide any remedies for infringement that occurred before the patent is issued. The commercial success of the Company will also depend upon successfully avoiding the infringement of current and future patents issued to competitors and upon maintaining the technology licenses upon which certain of the Company's current products are, or any future products under development might be, based. If competitors of the Company prepare and file patent applications in the United States that claim inventions also claimed by the Company or its collaborators, the Company or its collaborators may have to participate in interference proceedings declared by the PTO to determine the priority of invention, which could result in substantial cost to the Company, even if the outcome is favorable to the Company. An adverse outcome could subject the Company to significant liabilities to third parties and require the Company to license disputed rights from third parties or cease using the technology. From time to time the Company receives invitations from third parties to license patents owned or controlled by third parties. The Company evaluates these requests and intends to obtain licenses that are compatible with its business objectives. There can be no assurance, however, that the Company will be able to obtain any licenses on acceptable terms, if at all. The Company's inability to obtain or maintain patent protection or necessary licenses could have a material adverse effect on the business, financial condition and results of operations of the Company. A United States patent application is maintained under conditions of confidentiality while the application is pending in the PTO, so that the Company cannot determine the inventions being claimed in pending patent applications filed by its competitors in the PTO. A number of pharmaceutical and biotechnology companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to the Company's business. Some of these technologies, applications or patents may conflict with the Company's technologies or patent applications. Such conflict could limit the scope of the patents, if any, that the Company may be able to obtain, or result in the denial of the Company's patent applications. In addition, there can be no assurance that the Company would be able to obtain licenses to patents held by third parties that may cover the Company's activities at a reasonable cost, if at all, or that the Company would be able to develop or obtain any alternative technologies. The Company currently has certain licenses from third parties and in the future may require additional licenses from other parties in order to refine its Discovery Engine further and to allow its collaborators to develop, manufacture and market commercially viable products effectively. There can be no assurance that (i) such licenses will be obtainable on commercially reasonable terms, if at all, (ii) any patents underlying such licenses will be valid and enforceable or (iii) the proprietary nature of any patented 39 41 technology underlying such licenses will remain proprietary. The Company relies substantially on certain technologies that are not patentable or proprietary and are therefore available to the Company's competitors. The Company also relies on certain proprietary trade secrets and know-how that are not patentable. Although the Company has taken steps to protect its unpatented trade secrets and know-how, in part through the use of confidentiality agreements with its employees, consultants and certain of its contractors, there can be no assurance that (i) these agreements will not be breached, (ii) the Company would have adequate remedies for any breach or (iii) the Company's trade secrets will not otherwise become known or be independently developed or discovered by competitors. Failure by the Company to protect all or part of its patents, trade secrets and know-how could have a material adverse effect on the Company's business, financial condition and results of operations. GOVERNMENT REGULATION Regulation by governmental entities in the United States and other countries will be a significant factor in the production and marketing of any pharmaceutical products that may be developed by a customer or collaborator of the Company or, in the event the Company decides to develop a drug beyond the preclinical phase, by the Company. The nature and the extent to which such regulation may apply to the Company's customers will vary depending on the nature of any such pharmaceutical products. Virtually all pharmaceutical products developed by the Company's customers will require regulatory approval by governmental agencies prior to commercialization. In particular, human pharmaceutical therapeutic products are subject to rigorous preclinical and clinical testing and other approval procedures established by the FDA and by foreign regulatory authorities. Various federal and, in some cases, state statutes and regulations also govern or influence, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of such products. Non-compliance with applicable requirements can result in fines, warning letters, recall or seizure of products, clinical study holds or delays, total or partial suspension of production, refusal of the government to grant approvals, and civil and criminal penalties. The process of obtaining these approvals and the subsequent compliance with appropriate federal and foreign statutes and regulations are time-consuming and require the expenditure of substantial resources. Generally, in order to gain FDA approval, a company first must conduct preclinical studies in the laboratory and in animal models to gain preliminary information on a compound's efficacy and to identify any safety problems. Preclinical studies must be conducted by laboratories that comply with FDA regulations regarding Good Laboratory Practices. The results of these studies are submitted as a part of an IND that the FDA must review before human clinical trials of an investigational drug can begin. In order to commercialize any products, the Company or its customer will be required to sponsor and file an IND and will be responsible for initiating and overseeing the clinical studies to demonstrate the safety and efficacy that are necessary to obtain FDA and foreign regulatory authority approval of any such products. Clinical trials are normally done in three phases and generally take two to five years but may take longer to complete. After completion of clinical trials of a new product, FDA and foreign regulatory authority marketing approval must be obtained. If the product is classified as a new drug, the Company or its customer will be required to file an NDA and receive approval before commercial marketing of the drug. The testing and approval processes require substantial time and effort, and there can be no assurance that any approval will be granted on a timely basis, if at all. NDAs submitted to the FDA can take, on average, two to five years to obtain approval. If questions arise during the FDA review process, approval can take more than five years. Even if FDA regulatory clearances are obtained, a marketed product is still subject to continual review, and later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market, as well as possible civil or criminal sanctions. Domestic manufacturing facilities of the Company or its customers are subject to bannial inspections by the FDA and must comply with the FDA's current Good Manufacturing Practices regulations. To comply with such regulations, a manufacturer must spend funds, time and effort in the areas of production and quality control to ensure full technical 40 42 compliance. The FDA stringently applies regulatory standards for manufacturing. For marketing outside the United States, the Company or its customer will also be subject to foreign regulatory requirements governing human clinical trials and marketing approval for pharmaceutical products. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country. The research and development processes of the Company involve the controlled use of hazardous materials. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although the Company believes that its activities currently comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, the Company could be held liable for any damages that result, and any such liability could exceed the resources of the Company. In addition, there can be no assurance that the Company will not be required to incur significant costs to comply with environmental laws and regulations in the future. The occurrence of any such event could have a material adverse effect on the Company's business, financial condition and results of operations. MARKETING The Company markets its products directly to customers through participation in trade conferences and seminars and publications in scientific and trade journals. To date, the Company has sold its product offering to its collaborative partners primarily through the efforts of its senior management and dedicated business development professionals. In addition, the Company utilizes outside consultants to supplement its business development activities in targeted geographies or industries. FACILITIES The Company currently leases and occupies approximately 34,000 square feet of laboratory and office space in San Diego, California. The Company also leases and occupies approximately 6,000 square feet of office space in Palo Alto, California. The San Diego lease expires in May 2006; the Palo Alto lease expires in October 2002. EMPLOYEES As of March 31, 1998, the Company had 73 full-time employees, 44 of whom have Ph.D. degrees. Of these employees, 59 were engaged in research and development and 14 were engaged in marketing and general administration. None of the Company's employees is covered by collective bargaining agreements. Management considers its relations with its employees to be good. LEGAL PROCEEDINGS The Company is not a party to any legal proceedings. SCIENTIFIC ADVISORY BOARD The Company has formed a Scientific Advisory Board ("SAB"), which consists of eight individuals with demonstrated expertise in the fields of molecular biology, medicinal and synthetic chemistry, computer science and biochemistry. Members of the SAB review the Company's research, development and operations activities and are available for consultation with the Company's management and staff relating to their respective areas of expertise. The SAB holds regular meetings. The Scientific Advisors are reimbursed for their expenses in connection with their service and are paid for attending meetings. In addition, the Scientific Advisors either hold options to purchase Common Stock or own varying amounts of Common Stock of the Company that were purchased pursuant to their individual consulting agreements with the Company. The Scientific Advisors are expected to devote only a small portion of their time to the business of the Company. 41 43 The Scientific Advisors are all employed by or have consulting agreements with entities other than the Company. Each Scientific Advisor has entered into a consulting agreement with the Company that contains confidentiality and nondisclosure provisions that prohibit the disclosure of confidential information to anyone outside the Company. Also, the consulting agreements contain exclusivity provisions restricting the Scientific Advisors from providing services to or investing in any competitor of the Company without the Company's consent. All inventions, discoveries or other intellectual property that comes to the attention of each Scientific Advisor while performing services under a consulting agreement with the Company will be assigned to the Company. The current members of the SAB are as follows: Sydney Brenner, Ph.D. Dr. Brenner is the President and Director of Science at The Molecular Sciences Institute, Inc. This follows an academic career at the University of Cambridge, UK, where he pioneered many of the developments in modern biology and molecular biology. Dennis Curran, Ph.D. Dr. Curran is the Distinguished Service Professor of Chemistry and the Bayer Professor of Chemistry at The University of Pittsburgh. His research focus is fluorous chemistry. Samuel J. Danishefsky, Ph.D. Dr. Danishefsky holds a Chair in Chemistry at Columbia University and the Kettering Chair at The Sloan-Kettering Institute for Cancer Research. Following the award of his Ph.D. by Harvard University in 1962, he has had a distinguished career in synthetic and medicinal chemistry. Kim Janda, Ph.D. Dr. Janda is the Ely R. Callaway, Jr., Professor of Chemistry at The Scripps Research Institute ("TSRI"), Department of Chemistry and holds a joint appointment with The Skaggs Institute for Chemical Biology at TSRI. Dr. Janda is widely recognized for his work in combinatorial chemistry and biochemistry. Dr. Janda received a B.S. in Clinical Chemistry from the University of South Florida, a M.S. in Organic Chemistry from the University of Arizona and a Ph.D. in Organic Chemistry with a minor in Medicinal Chemistry from the University of Arizona. William Jorgensen, Ph.D. Dr. Jorgensen is the Whitehead Professor of Chemistry at Yale University, where he has been since 1990. Dr. Jorgensen is widely known for his work in organic and computational chemistry. He received a B.A. in Chemistry from Princeton and a Ph.D. in Chemical Physics from Harvard University. Richard Lathrop, Ph.D. Dr. Lathrop is an Assistant Professor at the University of California, Irvine in the Department of Information and Computer Science, where he has been since July 1995. Dr. Lathrop is widely recognized for his work in the area of advanced computational techniques with applications in the domain of molecular biology. Dr. Lathrop received a B.A. in Mathematics from Reed College in Portland, and an M.S. in Computer Science and a Ph.D. in Artificial Intelligence from the Massachusetts Institute of Technology. His research interests are focused on artificial intelligence and advanced computational techniques. William Scott, Ph.D. Dr. Scott received a Ph.D. in Biochemistry in 1967 from the California Institute of Technology. His subsequent career has spanned both academia at Rockefeller University, and industry with Bristol-Myers Squibb. Dr. Scott is also a Director of the Company. See "Management -- Executive Officers, Key Employees and Directors." Chi-Huey Wong, Ph.D. Dr. Wong is a Professor and Ernest W. Hahn Chair in Chemistry at TSRI, where he has been since 1989, and holds a joint appointment with The Skaggs Institute for Chemical Biology at TSRI. Dr. Wong has published numerous papers in the area of Bioorganic and Synthetic Chemistry. Dr. Wong received a B.S. in Chemistry and Biochemistry and an M.S. in Biochemistry from National Taiwan University, received a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and was a Postdoctoral Fellow in Chemistry at Harvard University. 42 44 MANAGEMENT EXECUTIVE OFFICERS, KEY EMPLOYEES AND DIRECTORS The executive officers, key employees and directors of the Company as of February 28, 1998, are as follows:
NAME AGE POSITION ---- --- -------- Pierre R. Lamond(2)....................... 67 Chairman of the Board and Director Vicente Anido, Jr., Ph.D.................. 45 President, Chief Executive Officer and Director Peter L. Myers, Ph.D...................... 54 Vice President, Chief Scientific Officer, Chief Operating Officer and Director Karin Eastham............................. 48 Vice President, Finance and Administration and Chief Financial Officer Klaus Gubernator, Ph.D. .................. 44 Vice President, Special Projects Lee R. McCracken.......................... 40 Vice President, Business Development John Saunders, Ph.D....................... 50 Vice President, Medicinal Chemistry Steven L. Teig............................ 36 Vice President, Advanced Technology Philippe O. Chambon, M.D., Ph.D.(2)....... 39 Director Arthur Reidel(1).......................... 47 Director William Scott, Ph.D.(1)................... 57 Director
- --------------- (1) Member of Compensation Committee. (2) Member of Audit Committee. Pierre R. Lamond. Mr. Lamond has served as Chairman of the Board and a Director of the Company since May 1995. Mr. Lamond is a General Partner of Sequoia Capital, a venture capital limited partnership with over $500 million under management. Prior to joining Sequoia Capital in 1981, Mr. Lamond was a Vice President and Technical Director of National Semiconductor Corporation ("National Semiconductor") from 1976 to 1981. He began his career in 1957 at Transitron Corporation and joined Fairchild Semiconductor Company in 1961. In 1967, he was one of the co-founders of National Semiconductor where he managed the semiconductor division until 1974. From 1974 through 1975, he was President of Coherent, Inc., a laser company. He served as President of Advent, an early pioneer of projection television from 1975 through 1976. Mr. Lamond is Chairman of Cypress Semiconductor Corporation and Vitesse Semiconductor Corporation, Director of CKS Group, and a director of a number of private companies. Vicente Anido, Jr., Ph.D. Dr. Anido has served as President and Chief Executive Officer and as a Director of the Company since joining the Company in March 1996. Prior to that, Dr. Anido served as President of the Americas Region at Allergan, Inc. from June 1993, where he was responsible for that company's commercial operations for North and South America with approximately $500 million in revenue. Prior to that, Dr. Anido spent almost 18 years at Marion Laboratories and Marion Merrell Dow, Inc. and served as Vice President, Business Management of its U.S. Prescription Products Division from 1991 until June 1993. Dr. Anido holds a B.S. in Pharmacy from West Virginia University, an M.S. in Pharmaceutical Sciences from West Virginia University and a Ph.D. in Pharmacy Administration from the University of Missouri, Kansas City. Peter L. Myers, Ph.D. Dr. Myers has served as a Director, Vice President and Chief Scientific Officer of the Company since joining the Company in March 1995. Dr. Myers has also served as Chief Operating Officer of the Company since September 1995 and served as the acting Chief Executive Officer from September 1995 to March 1996. Prior to joining the Company, Dr. Myers served as Vice President, Drug Discovery and Development at Onyx Pharmaceuticals Inc. from November 1993 through March 1995, where he was responsible for all aspects of drug discovery and development 43 45 leading to potential novel classes of anti-cancer drugs. Prior to that, Dr. Myers served as Vice President, Chemistry Research of Glaxo Inc. Research Institute from January 1991 through December 1993. Dr. Myers holds a B.S. in Chemistry and a Ph.D. in Organic Chemistry from Leeds University. Karin Eastham. Ms. Eastham joined the Company as Vice President, Finance and Administration and Chief Financial Officer in April 1997. Prior to joining the Company, Ms. Eastham served as Vice President, Finance and Administration and Chief Financial Officer of Cytel Corporation, a drug research and development company, from October 1992 through April 1997. Prior to that, Ms. Eastham was Vice President, Finance and Administration of Pritsker Corporation, a simulation-based computer software company, from May 1990 through October 1992. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University. She is a Certified Public Accountant. Klaus Gubernator, Ph.D. Dr. Gubernator joined the Company in August 1997 as Vice President, Special Projects. Prior to joining the Company, he served as Research Section Head in Pharmaceutical Research at F. Hoffmann-La Roche Ltd. in Basel, Switzerland from 1987 to 1997, contributing to cardiovascular and antibacterial projects as well as developing structure-based design and bioinformatics technologies. Dr. Gubernator received his Ph.D. degree in Chemistry from the University of Heidelberg. Lee R. McCracken. Mr. McCracken has served as Vice President, Business Development since joining the Company in May 1996. Prior to joining the Company, Mr. McCracken served as Vice President, Business Development at Watson Laboratories, the operating subsidiary of Watson Pharmaceuticals, from January 1996 through May 1996. Prior to that, Mr. McCracken served as Managing Director of Pacific Pharma and as Director, Business Development, for the Americas Region at Allergan, Inc. from May 1992 through December 1995. Prior to entering the pharmaceutical industry, Mr. McCracken was a venture capitalist with 3i Capital and Union Venture Corporation. Mr. McCracken received a B.S. in Marketing from Santa Clara University, an M.S. in Computer Science from the University of Dayton and an M.B.A. from The Anderson School at UCLA. John Saunders, Ph.D. Dr. Saunders joined the Company in October 1995 as Vice President, Medicinal Chemistry. Prior to joining the Company, Dr. Saunders served as Head of Medicinal Chemistry II from August 1989 through September 1995 and also as Head of the Antiviral Research Management Committee from July 1995 through September 1995 at Glaxo-Wellcome, plc. Dr. Saunders received a first class honors degree in Chemistry from Newcastle University in England and a Ph.D. from Cambridge University. Steven L. Teig. Mr. Teig has served as Vice President, Advanced Technology since February 1997 and previously served as Vice President, Design Technology from July 1995. Prior to joining the Company, Mr. Teig co-founded BioCAD Corp., a commercial developer of drug discovery software for medicinal chemists, in June 1989 and served as its Chief Technical Officer until its merger with Molecular Simulations, Inc. ("MSI"). Thereafter, Mr. Teig served as President and Chief Technical Officer of Entropix Corporation, a subsidiary of MSI, from August 1994 through July 1995. Prior to pursuing drug discovery technology, Mr. Teig co-founded Tangent Systems Corporation, a developer of integrated circuit design software, which was subsequently acquired by Cadence Design Systems, Inc. Mr. Teig holds a B.S.E. in Electrical Engineering and Computer Science from Princeton University. Philippe O. Chambon, M.D., Ph.D. Dr. Chambon has served as a Director of the Company since August 1995. Dr. Chambon is a General Partner of the Sprout Group. He joined Sprout in May 1995. From May 1993 to April 1995, Dr. Chambon served as Manager in the Healthcare Practice of The Boston Consulting Group, a leading management consulting firm. Previously, Dr. Chambon was an executive with Sandoz Pharmaceuticals Corporation, a leading pharmaceutical company, from September 1987 to April 1993. In his last capacity there, he was the Executive Director of New Product Management. He is currently a director of Transcend Therapeutics and of several private companies. Dr. Chambon received an M.D. (with honors) and Ph.D. from the University of Paris and an M.B.A. from Columbia University. 44 46 Arthur Reidel. Mr. Reidel has served as a Director of the Company since September 1997. He currently serves as President, Chief Executive Officer and Chairman of the Board of Pharsight Corporation, a privately held software corporation, a position he has held since April 1996, and as a director from April 1995. Prior to that, he was a private investor/consultant from April 1995 to March 1996. From October 1994 to March 1995, he served as Vice President, Business Development of Viewlogic Systems, Inc., a publicly held software firm. Mr. Reidel has served as a director of MacNeil Schwendler from December 1993 and as a director of Formation Systems, Inc. from 1996 to the present. Mr. Reidel has also served as President and Chief Executive Officer, Sunrise Test Systems, Inc., a privately held software firm, from December 1992 to March 1994 (Viewlogic Systems, Inc. acquired Sunrise Test Systems, Inc. in September 1994), and Vice President of Weitek Corporation from July 1991 to December 1992. Mr. Reidel received an B.S. in mathematics from Massachusetts Institute of Technology. William Scott, Ph.D. Dr. Scott has served as a Director of the Company since January 1997. Since March 1997, Dr. Scott has served as the Chief Executive Officer of Physiome Sciences, Inc. From 1983 until December 1996, Dr. Scott served in various executive positions with Bristol-Myers Squibb Pharmaceutical Research Institute and as its Senior Vice President, Drug Discovery Research since 1991. Dr. Scott received a B.S. in Chemistry from the University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology and was an NIH Postdoctoral Fellow at The Rockefeller University. Dr. Scott serves on the Board of Directors of a private company. Members of the Board currently hold office and serve until the next annual meeting of the stockholders of the Company or until their respective successors have been elected. The Board is currently comprised of six directors. Under the Company's Bylaws, as amended, beginning with the next annual meeting of stockholders the Company's Board will be classified into three classes of directors serving staggered three-year terms, with one class of directors to be elected at each annual meeting of stockholders. The classification of directors has the effect of making it more difficult to change the composition of the Board. See "Description of Capital Stock -- Possible Anti-Takeover Effect of Certain Charter Provisions." All executive officers are appointed annually by and serve at the discretion of the Board. All of the Company's executive officers are employed by the Company at will. Pursuant to the Company's 1997 Stock Incentive Plan, which was adopted by the Board and approved by the Company's stockholders in October 1997, directors who are not officers or employees of the Company will receive periodic option grants beginning with the next annual meeting of stockholders. See "-- Benefit Plans." COMMITTEES OF THE BOARD OF DIRECTORS The Company has a standing Compensation Committee currently composed of Mr. Reidel and Dr. Scott. The Compensation Committee reviews and acts on matters relating to compensation levels and benefit plans for executive officers and key employees of the Company, including salary and stock options. The Compensation Committee is also responsible for granting stock awards, stock options and stock appreciation rights and other awards to be made under the Company's existing incentive compensation plans. The Company also has a standing Audit Committee composed of Mr. Lamond and Dr. Chambon. The Audit Committee assists in selecting the Company's independent auditors and in designating services to be performed by, and maintaining effective communication with, those auditors. 45 47 EXECUTIVE COMPENSATION Summary of Cash and Certain Other Compensation The following table sets forth the aggregate compensation earned by the Company's President and Chief Executive Officer and each of the other four most highly compensated executive officers whose salary and bonus for 1997 exceeded $100,000 (the "Named Executive Officers") for services rendered in all capacities to the Company for the years ended December 31, 1996 and 1997: SUMMARY COMPENSATION TABLE(1)
LONG-TERM COMPENSATION AWARDS ANNUAL COMPENSATION --------------- ----------------------------------- SECURITIES OTHER ANNUAL UNDERLYING ALL OTHER NAME AND PRINCIPAL POSITION YEAR SALARY(2) BONUS(3) COMPENSATION OPTIONS/SARS(#) COMPENSATION --------------------------- ---- --------- -------- ------------ --------------- ------------ Vicente Anido, Jr., Ph.D.(4).... 1997 $273,593 $58,227 $ 0 100,001 $ 0 President, Chief Executive 1996 200,417 55,226 0 422,417 0 Officer and Director Peter L. Myers, Ph.D.(5)........ 1997 225,582 42,297 0 50,001 3,855(6) Chief Scientific Officer 1996 215,250 43,050 9,983(7) 0 4,960(6) and Chief Operating Officer and Director John Saunders, Ph.D............. 1997 153,700 26,129 15,952(7) 4,192 0 Vice President, 1996 145,000 23,200 27,125(8) 0 0 Medicinal Chemistry Lee R. McCracken(9)............. 1997 150,510 33,112 59,739(8) 12,500 0 Vice President, 1996 101,740 16,917 3,999(8) 72,500 0 Business Development Steven L. Teig.................. 1997 143,191 24,342 0 50,001 3,364(6) Vice President, 1996 137,025 21,924 0 -- 3,364(6) Advanced Technology
- --------------- (1) Pursuant to Instruction to Item 402(b) of Regulation S-K promulgated by the Securities and Exchange Commission (the "Commission"), information with respect to fiscal years prior to 1996 has not been included as the Company was not a reporting company pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the information has not been previously reported to the Commission in response to a filing requirement. (2) Includes amounts deferred pursuant to the Company's 401(k) Plan. (3) Includes cash payments for bonuses earned by the Named Executive Officers during each fiscal year. (4) Dr. Anido was hired in March 1996. (5) Dr. Myers served as the Company's Chief Executive Officer from August 1995 until March 1996. (6) Payments for life insurance premiums. (7) Amounts reimbursed for the payment of taxes. (8) Payments to cover relocation expenses. (9) Mr. McCracken was hired in May 1996. 46 48 Stock Options The following table sets forth information concerning stock option grants made to each of the Named Executive Officers for the year ended December 31, 1997. The Company granted no stock appreciation rights ("SARs") to Named Executive Officers during 1997. OPTION GRANTS IN LAST FISCAL YEAR
INDIVIDUAL GRANTS POTENTIAL REALIZABLE ------------------------------------------------------- VALUE AT ASSUMED NUMBER OF % OF TOTAL ANNUAL RATES OF STOCK SECURITIES OPTIONS PRICE APPRECIATION FOR UNDERLYING GRANTED TO EXERCISE OPTION TERMS(3) OPTIONS/SARS EMPLOYEES IN PRICE EXPIRATION ----------------------- NAME GRANTED(1) FISCAL YEAR PER SHARE(2) DATE 5% 10% ---- ------------ ------------ ------------ ---------- --------- ----------- Vicente Anido, Jr., Ph.D.................... 100,001 13.9% $4.00 09/16/07 $651,564 $1,037,507 Peter L. Myers, Ph.D...... 50,001 6.9 4.00 09/16/07 325,785 518,759 John Saunders, Ph.D....... 4,192 0.6 5.00 10/07/07 34,141 54,365 Lee R. McCracken.......... 12,500 1.7 4.00 09/16/07 81,445 129,687 Steven L. Teig............ 50,001 6.9 4.00 09/16/07 325,785 518,759
- --------------- (1) The grant dates for these options are as follows: September 17, 1997 for Dr. Anido's, Dr. Myers', Mr. McCracken's and Mr. Teig's options and October 8, 1997 for Dr. Saunders' option. Each option has a maximum term of 10 years measured from the grant date, subject to earlier termination upon the optionee's cessation of service with the Company. Each option is immediately exercisable for all the option shares; however, any shares purchased under the option will be subject to repurchase by the Company, at the option exercise price paid per share, should the optionee leave the Company prior to vesting in the shares. The shares subject to these options vest as follows: (a) for Dr. Anido's, Dr. Myers' and Mr. Teig's options, 50% upon their completion of 24 months of service measured from the grant date with the remaining 50% upon the completion of an additional 24 months of service, and (b) for all other optionees, 25% upon completion of one year of service measured from the grant date and the balance in a series of 36 successive equal monthly installments over a continued period of service thereafter. The options were granted under the 1995 Stock Option/Stock Issuance Plan and will be incorporated into the new 1997 Stock Incentive Plan on the effective date of the Offering, but will continue to be governed by their existing terms. See "Benefit Plans -- 1997 Stock Incentive Plan." (2) The exercise price per share of options granted represented the fair market value of the underlying shares of Common Stock on the dates the respective options were granted as determined by the Board, considering all relevant factors. The exercise price may be paid in cash or in shares of Common Stock valued at fair market value on the exercise date or a combination of cash and shares or any other form of consideration approved by the Board. After the effective date of the Registration Statement of which this Prospectus is a part, the fair market value of shares of Common Stock will be determined in accordance with certain provisions of the Company's 1995 Stock Option/Stock Issuance Plan based on the closing selling price per share of Common Stock on the date in question on the primary exchange or national market system on which the Company's common stock is listed or reported. If shares of the Common Stock are not listed or admitted to trading on any stock exchange nor traded on the Nasdaq National Market, then the fair market value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate. (3) The 5% and 10% assumed annual rates of compounded stock price appreciation are mandated by rules of the Commission. The price used in this table for computing this appreciation is the exercise price of the options, not the price of Common Stock in this offering. There is no assurance provided to any executive officer or any other holder of the Company's securities that the actual stock price appreciation over the 10-year option term will be at the assumed 5% or 10% levels or at any other defined level. Assuming the fair market value of the Common Stock at the date of grant 47 49 is an assumed initial public offering price of $9.00, the potential realizable value of these options (a) at a 5% assumed annual rate of stock price appreciation would be $1,466,020 for Dr. Anido's options, $733,017 for Dr. Myers' options, $61,455 for Dr. Saunders' options, $183,251 for Mr. McCracken's options and $733,017 for Mr. Teig's options and (b) at a 10% assumed annual rate of stock price appreciation would be $2,334,392 for Dr. Anido's options, $1,167,207 for Dr. Myers' options, $97,857 for Dr. Saunders' options, $291,796 for Mr. McCracken's options and $1,167,207 for Mr. Teig's options. Option Exercises and Holdings The following table provides information concerning option exercises during 1997 by the Named Executive Officers and the value of unexercised options held by each of the Named Executive Officers as of December 31, 1997. No SARs were exercised during 1997 or outstanding as of December 31, 1997. AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES
NUMBER OF SECURITIES UNDERLYING VALUE OF UNEXERCISED SHARES UNEXERCISED OPTIONS AT IN-THE-MONEY OPTIONS ACQUIRED DECEMBER 31, 1997(#) AT DECEMBER 31, 1997(3) ON VALUE ------------------------------ ------------------------------ NAME EXERCISE(#) REALIZED(1) EXERCISABLE(2) UNEXERCISABLE EXERCISABLE(2) UNEXERCISABLE ---- ----------- ----------- -------------- ------------- -------------- ------------- Vicente Anido, Jr., Ph.D. ................... 422,417 $42,242 100,001 -- $400,004 $-- Peter L. Myers, Ph.D....... 135,000 13,500 50,001 -- 200,004 -- John Saunders, Ph.D........ 83,825 12,741 4,192 -- 12,576 -- Lee R. McCracken........... 12,500 0 0 -- 0 -- Steven L. Teig............. 111,250 11,125 50,001 30,625 200,004 241,938
- --------------- (1) "Value realized" is calculated on the basis of the fair market value of the Common Stock on the date of exercise minus the exercise price and does not necessarily indicate that the optionee sold such stock. (2) The options are immediately exercisable, but any shares purchased thereunder will be subject to repurchase by the Company, at the original option exercise price paid per share, should the employee leave the Company prior to vesting in the shares. As of February 28, 1998, none of these shares had vested. (3) "Value" is calculated in this table as the fair market price of the Common Stock at fiscal year-end ($8.00) less exercise price. Assuming the fair market value of the Common Stock at December 31, 1997 is an assumed initial public offering price of $9.00, the value of these options (a) for exercisable options would be $500,005 for Dr. Anido's options, $250,005 for Dr. Myers' options, $16,768 for Dr. Saunders' options, $0 for Mr. McCracken's options, and $250,005 for Mr. Teig's options and (b) for unexercisable options, $272,563 for Mr. Teig's options. COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION During the year ended December 31, 1997, the Compensation Committee of the Company's Board established the levels of compensation for the Company's executive officers. The current members of the Company's Compensation Committee are Mr. Reidel and Dr. Scott. See "Certain Transactions." EMPLOYMENT ARRANGEMENTS AND CHANGE OF CONTROL ARRANGEMENTS In March 1996, the Company and Dr. Anido entered into an agreement whereby Dr. Anido is employed as President and Chief Executive Officer of the Company. Pursuant to his agreement, Dr. Anido receives an annual base salary of $260,000, which is reviewed annually by the Board of Directors, and is eligible for a bonus of up to 25% of his annual base salary to be awarded at the discretion of the Board of Directors. In the event the Company terminates Dr. Anido's employment 48 50 without "cause," Dr. Anido will be entitled to receive an aggregate severance benefit of 12 months of his base salary and benefits less amounts received by Dr. Anido from other full-time employment during that period. In addition, pursuant to his employment agreement Dr. Anido received options to purchase 420,000 shares of Common Stock with an exercise price of $0.30 per share. The shares subject to the option vest over Dr. Anido's four-year period of service with the Company measured from the option grant date. Dr. Anido's employment agreement also provides Dr. Anido with a right to maintain his pro rata interest in the Company by purchasing new securities issued in a financing other than a public offering, subject to certain exceptions. In March 1995, the Company and Dr. Myers entered into an agreement whereby Dr. Myers is employed as Chief Scientific Officer and Chief Operating Officer of the Company. Pursuant to his agreement, Dr. Myers (i) received a signing bonus of $26,250 towards the purchase of Company stock, (ii) receives an annual base salary of $210,000, which is reviewed annually by the President and Chief Executive Officer, and (iii) is eligible for a bonus of up to 25% of his annual base salary to be awarded at the discretion of the Board of Directors. In connection with the employment agreement, Dr. Myers was provided a home loan. In the event the Company terminates Dr. Myers' employment without "cause," Dr. Myers will be entitled to receive an aggregate severance benefit of nine months of his base salary and benefits, unless he obtains full-time employment prior to the end of that period, and nine months accelerated vesting to be applied to any vesting requirements under any stock option or stock purchase agreements outstanding between Dr. Myers and the Company at the time of his termination without cause. Simultaneous with the execution of Dr. Myers' employment agreement, the Company and Dr. Myers entered into a Stock Purchase Agreement whereby Dr. Myers purchased 87,500 shares of Common Stock at $0.30 per share. Those shares vest over Dr. Myers' four-year period of service with the Company measured from the option grant date. In March 1997, the Company and Ms. Eastham entered into an agreement whereby she is employed as Vice President, Finance and Administration and Chief Financial Officer. Pursuant to her agreement, Ms. Eastham (i) receives an annual base salary of $186,000, which is reviewed annually by the Chief Executive Officer and Board of Directors, and (ii) is eligible for a bonus of up to 20% of her annual base salary to be awarded at the discretion of the Board of Directors. In the event the Company terminates Ms. Eastham's employment without "cause" within two years after her date of hire, Ms. Eastham will be entitled to receive an aggregate severance benefit of her base salary and benefits for six months, unless she obtains full-time employment prior to the end of that six-month period. Simultaneous with the execution of Ms. Eastham's employment agreement, the Company and Ms. Eastham entered into a Stock Option Agreement granting her an option to purchase 87,500 shares of Common Stock with an exercise price of $0.40 per share. The shares subject to the option vest over her four-year period of service with the Company measured from the grant date. In January 1996, the Company and Dr. Saunders entered into an agreement whereby Dr. Saunders is employed as Vice President, Medicinal Chemistry of the Company. Pursuant to his agreement, Dr. Saunders receives an annual base salary of $145,000, which is reviewed annually by the President and Chief Executive Officer, and is eligible for a bonus of up to 20% of his annual base salary to be awarded at the discretion of the Board of Directors. Simultaneous with the execution of the employment agreement, the Company and Dr. Saunders entered into a stock option agreement granting him an option to purchase 83,825 shares of the Company's common stock with an exercise price of $0.248 per share. The shares subject to that option vest over Dr. Saunders' four-year period of service with the Company measured from the option grant date. In May 1996, the Company and Mr. McCracken entered into an agreement whereby he is employed as Vice President, Business Development of the Company. Pursuant to his agreement, Mr. McCracken received a signing bonus of $10,000 and receives an annual base salary of $145,000, which is reviewed annually by the President and Chief Executive Officer. In addition, Mr. McCracken is eligible for a bonus of up to 20% of his annual base salary. In the event the Company terminates Mr. McCracken's employment without "cause," Mr. McCracken will be entitled to receive an aggregate severance benefit of nine months of his base salary and benefits. Simultaneous with the 49 51 execution of Mr. McCracken's employment agreement, the Company and Mr. McCracken entered into a stock option agreement granting Mr. McCracken an option to purchase 72,500 shares of Common Stock with an exercise price of $0.30 per share. The shares subject to the option vest over Mr. McCracken's four-year period of service measured from the option grant date. In July 1995, the Company and Mr. Teig entered into an agreement whereby he is employed as Vice President of the Company. Pursuant to his agreement, Mr. Teig receives an annual base salary of $135,000, which is reviewed annually by the Board of Directors. In addition, Mr. Teig is eligible for a bonus of up to 20% of his annual base salary to be awarded at the discretion of the Board of Directors. Simultaneous with the execution of the employment agreement, the Company and Mr. Teig entered into a stock purchase agreement whereby Mr. Teig purchased 50,000 shares of Common Stock at $0.30 per share. Under such stock purchase agreement, the shares will vest, and the Company's repurchase rights will accordingly lapse over Mr. Teig's four-year period of employment measured from the date of issuance. Pursuant to his employment agreement, Mr. Teig was granted an option to purchase 61,250 shares of Company's Series J convertible preferred stock with an exercise price of $0.40 per share. Those shares vest over Mr. Teig's four-year period of service beginning on the fifth anniversary of the option grant date, with provisions for early vesting upon meeting certain milestones. All of the shares are currently vested. In connection with an acquisition of the Company by merger or asset sale, each outstanding option held by the Chief Executive Officer and the other Named Executive Officers under the Predecessor Plan and any options granted to such individuals in the future under the 1997 Stock Incentive Plan will automatically accelerate in full, except to the extent such options are to be assumed by the successor corporation. See "Benefit Plans -- 1997 Stock Incentive Plan." In addition, the Compensation Committee as Plan Administrator of the 1997 Stock Incentive Plan will have the authority to provide for the accelerated vesting of the shares of Common Stock subject to outstanding options held by the Chief Executive Officer and the Named Executive Officers, or any unvested shares of Common Stock subject to direct issuances held by such individuals, in connection with the termination of the officer's employment following: (i) a merger or asset sale in which these options are assumed or the repurchase rights applicable to those shares are assigned or (ii) certain changes in control of the Company. DIRECTOR COMPENSATION The Company reimburses its directors for all reasonable and necessary travel and other incidental expenses incurred in connection with their attendance at meetings of the Board. Directors are not currently compensated for serving on the Board. The Company has previously granted to certain non- employee Board members an option to purchase 20,000 shares of Common Stock. Each non-employee Board member who is serving as such on the effective date of the 1997 Stock Incentive Plan will receive a similar 20,000-share option, provided he or she has not received a prior option grant from the Company. Each individual who first becomes a non-employee Board member at any time after this offering will receive a 20,000-share option grant on the date such individual joins the Board. In addition, beginning with the first annual meeting of stockholders following this offering, each such non-employee Board member who is to continue to serve as a non-employee Board member will automatically be granted an option to purchase 5,000 shares of Common Stock, provided such individual has served on the Board for at least six months. These options will have an exercise price equal to 100% of the fair market value of the Common Stock on the grant date. The shares subject to each 20,000-share automatic option grant will vest over a four-year period, with 25% of the option shares vesting upon completion of one year of Board service from the grant date and the balance of the option shares vesting in equal monthly installments over the optionee's continued period of Board service over the next three years. The shares subject to each 5,000-share annual automatic option will vest upon the optionee's completion of one year of Board service measured from the grant date. See "-- Benefit Plans -- 1997 Stock Incentive Plan." 50 52 BENEFIT PLANS 1997 Stock Incentive Plan The Company's 1997 Stock Incentive Plan (the "1997 Plan") is intended to serve as the successor equity incentive program to the Company's 1995 Stock Option/Stock Issuance Plan, as amended (the "Predecessor Plan"). The 1997 Plan was adopted by the Board and the stockholders on October 7, 1997. The 1997 Plan is to become effective on the date the Underwriting Agreement for this offering is executed (the "Plan Effective Date"). A total of 1,072,170 shares of Common Stock have been authorized for issuance under the 1997 Plan. Such share reserve consists of (i) the number of shares available for issuance under the Predecessor Plan on the Plan Effective Date, including the shares subject to outstanding options, and (ii) an additional increase of approximately 800,000 shares. To the extent any unvested shares of Common Stock issued under the Predecessor Plan are repurchased by the Company after the Plan Effective Date, at the exercise price paid per share, in connection with the holder's termination of service, those repurchased shares will be added to the reserve of Common Stock available for issuance under the 1997 Plan. In no event may any one participant in the 1997 Plan receive option grants, separately exercisable stock appreciation rights or direct stock issuances for more than 500,000 shares of Common Stock in the aggregate per calendar year. On the Plan Effective Date, outstanding options and unvested shares issued under the Predecessor Plan will be incorporated into the 1997 Plan, and no further option grants will be made under the Predecessor Plan. The incorporated options will continue to be governed by their existing terms, unless the Plan Administrator elects to extend one or more features of the 1997 Plan to those options. Except as otherwise noted below, the incorporated options have substantially the same terms as will be in effect for grants made under the Discretionary Option Grant Program of the 1997 Plan. The 1997 Plan is divided into five separate components: (i) the Discretionary Option Grant Program under which eligible individuals in the Company's employ or service (including officers, non-employee Board members and consultants) may, at the discretion of the Plan Administrator, be granted options to purchase shares of Common Stock at an exercise price not less than 100% of their fair market value on the grant date, (ii) the Stock Issuance Program under which such individuals may, in the Plan Administrator's discretion, be issued shares of Common Stock directly, through the purchase of such shares at a price not less than 100% of their fair market value at the time of issuance or as a bonus tied to the performance of services, (iii) the Salary Investment Option Grant Program which may, in the Plan Administrator's sole discretion, be activated for one or more calendar years and, if so activated, will allow executive officers and other highly compensated employees the opportunity to apply a portion of their base salary to the acquisition of special below-market stock option grants, (iv) the Automatic Option Grant Program under which option grants will automatically be made at periodic intervals to eligible non-employee Board members to purchase shares of Common Stock at an exercise price equal to 100% of their fair market value on the grant date and (v) the Director Fee Option Grant Program which may, in the Plan Administrator's sole discretion, be activated for one or more calendar years and, if so activated, will allow non-employee Board members the opportunity to apply a portion of the annual retainer fee, if any, otherwise payable to them in cash each year to the acquisition of special below-market option grants. The Discretionary Option Grant Program and the Stock Issuance Program will be administered by the Compensation Committee. The Compensation Committee as Plan Administrator will have complete discretion to determine which eligible individuals are to receive option grants or stock issuances under those programs, the time or times when such option grants or stock issuances are to be made, the number of shares subject to each such grant or issuance, the status of any granted option as either an incentive stock option or a non-statutory stock option under the Federal tax laws, the vesting schedule to be in effect for the option grant or stock issuance and the maximum term for which any granted option is to remain outstanding. The Compensation Committee will also have the exclusive authority to select the executive officers and other highly compensated employees who may partici- 51 53 pate in the Salary Investment Option Grant Program in the event that program is activated for one or more calendar years, but neither the Compensation Committee nor the Board will exercise any administrative discretion with respect to option grants under the Salary Investment Option Grant Program or under the Automatic Option Grant or Director Fee Option Grant Program for the non-employee Board members. All grants under those three latter programs will be made in strict compliance with the express provisions of each such program. The exercise price for the shares of Common Stock subject to option grants made under the 1997 Plan may be paid in cash or in shares of Common Stock valued at fair market value on the exercise date. The option may also be exercised through a same-day sale program without any cash outlay by the optionee. In addition, the Plan Administrator may provide financial assistance to one or more optionees in the exercise of their outstanding options or the purchase of their unvested shares by allowing such individuals to deliver a full-recourse, interest-bearing promissory note in payment of the exercise price and any associated withholding taxes incurred in connection with such exercise or purchase. The Plan Administrator will have the authority, with the consent of the affected option holders, to effect the cancellation of outstanding options under the Discretionary Option Grant Program (including options incorporated from the Predecessor Plan) in return for the grant of new options for the same or different number of option shares with an exercise price per share based upon the fair market value of the Common Stock on the new grant date. Stock appreciation rights are authorized for issuance under the Discretionary Option Grant Program which provide the holders with the election to surrender their outstanding options for an appreciation distribution from the Company equal to the excess of (i) the fair market value of the vested shares of Common Stock subject to the surrendered option over (ii) the aggregate exercise price payable for such shares. Such appreciation distribution may be made in cash or in shares of Common Stock. None of the incorporated options from the Predecessor Plan contain any stock appreciation rights. In the event that the Company is acquired by merger or asset sale, each outstanding option under the Discretionary Option Grant Program which is not to be assumed by the successor corporation will automatically accelerate in full, and all unvested shares under the Discretionary Option Grant and Stock Issuance Programs will immediately vest, except to the extent the Company's repurchase rights with respect to those shares are to be assigned to the successor corporation. The Plan Administrator will have complete discretion to grant one or more options under the Discretionary Option Grant Program which will become fully exercisable for all the option shares in the event those options are assumed in the acquisition and the optionee's service with the Company or the acquiring entity terminates within a designated period following such acquisition. The vesting of outstanding shares under the Stock Issuance Program may be accelerated upon similar terms and conditions. The Plan Administrator will also have the authority to grant options which will immediately vest upon an acquisition of the Company, whether or not those options are assumed by the successor corporation. The Plan Administrator is also authorized under the Discretionary Option Grant and Stock Issuance Programs to grant options and to structure repurchase rights so that the shares subject to those options or repurchase rights will immediately vest in connection with a change in control of the Company (whether by successful tender offer for more than 50% of the outstanding voting stock or a change in the majority of the Board by reason of one or more contested elections for Board membership), with such vesting to occur either at the time of such change in control or upon the subsequent termination of the individual's service within a designated period following such change in control. The options incorporated from the Predecessor Plan will similarly accelerate and immediately vest upon an acquisition of the Company by merger or asset sale, unless those options are assumed by the successor entity. In the event the Plan Administrator elects to activate the Salary Investment Option Grant Program for one or more calendar years, each executive officer and other highly compensated employee of the 52 54 Company selected for participation may elect, prior to the start of the calendar year, to reduce his or her base salary for that calendar year by a specified dollar amount not less than $10,000 nor more than $50,000. If such election is approved by the Plan Administrator, the individual will automatically be granted, on the first trading day in January of the calendar year for which that salary reduction is to be in effect, a non-statutory option to purchase that number of shares of Common Stock determined by dividing the salary reduction amount by two-thirds of the fair market value per share of Common Stock on the grant date. The option will be exercisable at a price per share equal to one-third of the fair market value of the option shares on the grant date. As a result, the total spread on the option shares at the time of grant (the fair market value of the option shares on the grant date less the aggregate exercise price payable for those shares) will be equal to the amount of salary invested in that option. The option will vest in a series of 12 equal monthly installments over the calendar year for which the salary reduction is to be in effect and will be subject to full and immediate vesting upon certain changes in the ownership or control of the Company. The Company has previously granted to certain non-employee Board members an option to purchase 20,000 shares of Common Stock, and each non-employee Board member who is serving as such on the Plan Effective Date and who has not received such a grant will automatically receive an option at that time to purchase 20,000 shares of Common Stock. Each individual who first becomes a non-employee Board member at any time after the Plan Effective Date will also receive a 20,000-share option grant on the date such individual joins the Board. In addition and on the date of each Annual Stockholders Meeting held after the Plan Effective Date, each such non-employee Board member who is to continue to serve as a non-employee Board member will automatically be granted an option to purchase 5,000 shares of Common Stock, provided such individual has served on the Board for at least six months. Each automatic grant for the non-employee Board members will have a term of 10 years, subject to earlier termination following the optionee's cessation of Board service. Each automatic option will be immediately exercisable for all of the option shares; however, any unvested shares purchased under the option will be subject to repurchase by the Company, at the exercise price paid per share, should the optionee cease Board service prior to vesting in those shares. The shares subject to each initial 20,000-share automatic option grant will vest over a four-year period, as follows: (i) 25% of the option shares upon the optionee's completion of one year of Board service measured from the grant date and (ii) the balance of the option shares in a series of 36 successive equal monthly installments upon the optionee's completion of each additional month of service measured from the first anniversary of the grant date. The shares subject to each annual 5,000-share grant will vest upon the optionee's completion of one year of Board service measured from the grant date. However, the shares subject to each automatic option grant will immediately vest in full upon certain changes in control or ownership of the Company or upon the optionee's death or disability while a Board member. Should the Director Fee Option Grant Program be activated in the future, each non-employee Board member will have the opportunity to apply all or a portion of any annual retainer fee otherwise payable in cash to the acquisition of a below-market option grant. The option grant will automatically be made on the first trading day in January in the year for which the retainer fee would otherwise be payable in cash. The option will have an exercise price per share equal to one-third of the fair market value of the option shares on the grant date, and the number of shares subject to the option will be determined by dividing the amount of the retainer fee applied to the program by two-thirds of the fair market value per share of Common Stock on the grant date. As a result, the total spread on the option (the fair market value of the option shares on the grant date less the aggregate exercise price payable for those shares) will be equal to the portion of the retainer fee invested in that option. The option will become exercisable for the option shares in a series of 12 equal monthly installments over the calendar year for which the election is to be in effect. However, the option will become immediately exercisable for all the option shares upon (i) certain changes in the ownership or control of the Company or (ii) the death or disability of the optionee while serving as a Board member. 53 55 The shares subject to each option under the Salary Investment Option Grant, Automatic Option Grant and Director Fee Option Grant Programs will immediately vest upon (i) an acquisition of the Company by merger or asset sale or (ii) the successful completion of a tender offer for more than 50% of the Company's outstanding voting stock or a change in the majority of the Board effected through one or more contested elections for Board membership. Limited stock appreciation rights will automatically be included as part of each grant made under the Automatic Option Grant, Salary Investment Option Grant and Director Fee Option Grant Programs and may be granted to one or more officers of the Company as part of their option grants under the Discretionary Option Grant Program. Options with such a limited stock appreciation right may be surrendered to the Company upon the successful completion of a hostile tender offer for more than 50% of the Company's outstanding voting stock. In return for the surrendered option, the optionee will be entitled to a cash distribution from the Company in an amount per surrendered option share equal to the excess of (i) the highest price per share of Common Stock paid in connection with the tender offer over (ii) the exercise price payable for such share. The Board may amend or modify the 1997 Plan at any time, subject to any required stockholder approval. The 1997 Plan will terminate on the earliest of (i) October 31, 2007, (ii) the date on which all shares available for issuance under the 1997 Plan have been issued as fully vested shares or (iii) the termination of all outstanding options in connection with certain changes in control or ownership of the Company. 1997 Employee Stock Purchase Plan The Company's 1997 Employee Stock Purchase Plan (the "Purchase Plan") was adopted by the Board and approved by the stockholders in October 1997 and will become effective immediately upon the execution of the Underwriting Agreement for this offering. The Purchase Plan is designed to allow eligible employees of the Company and participating subsidiaries to purchase shares of Common Stock, at semi-annual intervals, through their periodic payroll deductions under the Purchase Plan, and a reserve of 150,000 shares of Common Stock has been established for this purpose. The Purchase Plan will be implemented in a series of successive offering periods, each with a maximum duration for 12 months. However, the initial offering period will begin on the execution date of the Underwriting Agreement and will end on the last business day in January 1999. The next offering period will commence on the first business day in February 1999, and subsequent offering periods will commence as designated by the Plan Administrator. Individuals who are eligible employees (scheduled to work more than 20 hours per week for more than 5 calendar months per year) on the start date of any offering period may enter the Purchase Plan on that start date or on any subsequent semi-annual entry date (the first business day of February or August each year). Individuals who become eligible employees after the start date of the offering period may join the Purchase Plan on any subsequent semi-annual entry date within that offering period. Payroll deductions may not exceed 10% of the employee's base salary, and the accumulated payroll deductions of each participant will be applied to the purchase of shares on his or her behalf on each semi-annual purchase date (the last business day in January and July each year) at a purchase price per share equal to 85% of the lower of (i) the fair market value of the Common Stock on the participant's entry date into the offering period or (ii) the fair market value on the semi-annual purchase date. In no event, however, may any participant purchase more than 1,250 shares on any one semi-annual purchase date. Should the fair market value per share of Common Stock on any purchase date be less than the fair market value per share on the start date of the two-year offering period, then that offering period will automatically terminate, and a new two-year offering period will begin on the next business day, with all participants in the terminated offering to be automatically transferred to the new offering period. 54 56 In the event the Company is acquired by merger or asset sale, all outstanding purchase rights will automatically be exercised immediately prior to the effective date of such acquisition. The purchase price will be equal to 85% of the lower of (i) the fair market value per share of Common Stock on the participant's entry date into the offering period in which such acquisition occurs or (ii) the fair market value per share of Common Stock immediately prior to such acquisition. The Purchase Plan will terminate on the earlier of (i) the last business day in July 2007, (ii) the date on which all shares available for issuance under the Purchase Plan shall have been sold pursuant to purchase rights exercised thereunder or (iii) the date on which all purchase rights are exercised in connection with an acquisition of the Company by merger or asset sale. The Board may at any time alter, suspend or discontinue the Purchase Plan. However, certain amendments to the Purchase Plan may require stockholder approval. LIMITATIONS ON LIABILITY AND INDEMNIFICATION MATTERS The Company's Certificate of Incorporation eliminates, subject to certain exceptions, directors' personal liability to the Company or its stockholders for monetary damages for breaches of fiduciary duties. The Certificate of Incorporation does not, however, eliminate or limit the personal liability of a director for (i) any breach of the director's duty of loyalty to the Company or its stockholders, (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law or (iv) any transaction from which the director derived an improper personal benefit. The Company's Bylaws provide that the Company shall indemnify its directors and executive officers to the fullest extent permitted under the Delaware General Corporation Law and may indemnify its other officers, employees and other agents as set forth in the Delaware General Corporation Law. In addition, the Company has entered into indemnification agreements with its directors and officers. The indemnification agreements contain provisions that require the Company, among other things, to indemnify its directors and executive officers against certain liabilities (other than liabilities arising from intentional or knowing and culpable violations of law) that may arise by reason of their status or service as directors or executive officers of the Company or other entities to which they provide service at the request of the Company and to advance expenses they may incur as a result of any proceeding against them as to which they could be indemnified. The Company believes that these provisions and agreements are necessary to attract and retain qualified directors and officers. The Company has obtained an insurance policy covering directors and officers for claims that such directors and officers may otherwise be required to pay or for which the Company is required to indemnify them, subject to certain exclusions. 55 57 CERTAIN TRANSACTIONS In October 1997, the Company effected a one-for-four reverse stock split of the Common Stock. The following discussion gives effect to such split upon the conversion of the Preferred Stock into Common Stock upon the completion of this offering. Since its formation in May 1994, the Company has issued, in private placement transactions, shares of its Preferred Stock as follows: 250,000 shares of Series A Preferred Stock at a price of $2.00 per share in August and November 1994; 556,669 shares of Series B Preferred Stock at a price of $3.00 per share in November 1994; 4,289,634 shares of Series C Preferred Stock at a price of $2.48 per share in August 1995, September 1995 and April 1996; 2,467,310 shares of Series D Preferred Stock at a price of $4.00 per share in November 1996; 58,125 shares of Series J Preferred Stock at a price of $0.40 per share in June 1997; 50,000 shares of Series Z Preferred Stock at a price of $2.00 in October 1994; and 83,195 shares of Series Z as consideration pursuant to an asset purchase agreement. The purchasers of Preferred Stock include, among others, the following directors, executive officers and holders of more than 5% of the Company's outstanding stock and their respective affiliates:
PREFERRED STOCK EXECUTIVE OFFICERS, DIRECTORS ------------------------------------------------------ TOTAL AND 5% STOCKHOLDERS SERIES A SERIES B SERIES C SERIES D SERIES J CONSIDERATION ----------------------------- -------- -------- --------- --------- -------- ------------- Pierre R. Lamond(1)........................ 100,000 333,335 542,453 237,211 -- $3,494,114 Philippe O. Chambon, M.D., Ph.D.(2)........ -- -- 1,209,679 292,050 -- 4,168,198 Vicente Anido, Jr., Ph.D................... -- -- -- 60,000 -- 240,000 Lee R. McCracken(3)........................ -- -- -- 8,750 -- 35,000 Steven L. Teig............................. -- -- -- 5,000 30,625 32,250 Entities affiliated with Sequoia Capital(1)............................... 100,000 333,335 542,453 237,211 -- 3,494,114 Entities affiliated with Sprout Capital(2)............................... -- -- 1,209,679 292,050 -- 4,168,198 Entities affiliated with Sorrento Growth Partners(4).............................. -- -- 604,841 146,026 -- 2,084,100 Entities affiliated with Brinson Venture Capital Fund(5).......................... -- -- 806,453 150,000 -- 2,600,000
- --------------- (1) Includes 1,087,212 shares purchased by Sequoia Capital VI, 59,738 shares purchased by Sequoia Technology Partners VI, 32,012 shares purchased by Sequoia XXIV and 15,780 shares purchased by Sequoia 1995, each of which is affiliated with Sequoia Partners. Sequoia Partners is the general partner of Sequoia Capital VI. Sequoia Partners has eight general partners, who are also the general partners of Sequoia Technology Partners VI. Also includes 18,257 shares issuable to the entities affiliated with Sequoia Partners upon exercise of warrants at an exercise price of $2.48 per share. In addition, the entities affiliated with Sequoia Partners purchased 25,000 shares of Common Stock of the Company in November 1994 (see below). Mr. Lamond is a Director of the Company and a general partner of Sequoia Partners. Mr. Lamond disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. (2) Includes 1,386,331 shares purchased by Sprout Capital VII, L.P. and 115,398 shares purchased by DLJ Capital Corporation. Dr. Chambon is a Director of the Company and a general partner of Sprout Capital VII, L.P., and DLJ Capital Corporation is the general partner of Sprout Capital VII, L.P. Dr. Chambon is a Divisional Vice President of DLJ Capital Corporation. Dr. Chambon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. (3) Held by The Rufus L. McCracken Trust, dated 6/21/91, of which Mr. McCracken is the sole trustee. (4) Includes 249,803 shares purchased by Sorrento Ventures II, L.P. and 501,064 shares purchased by Sorrento Growth Partners I, L.P. (5) Includes 134,113 shares purchased by the First National Bank of Chicago as Custodian to the Brinson Trust Company as Trustee of the Brinson MAP Venture Capital Fund III and 822,340 shares 56 58 purchased by the First National Bank of Chicago as Custodian to the Brinson Venture Capital Fund III, L.P. Holders of Preferred Stock are entitled to certain registration rights with respect to the Common Stock issued or issuable upon conversion thereof. See "Description of Capital Stock -- Registration Rights." In November 1994, the Company sold the following number of shares of Common Stock to the respective entities at a price of $0.20 per share: 22,750 shares to Sequoia Capital VI; 1,250 shares to Sequoia Technology Partners VI; and 1,000 shares to Sequoia XXIV. In October 1997, the Company sold 1,000,000 shares of its Common Stock to Elan International Services Ltd. in conjunction with entering into a collaborative agreement. In February 1997 as incentive for employment, and in June 1997 under an employee loan program provided for the exercise of options, the Company made loans in the amounts of $96,000 and $23,044, respectively, to Dr. Anido, the President, Chief Executive Officer and a Director of the Company, for an aggregate indebtedness as of March 31, 1998 of $119,751, which includes accrued interest. Each loan is secured by shares of Common Stock held by Dr. Anido. The loan for $96,000 is represented by a promissory note which is due and payable on the earlier of February 23, 2002 or the occurrence of certain events, such as the expiration of the 190-day period following the completion of an initial public offering. This loan bears no interest. The loan for $23,044 is represented by a promissory note which is due and payable in three annual installments and is due in full upon the third anniversary of the loan. This loan bears an interest rate of 6.14%. The aggregate indebtedness of $119,751 at March 31, 1998 represents the largest amount of indebtedness outstanding since the beginning of the last fiscal year. At December 31, 1997, 1996 and 1995, Dr. Anido's outstanding loan balance, including accrued interest, was $119,751, $0 and $0, respectively. In September 1995 as incentive for employment, and in June 1997 under an employee loan program provided for the exercise of options, the Company made loans in the amounts of $150,000 and $30,375, respectively, to Dr. Myers, the Vice President, Chief Scientific Officer and a Director of the Company, for an aggregate indebtedness as of March 31, 1998 of $203,749, which includes accrued interest. Each loan is secured by shares of Common Stock held by Dr. Myers. The loan for $150,000 is represented by a promissory note which is due and payable on the earlier of September 5, 2000 or the occurrence of certain events, such as the expiration of the 180-day period following the completion of an initial public offering. This loan bears an interest rate equal to the applicable minimum Federal rate on the date of the loan. The loan for $30,375 is represented by a promissory note which is due and payable in three annual installments and is due in full upon the third anniversary of the loan. This loan bears an interest rate of 6.14%. The aggregate indebtedness of $203,749 at March 31, 1998 represents the largest amount of indebtedness outstanding since the beginning of the last fiscal year. At December 31, 1997, 1996 and 1995, Dr. Myers' outstanding loan balance, including accrued interest, was $201,574, $161,566 and $152,866, respectively. In August 1996 as incentive for employment, and in June 1997 under an employee loan program provided for the exercise of options, the Company made loans in the amounts of $66,125 and $15,591, respectively, to Dr. Saunders, the Vice President, Medicinal Chemistry of the Company, for an aggregate indebtedness as of March 31, 1998 of $60,195, which includes accrued interest. The loan for $66,125, which is secured by a deed of trust, is represented by a promissory note which is due and payable on the earlier of August 28, 1999 or the occurrence of certain events, such as the expiration of the 30-day period following the date Dr. Saunders ceases to be a full-time employee of the Company. This loan bears no interest. The loan for $15,591, which is secured by shares of Common Stock held by Dr. Saunders, is represented by a promissory note which is due and payable in three annual installments and is due in full upon the third anniversary of the loan. This loan bears an interest rate of 6.14%. The largest amount of indebtedness outstanding since the beginning of the last fiscal year was $81,716. At December 31, 1997, 1996 and 1995, Dr. Saunders' outstanding loan balance, including accrued interest, was $60,195, $66,125 and $0, respectively. 57 59 For information regarding employment agreements with Named Executive Officers, see "Management -- Employment Agreements and Change of Control Arrangements." All of the Company's officers are employed by the Company at will. The Company has entered into indemnification agreements with each of its directors and executive officers. See "Management -- Limitations on Liability and Indemnification Matters." The Company expects that all future transactions between the Company and its officers, directors and principal stockholders and their affiliates will be approved in accordance with the Delaware General Corporation Law by a majority of the Board, as well as by a majority of the independent and disinterested directors of the Board, and will be on terms no less favorable to the Company than could be obtained from unaffiliated third parties. 58 60 PRINCIPAL STOCKHOLDERS The following table sets forth certain information regarding the beneficial ownership of the Common Stock as of February 28, 1998, after giving effect to the conversion of all outstanding shares of Preferred Stock into Common Stock upon the closing of this offering and as adjusted to reflect the sale of the shares of the Common Stock offered hereby by the Company, by (i) all those known by the Company to be beneficial owners of more than 5% of its outstanding Common Stock, (ii) each director of the Company, (iii) each of the Named Executive Officers of the Company and (iv) all directors and executive officers of the Company as a group.
PERCENTAGE OF SHARES SHARES BENEFICIALLY OWNED(2) BENEFICIALLY ---------------------------------- NAME AND ADDRESS OF BENEFICIAL OWNER OWNED(1) PRIOR TO OFFERING AFTER OFFERING ------------------------------------ ------------ ----------------- -------------- Sprout Capital VII, L.P. and affiliated entities(3)..... 1,501,729 13.7% 11.3% 3000 Sand Hill Road Building 3, Suite 170 Menlo Park, CA 94025 Sequoia Capital VI and affiliated entities(4)........... 1,237,999 11.3% 9.3% 3000 Sand Hill Road Building 4, Suite 280 Menlo Park, CA 94025 Elan International Services Ltd.(5)..................... 1,000,000 9.1% 7.6% 102 St. James Court Flatts Smiths, FL04 Bermuda Brinson MAP Venture Capital Fund III and affiliated entities(6)........................................... 956,453 8.7% 7.2% 209 S. LaSalle Street Chicago, IL 60604-1295 Sorrento Growth Partners I, L.P. and affiliated entities(7)........................................... 750,867 6.8% 5.7% 4370 La Jolla Village Dr., Suite 1040 San Diego, CA 92122 Pierre R. Lamond(4)..................................... 1,237,999 11.3% 9.3% Vicente Anido, Jr., Ph.D.(8)............................ 582,418 5.3% 4.4% Peter L. Myers, Ph.D.(9)................................ 272,501 2.5% 2.1% Philippe O. Chambon, MD., Ph.D.(3)...................... 1,501,729 13.7% 11.3% Arthur Reidel(10)....................................... 20,000 * * William Scott, Ph.D.(11)................................ 20,000 * * Lee R. McCracken(12).................................... 93,750 * * John Saunders, Ph.D.(13)................................ 88,017 * * Steven L. Teig(14)...................................... 246,876 2.2% 1.9% All directors and executive officers as a group (10 persons)(15)........................... 4,155,165 37.0% 30.8%
- --------------- * Represents beneficial ownership of less than one percent of the outstanding shares of the Company's Common Stock. (1) Except as indicated in the footnotes to this table, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them. Share ownership in each case includes shares issuable upon exercise of certain outstanding options as described in the footnotes below. The address for those individuals for which an address is not otherwise indicated is: 9050 Camino Santa Fe, San Diego, CA 92121. 59 61 (2) Percentage of ownership is calculated pursuant to Commission Rule 13d-3(d)(1). (3) Includes 1,386,331 shares purchased by Sprout Capital VII, L.P. and 115,398 shares purchased by DLJ Capital Corporation. DLJ Capital Corporation is the managing general partner of Sprout Capital VII, L.P. Dr. Chambon is a Director of the Company, a general partner of Sprout Capital VII, L.P. and Divisional Vice President of DLJ Capital Corporation. Dr. Chambon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. (4) Includes 1,109,962 shares held by Sequoia Capital VI, 60,988 shares held by Sequoia Technology Partners VI, 33,012 shares held by Sequoia XXIV and 15,780 shares held by Sequoia 1995, each of which is affiliated with Sequoia Partners. Sequoia Partners is the general partner of Sequoia Capital VI. Sequoia Partners has eight general partners, who are also the general partners of Sequoia Technology Partners VI. Also includes 16,613 shares, 913 shares and 731 shares held by Sequoia Capital VI, Sequoia Technology Partners VI and Sequoia XXIV, respectively, issuable upon exercise of warrants exercisable within 60 days of February 28, 1998. Mr. Lamond is a Director of the Company and a general partner of Sequoia Partners. Mr. Lamond disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. (5) In the event the expression of interest by Elan International Services Ltd. in acquiring approximately $2 million of the shares of Common Stock offered hereby is realized (at an assumed initial public offering price of $9.00 per share), "Shares Beneficially Owned" would be 1,222,222 and "Percentage of Shares Beneficially Owned After Offering" would be 9.2%. (6) Includes 134,113 shares purchased by the First National Bank of Chicago as Custodian to the Brinson Trust Company as Trustee of the Brinson MAP Venture Capital Fund III and 822,340 shares purchased by The First National Bank of Chicago as Custodian to the Brinson Venture Capital Fund III, L.P. (7) Includes 249,803 shares held by Sorrento Ventures II, L.P. and 501,064 shares held by Sorrento Growth Partners I, L.P. (8) Includes 100,001 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (9) Includes 50,001 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (10) Includes 20,000 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (11) Includes 20,000 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (12) Includes 8,750 shares held by the Rufus L. McCracken Trust, dated 6/21/91, of which Mr. McCracken is the sole Trustee. (13) Includes 4,192 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (14) Includes 50,001 shares issuable upon exercise of options exercisable within 60 days of February 28, 1998. (15) Includes 262,451 shares issuable upon the exercise of options or warrants exercisable within 60 days of February 28, 1998. 60 62 DESCRIPTION OF CAPITAL STOCK Upon completion of this offering, the Company will be authorized to issue 40,000,000 shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of undesignated Preferred Stock, $0.001 par value per share. COMMON STOCK As of March 31, 1998, there were outstanding, and held of record by approximately 130 stockholders, 3,227,005 shares of Common Stock and shares of Preferred Stock that will be converted into 7,754,933 shares of Common Stock upon the completion of this offering. The holders of Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Subject to preferences that may be applicable to any outstanding shares of Preferred Stock, holders of Common Stock are entitled to receive ratably such dividends as may be declared by the Board out of funds legally available. See "Dividend Policy." All outstanding shares of Common Stock are fully paid and nonassessable. PREFERRED STOCK After completion of this offering, the Board will have the authority, without further action by the stockholders, to issue up to 5,000,000 shares of Preferred Stock in one or more series and to fix the rights, priorities, preferences, qualifications, limitations and restrictions, including dividend rights, conversion rights, voting rights, terms of redemption, terms of sinking funds, liquidation preferences and the number of shares constituting any series or the designation of such series, which could decrease the amount of earnings and assets available for distribution to holders of Common Stock or adversely affect the rights and powers, including voting rights, of the holders of the Common Stock. The issuance of Preferred Stock could have the effect of delaying or preventing a change in control of the Company or make removal of management more difficult. Additionally, the issuance of Preferred Stock may have the effect of decreasing the market price of the Common Stock and may adversely affect the voting and other rights of the holders of Common Stock. There are currently no shares of Preferred Stock outstanding and the Company has no current plans to issue any of the Preferred Stock. WARRANTS In December 1994, in conjunction with an equipment lease financing, the Company issued a warrant to Comdisco, Inc. to purchase up to 20,914 shares of Common Stock at $2.00 per share, exercisable at any time and prior to the earlier of December 20, 2004 or five years following the Company's initial public offering. The warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of the warrant under certain circumstances, including stock dividends, stock splits, reorganizations, reclassifications or consolidations. The warrant provides that the warrant holder may exercise the warrant without payment of cash by surrendering the warrant and receiving shares of Common Stock equal to the value of the warrant surrendered. In June 1995, in connection with a product development collaboration, the Company issued a warrant to LJL BioSystems, Inc. to purchase 8,750 shares of Common Stock, exercisable at any time and prior to June 15, 2000, at $0.30 per share. The warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of the warrant under certain circumstances, including stock dividends, stock splits, reorganizations, reclassifications or consolidations. In August 1995, in connection with the Series C Preferred Stock private placement, the Company issued warrants to five investors to purchase an aggregate of 30,242 shares of Common Stock, exercisable at any time and prior to August 2000 at $2.48 per share. Each warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of the warrant under certain circumstances, including stock dividends, stock splits, reorganizations, 61 63 reclassifications or consolidations. Each warrant provides that the warrant holder may exercise the warrant without payment of cash by surrendering the warrant and receiving shares of Common Stock equal to the value of the warrant surrendered. In April 1996, in conjunction with equipment lease financings, the Company issued warrants to Comdisco, Inc. to purchase up to an aggregate of 35,383 shares of Common Stock at $2.48 per share, exercisable at any time and prior to the earlier of April 2003 or three years after the Company's initial public offering. The number of shares issuable pursuant to these warrants was dependent on the aggregate amount financed with Comdisco, and pursuant to these warrants, Comdisco has the right to purchase an aggregate of 26,647 shares of the Company. Each warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of each warrant under certain circumstances, including stock dividends, stock splits, reorganizations, reclassifications or consolidations. Each warrant provides that the warrant holder may exercise the warrant without payment of cash by surrendering the warrant and receiving shares of Common Stock equal to the value of the warrant surrendered. In May 1996, in conjunction with an equipment lease financing, the Company issued warrants to Silicon Valley Bank and MMC/GATX Partnership No. 1 to purchase up to 6,896 and 21,331 shares of Common Stock, respectively, at $2.48 per share, respectively, exercisable at any time and prior to the earlier of May 2006 or five years following the Company's initial public offering. Each warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of each warrant under certain circumstances, including stock dividends, stock splits, reorganizations, reclassifications or consolidations. Each warrant provides that the warrant holder may exercise the warrant without payment of cash by surrendering the warrant and receiving shares of Common Stock equal to the value of the warrant surrendered. In June 1996, in conjunction with equipment lease financings, the Company issued warrants to Comdisco, Inc. to purchase up to an aggregate of 24,698 shares of Common Stock at $2.48 per share, exercisable at any time and prior to the earlier of June 2003 or three years after the Company's initial public offering. Each warrant contains provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon exercise of each warrant under certain circumstances, including stock dividends, stock splits, reorganizations, reclassifications or consolidations. Each warrant provides that the warrant holder may exercise the warrant without payment of cash by surrendering the warrant and receiving shares of Common Stock equal to the value of the warrant surrendered. REGISTRATION RIGHTS The holders of approximately 7,754,933 shares of Common Stock or their permitted transferees (the "Holders") are entitled to certain rights with respect to the registration of such shares under the Securities Act. Under the terms of agreements between the Company and such Holders, if the Company proposes to register any of its securities under the Securities Act for its own account, such Holders are entitled to notice of such registration and are entitled to include shares of such Common Stock therein, provided, among other conditions, that the underwriters of any such offering have the right to limit the number of shares included in such registration. In addition, Holders of at least 50% of approximately 7,754,933 shares of Common Stock with demand registration rights may require the Company to prepare and file a registration statement under the Securities Act with respect to the shares entitled to demand registration rights, and the Company is required to use its diligent best efforts to effect such registration, subject to certain conditions and limitations. The Company is not obligated to effect more than two of these stockholder-initiated registrations nor to effect such a registration within 180 days following an offering of the Company's securities, including the Offering made hereby. The Holders may also request the Company to register such shares on Form S-3 provided the shares registered have an aggregate market value of at least $500,000. The Company is not obligated to effect more than one of these registrations pursuant to Form S-3 in any 12-month period. Generally, the Company is required to bear the expense of all such registrations. The registration 62 64 rights of each Holder expires at such time after the Offering as all shares held by such Holder can be sold within any three-month period pursuant to Rule 144. All rights of the Holders to require registration of the resale of their shares in connection with this Offering have been waived. POSSIBLE ANTI-TAKEOVER EFFECT OF CERTAIN CHARTER PROVISIONS Certificate of Incorporation and Restated Bylaws The Company's Certificate of Incorporation authorizes the Board to establish one or more series of undesignated Preferred Stock, the terms of which can be determined by the Board at the time of issuance. See "-- Preferred Stock." The Certificate of Incorporation also provides that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing. The Company's Restated Bylaws provide that the Company's Board will be classified into three classes of directors beginning at the next annual meeting of stockholders. See "Management -- Executive Officers, Key Employees and Directors." In addition, the Restated Bylaws do not permit stockholders of the Company to call a special meeting of stockholders; only the Company's Chief Executive Officer, President, Chairman of the Board or a majority of the Board are permitted to call a special meeting of stockholders. The Restated Bylaws also require that stockholders give advance notice to the Company's secretary of any nominations for director or other business to be brought by stockholders at any stockholders' meeting and require a supermajority vote of members of the Board and/or stockholders to amend certain Restated Bylaw provisions. These provisions of the Certificate of Incorporation and the Restated Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control of the Company. Such provisions may also have the effect of preventing changes in the management of the Company. Delaware Anti-Takeover Statute The Company is subject to Section 203 of the Delaware General Corporation Law ("Section 203") which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any business combination with any interested stockholder (defined as any person or entity that is the beneficial owner of at least 15% of a corporation's voting stock) for a period of three years following the time that such stockholder became an interested stockholder, unless: (i) prior to such time, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder's becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder's becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding, for purposes of determining the number of shares outstanding, those shares owned (x) by persons who are directors and also officers and (y) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) at or subsequent to such time, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. Section 203 defines business combination to include:. (i) any merger or consolidation involving the corporation and the interested stockholder; (ii) any sale, lease, exchange, mortgage, transfer, pledge or other disposition involving the interested stockholder and 10% or more of the assets of the corporation; (iii) subject to certain exceptions, any transaction which results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; (iv) any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or (v) the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. TRANSFER AGENT AND REGISTRAR The transfer agent and registrar for the Common Stock is American Stock Transfer and Trust Company. 63 65 SHARES ELIGIBLE FOR FUTURE SALE Based upon the number of shares outstanding as of March 31, 1998 upon completion of this offering, there will be 13,231,938 shares of Common Stock of the Company outstanding. There were also approximately 49,000 shares covered by vested options outstanding, which are not considered to be outstanding shares. Of the outstanding shares, approximately 4,108,000 shares, including the 2,250,000 shares of Common Stock sold in this offering, will be immediately eligible for resale in the public market without restriction under the Securities Act, except that any shares purchased in this offering by affiliates of the Company ("Affiliates"), as that term is defined in Rule 144 under the Securities Act ("Rule 144"), may generally only be resold in compliance with applicable provisions of Rule 144. Beginning approximately 90 days after the date of this Prospectus, approximately 411,000 additional shares of Common Stock (including approximately 65,000 shares covered by options exercisable within the 90-day period following the date of this Prospectus) will become eligible for immediate resale in the public market, subject to compliance as to certain of such shares with applicable provisions of Rules 144 and 701. The Company, the executive officers and directors of the Company and certain security holders have agreed pursuant to lock-up agreements that they will not, without the prior written consent of BancAmerica Robertson Stephens, offer, sell or otherwise dispose of the shares of Common Stock beneficially owned by them for a period of 180 days from the date of this Prospectus. Each holder who signed a lock-up agreement has agreed, subject to certain limited exceptions, not to sell or otherwise dispose of any of the shares held by them as of the date of this Prospectus for a period of 180 days after the date of this Prospectus without the prior written consent of BancAmerica Robertson Stephens. At the end of such 180-day period, approximately 8,980,000 shares of Common Stock (including approximately 121,000 shares issuable upon exercise of vested options) will be eligible for immediate resale, subject to compliance with Rule 144 and Rule 701. The remainder of the approximately 4,252,000 shares of Common Stock outstanding or issuable upon exercise of options held by existing stockholders or option holders will become eligible for sale at various times over a period of less than two years and could be sold earlier if the holders exercise any available registration rights or upon vesting pursuant to the Company's standard four year vesting schedule. In general, under Rule 144 as recently amended, beginning approximately 90 days after the effective date of the Registration Statement of which this Prospectus is a part, a stockholder, including an Affiliate, who has beneficially owned his or her restricted securities (as that term is defined in Rule 144) for at least one year from the later of the date such securities were acquired from the Company or (if applicable) the date they were acquired from an Affiliate is entitled to sell, within any three-month period, a number of such shares that does not exceed the greater of 1% of the then outstanding shares of Common Stock (approximately 132,000 shares immediately after the offering) or the average weekly trading volume in the Common Stock during the four calendar weeks preceding the date on which notice of such sale was filed under Rule 144, provided certain requirements concerning availability of public information, manner of sale and notice of sale are satisfied. In addition, under Rule 144(k), if a period of at least two years has elapsed between the later of the date restricted securities were acquired from the Company or (if applicable) the date they were acquired from an Affiliate of the Company, a stockholder who is not an Affiliate of the Company at the time of sale and has not been an Affiliate of the Company for at least three months prior to the sale is entitled to sell the shares immediately without compliance with the foregoing requirements under Rule 144. Securities issued in reliance on Rule 701 (such as shares of Common Stock that may be acquired pursuant to the exercise of certain options granted prior to this offering) are also restricted securities and, beginning 90 days after the date of this Prospectus, may be sold by stockholders other than an Affiliate of the Company subject only to the manner of sale provisions of Rule 144 and by an Affiliate under Rule 144 without compliance with its one-year holding period requirement. Prior to this offering, there has been no public market for the Common Stock. No prediction can be made as to the effect, if any, that market sales of shares or the availability of shares for sale will have 64 66 on the market price of the Common Stock prevailing from time to time. The Company is unable to estimate the number of shares that may be sold in the public market pursuant to Rule 144, since this will depend on the market price of the Common Stock, the personal circumstances of the sellers and other factors. Nevertheless, sales of significant amounts of the Common Stock of the Company in the public market could adversely affect the market price of the Common Stock and could impair the Company's ability to raise capital through an offering of its equity securities. In addition, the Company intends to register on the effective date of this offering 1,072,170 shares of Common Stock subject to outstanding options or reserved for issuance under the Company's 1997 Stock Incentive Plan plus 150,000 shares of Common Stock reserved for issuance under its 1997 Employee Stock Purchase Plan. Further, upon expiration of such lock-up agreements, holders of approximately 7,754,933 shares of Common Stock will be entitled to certain registration rights with respect to such shares. If such holders, by exercising their registration rights, cause a large number of shares to be registered and sold in the public market, such sales could have a material adverse effect on the market price of the Common Stock. 65 67 UNDERWRITING The Underwriters named below, acting through their representatives, BancAmerica Robertson Stephens, Donaldson, Lufkin & Jenrette Securities Corporation and Smith Barney Inc. (the "Representatives"), have severally agreed with the Company, subject to the terms and conditions of the Underwriting Agreement, to purchase the numbers of shares of Common Stock set forth opposite their respective names below. The Underwriters are committed to purchase and pay for all such shares if any are purchased.
NUMBER OF UNDERWRITER SHARES ----------- --------- BancAmerica Robertson Stephens.............................. Donaldson, Lufkin & Jenrette Securities Corporation......... Smith Barney Inc............................................ --------- Total............................................. 2,250,000 =========
The Representatives have advised the Company that the Underwriters propose to offer shares of the Common Stock to the public at the initial public offering price set forth on the cover page of this Prospectus and to certain dealers at such price less a concession of not in excess of $ per share, of which $ may be reallowed to other dealers. After the initial public offering, the public offering price, concession and reallowance to dealers may be reduced by the Representatives. No such reduction shall change the amount of proceeds to be received by the Company as set forth on the cover page of this Prospectus. The Company has granted to the Underwriters an option, exercisable during the 30-day period after the date of this Prospectus, to purchase up to 337,500 additional shares of Common Stock, at the same price per share as will be paid for the 2,250,000 shares that the Underwriters have agreed to purchase. To the extent that the Underwriters exercise such option, each of the Underwriters will have a firm commitment to purchase approximately the same percentage of such additional shares that the number of shares of Common Stock to be purchased by it shown in the above table represents as a percentage of the 2,250,000 shares offered hereby. If purchased, such additional shares will be sold by the Underwriters on the same terms as those on which the 2,250,000 shares are being sold. The Underwriting Agreement contains covenants of indemnity among the Underwriters and the Company against certain civil liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in the Underwriting Agreement. Each officer and director and certain holders of shares of the Company's Common Stock have agreed with the Representatives, for a period of 180 days after the date of this Prospectus (the "Lock-Up Period"), subject to certain exceptions, not to offer to sell, contract to sell, or otherwise sell, dispose of, loan, pledge or grant any rights with respect to any shares of Common Stock, any options or warrants to purchase any shares of Common Stock, or any securities convertible into or exchangeable for shares of Common Stock owned as of the date of this Prospectus or thereafter acquired directly by such holders or with respect to which they have or hereafter acquire the power of disposition, without the prior written consent of BancAmerica Robertson Stephens. However, BancAmerica Robertson Stephens may, in its sole discretion and at any time without notice, release all or any portion of the securities subject to lock-up agreements. There are no agreements between the Representatives and any of the Company's stockholders providing consent by the Representatives to the sale of shares prior to the expiration of the Lock-Up Period. The Company has agreed that during the Lock-Up Period, the Company will not, subject to certain exceptions, without the prior written consent of BancAmerica Robertson Stephens, (i) consent to the disposition of any shares held by stockholders prior to the expiration of the Lock-Up Period or (ii) issue, sell, contract to sell or otherwise dispose of, any shares of Common Stock, any options or warrants to purchase any shares of Common Stock or any securities convertible into, exercisable for or exchangeable for shares of Common Stock, other than the Company's sale of shares in this offering, the issuance of Common Stock upon the exercise of 66 68 outstanding options and warrants and the Company's issuance of options and stock under the existing stock option and stock purchase plans. See "Shares Eligible for Future Sale." The Underwriters do not intend to confirm sales to any accounts over which they exercise discretionary authority in excess of 5% of the number of shares of Common Stock offered hereby. Prior to this offering, there has been no public market for the Common Stock of the Company. Consequently, the initial public offering price for the Common Stock offered hereby will be determined through negotiations between the Company and the Representatives. Among the factors to be considered in such negotiations are prevailing market conditions, certain financial information of the Company, market valuations of other companies that the Company and the Representatives believe to be comparable to the Company, estimates of the business potential of the Company, the present state of the Company's development and other factors deemed relevant. Certain persons participating in this offering may engage in transactions, including syndicate covering transactions or the imposition of penalty bids, which may involve the purchase of Common Stock on the Nasdaq National Market or otherwise. Such transactions may stabilize or maintain the market price of the Common Stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. The Representatives have advised the Company that, pursuant to Regulation M under the Securities Act, certain persons participating in the offering may engage in transactions, including stabilizing bids, syndicate covering transactions or the imposition of penalty bids, which may have the effect of stabilizing or maintaining the market price of the Common Stock at a level above that which might otherwise prevail in the open market. A "stabilizing bid" is a bid for or the purchase of the Common Stock on behalf of the Underwriters for the purpose of fixing or maintaining the price of the Common Stock. A "syndicate covering transaction" is the bid for or the purchase of the Common Stock on behalf of the Underwriters to reduce a short position incurred by the Underwriters in connection with the offering. A "penalty bid" is an arrangement permitting the Representatives to reclaim the selling concession otherwise accruing to an Underwriter or syndicate member in connection with the offering if the Common Stock originally sold by such Underwriter or syndicate member is purchased by the Representatives in a syndicate covering transaction and has therefore not been effectively placed by such Underwriter or syndicate member. The Representatives have advised the Company that such transactions may be effected on the Nasdaq National Market or otherwise and, if commenced, may be discontinued at any time. The offering is being conducted in accordance with Rule 2720 ("Rule 2720") of the National Association of Securities Dealers, Inc. (the "NASD") which provides that, among other things, when an NASD member firm participates in the offering of equity securities of a company with whom such member has a "conflict of interest" (as defined in Rule 2720), the initial public offering price can be no higher than that recommended by a "qualified independent underwriter" (as defined in Rule 2720) (a "QIU"). BancAmerica Robertson Stephens is serving as the QIU in the offering and will recommend a price in compliance with the requirements of Rule 2720. BancAmerica Robertson Stephens has performed due diligence investigations and reviewed and participated in the preparation of this Prospectus and the Registration Statement of which this Prospectus forms a part. BancAmerica Robertson Stephens, in its capacity as QIU, will receive no additional compensation as such in connection with the offering. 67 69 LEGAL MATTERS The validity of the Common Stock offered hereby will be passed upon for the Company by Brobeck, Phleger & Harrison LLP, San Diego, California. Partners of such firm own 2,500 shares of the Company's Common Stock. Certain legal matters will be passed upon for the Underwriters by Cooley Godward LLP, San Diego, California. EXPERTS The financial statements of CombiChem for the years ended December 31, 1995, 1996 and 1997 appearing in this Prospectus and the Registration Statement have been audited by Ernst & Young LLP, independent auditors, as set forth in their report thereon appearing elsewhere herein and are included in reliance upon such report given upon the authority of such firm as experts in accounting and auditing. ADDITIONAL INFORMATION The Company has filed with the Commission the Registration Statement under the Securities Act with respect to the Common Stock offered hereby. This Prospectus, which is part of the Registration Statement, does not contain all of the information set forth in the Registration Statement and the exhibits and schedules filed therewith. For further information with respect to the Company and the Common Stock offered hereby, reference is hereby made to such Registration Statement and to the exhibits and schedules filed therewith. Statements contained in this Prospectus regarding the contents of any contract or other document are not necessarily complete, and in each instance reference is made to the copy of such contract or document filed as an exhibit to the Registration Statement, each such statement being qualified in all respect by such reference. The Registration Statement, including the exhibits and schedules thereto, may be inspected without charge at the principal office of the Commission, 450 Fifth Street, N.W., Washington, D.C. 20549, and at the regional offices of the Commission located at Seven World Trade Center, Suite 1300, New York, New York 10048 and Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and copies of all of any part thereof may be obtained at prescribed rates from the Commission's Public Reference Section at such addresses. Also, the Commission maintains a World Wide Web site on the Internet at http://www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission. Upon approval of the Common Stock for quotation on the Nasdaq National Market, such reports, proxy and information statements and other information also can be inspected at the office of Nasdaq Operations, 1735 K Street, N.W., Washington, D.C. 20006. 68 70 COMBICHEM, INC. INDEX TO FINANCIAL STATEMENTS Report of Ernst & Young LLP, Independent Auditors........... F-2 Balance Sheets at December 31, 1996 and 1997 and March 31, 1998 (unaudited).......................................... F-3 Statements of Operations for the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1997 (unaudited) and 1998 (unaudited)..................... F-4 Statements of Redeemable Preferred Stock and Stockholders' Equity (Deficit) for the three years in the period ended December 31, 1997 and the three months ended March 31, 1998 (unaudited).......................................... F-5 Statements of Cash Flows for the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1997 (unaudited) and 1998 (unaudited)..................... F-6 Notes to Financial Statements............................... F-7
F-1 71 REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS The Board of Directors and Stockholders CombiChem, Inc. We have audited the accompanying balance sheets of CombiChem, Inc. as of December 31, 1996 and 1997, and the related statements of operations, redeemable preferred stock and stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 1997. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CombiChem, Inc. at December 31, 1996 and 1997, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 1997, in conformity with generally accepted accounting principles. ERNST & YOUNG LLP San Diego, California January 13, 1998, except for Note 10, as to which the date is March 31, 1998 F-2 72 COMBICHEM, INC. BALANCE SHEETS ASSETS
PRO FORMA STOCKHOLDERS' DECEMBER 31, EQUITY AT --------------------------- MARCH 31, MARCH 31, 1996 1997 1998 1998 ------------ ------------ ------------ ------------- (UNAUDITED) (UNAUDITED) Current assets: Cash and cash equivalents.................. $ 366,983 $ 5,866,635 $ 3,913,546 Short-term investments..................... 12,166,132 11,054,725 10,574,926 Accounts receivable........................ 198,419 527,633 1,921,921 Prepaid expenses and other current assets................................... 345,228 767,594 894,540 ------------ ------------ ------------ Total current assets................ 13,076,762 18,216,587 17,304,933 Restricted cash.............................. 325,000 262,143 262,143 Property and equipment, net.................. 2,899,155 5,961,177 7,123,643 Deposits and other assets.................... 138,095 879,845 1,029,431 Notes receivable from employee/stockholders...................... 218,991 206,303 206,303 ------------ ------------ ------------ Total assets........................ $ 16,658,003 $ 25,526,055 $ 25,926,453 ============ ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable........................... $ 508,538 $ 881,436 $ 957,836 Accrued liabilities........................ 734,601 1,394,046 1,343,158 Deferred revenue........................... 2,130,000 1,475,752 2,666,666 Current portion of obligations under capital leases........................... 758,085 1,569,197 1,770,746 ------------ ------------ ------------ Total current liabilities........... 4,131,224 5,320,431 6,738,406 Deferred rent................................ 30,409 91,227 103,863 Obligations under capital leases, less current portion............................ 1,752,646 3,283,373 3,566,327 Commitments Redeemable convertible preferred stock, $.001 par value, 63,196,296 shares authorized; 30,787,135, 31,019,635 and 31,019,635 shares issued and outstanding at December 31, 1996 and 1997, and March 31, 1998, respectively (5,000,000 shares authorized, no shares issued and outstanding pro forma)..................................... 23,106,728 23,129,968 23,129,968 $ -- Stockholders' equity (deficit): Common stock, $.001 par value, 80,000,000 shares authorized; 711,605, 3,227,005 and 3,227,005 shares issued and outstanding at December 31, 1996 and 1997 and March 31, 1998, respectively, (40,000,000 shares authorized, 10,981,938 shares issued and outstanding pro forma)........ 712 3,227 3,227 10,982 Additional paid-in capital................. 135,340 12,519,952 12,519,952 35,642,165 Deferred compensation...................... -- (1,582,320) (1,471,911) (1,471,911) Notes receivable from stockholders......... -- (419,061) (419,061) (419,061) Accumulated deficit........................ (12,499,056) (16,820,742) (18,244,318) (18,244,318) ------------ ------------ ------------ ------------ Total stockholders' equity (deficit)......................... (12,363,004) (6,298,944) (7,612,111) $ 15,517,857 ------------ ------------ ------------ ============ Total liabilities and stockholders' equity (deficit).................. $ 16,658,003 $ 25,526,055 $ 25,926,453 ============ ============ ============
See accompanying notes. F-3 73 COMBICHEM, INC. STATEMENTS OF OPERATIONS
THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, --------------------------------------- ------------------------- 1995 1996 1997 1997 1998 ----------- ----------- ----------- ----------- ----------- (UNAUDITED) Revenue: Revenue under collaborative agreements: Project initiation fees and milestone payments....... $ -- $ 2,500,000 $ 3,333,331 $ -- $ 750,000 Research and development funding.................. -- 420,000 4,137,250 490,832 1,871,586 Grant revenue................. 50,440 47,400 -- -- -- ----------- ----------- ----------- ----------- ----------- Total revenue......... 50,440 2,967,400 7,470,581 490,832 2,621,586 Operating expenses: Research and development: Collaborative.............. -- 420,000 4,316,938 137,484 1,923,191 Proprietary................ 4,763,043 4,820,253 4,399,620 1,237,358 1,314,947 ----------- ----------- ----------- ----------- ----------- 4,763,043 5,240,253 8,716,558 1,374,842 3,238,138 General and administrative.... 2,000,652 2,845,074 3,286,569 872,413 891,481 ----------- ----------- ----------- ----------- ----------- Total operating expenses............ 6,763,695 8,085,327 12,003,127 2,247,255 4,129,619 Loss from operations............ (6,713,255) (5,117,927) (4,532,546) (1,756,423) (1,508,033) Interest income................. 94,737 144,639 662,525 189,386 235,706 Interest expense................ (56,040) (145,139) (251,665) (60,168) (121,249) Foreign tax expense............. -- -- (200,000) -- (30,000) ----------- ----------- ----------- ----------- ----------- Net loss........................ $(6,674,558) $(5,118,427) $(4,321,686) (1,627,205) (1,423,576) =========== =========== =========== =========== =========== Pro forma basic net loss per share......................... $ (0.49) $ (0.14) =========== =========== Shares used in computing pro forma basic net loss per share......................... 8,804,000 10,202,000 =========== ===========
See accompanying notes. F-4 74 COMBICHEM, INC. STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
STOCKHOLDERS' EQUITY (DEFICIT) REDEEMABLE ------------------------------------------------------------------ CONVERTIBLE NOTES PREFERRED STOCK COMMON STOCK ADDITIONAL RECEIVABLE ------------------------ ------------------- PAID-IN DEFERRED FROM SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION STOCKHOLDERS ---------- ----------- --------- ------ ----------- ------------ ------------ Balance at December 31, 1994....... 3,400,000 $ 2,250,000 433,125 $ 433 $ 23,567 $ -- $ -- Sale of common stock............. -- -- 194,750 195 58,230 -- -- Issuance of common stock for technology..................... -- -- 100,000 100 39,900 -- -- Sale of Series B preferred stock.......................... 26,667 20,000 -- -- -- -- -- Sale of Series C preferred stock.......................... 11,234,809 6,877,749 -- -- -- -- -- Conversion of notes payable and interest into Series C preferred stock................ 810,767 502,676 -- -- -- -- -- Repurchase and cancelation of common stock................... -- -- (67,710) (68) (2,640) -- -- Net loss......................... -- -- -- -- -- -- -- ---------- ----------- --------- ------ ----------- ----------- --------- Balance at December 31, 1995....... 15,472,243 9,650,425 660,165 660 119,057 -- -- Sale of common stock............. -- -- 74,000 74 22,126 -- -- Sale of Series C preferred stock.......................... 5,112,910 3,142,045 -- -- -- -- -- Sale of Series D preferred stock.......................... 9,869,205 9,853,345 -- -- -- -- -- Conversion of notes payable and interest into Series Z preferred stock................ 332,777 460,913 -- -- -- -- -- Repurchase and cancellation of common stock................... -- -- (22,560) (22) (5,843) -- -- Net loss......................... -- -- -- -- -- -- -- ---------- ----------- --------- ------ ----------- ----------- --------- Balance at December 31, 1996....... 30,787,135 23,106,728 711,605 712 135,340 -- -- Sale of common stock............. -- -- 1,305,090 1,305 10,071,414 -- -- Sale of Series J preferred stock.......................... 232,500 23,240 -- -- -- -- -- Deferred compensation related to stock options.................. -- -- -- -- 1,773,973 (1,773,973) -- Amortization of deferred compensation................... -- -- -- -- -- 191,653 -- Sale of common stock for notes receivable..................... -- -- 1,210,310 1,210 539,225 -- (540,435) Repayment of notes receivable.... -- -- -- -- -- -- 121,374 Net loss......................... -- -- -- -- -- -- -- ---------- ----------- --------- ------ ----------- ----------- --------- Balance at December 31, 1997....... 31,019,635 23,129,968 3,227,005 3,227 12,519,952 (1,582,320) (419,061) Amortization of deferred compensation (unaudited)....... -- -- -- -- -- 110,409 -- Net loss (unaudited)............. -- -- -- -- -- -- -- ---------- ----------- --------- ------ ----------- ----------- --------- Balance at March 31, 1998 (unaudited)...................... 31,019,635 $23,129,968 3,227,005 $3,227 $12,519,952 $(1,471,911) $(419,061) ========== =========== ========= ====== =========== =========== ========= STOCKHOLDERS' EQUITY (DEFICIT) -------------------------------- TOTAL STOCKHOLDERS' ACCUMULATED EQUITY DEFICIT (DEFICIT) ------------ ---------------- Balance at December 31, 1994....... $ (706,071) $ (682,071) Sale of common stock............. -- 58,425 Issuance of common stock for technology..................... -- 40,000 Sale of Series B preferred stock.......................... -- -- Sale of Series C preferred stock.......................... -- -- Conversion of notes payable and interest into Series C preferred stock................ -- -- Repurchase and cancelation of common stock................... -- (2,708) Net loss......................... (6,674,558) (6,674,558) ------------ ------------ Balance at December 31, 1995....... (7,380,629) (7,260,912) Sale of common stock............. -- 22,200 Sale of Series C preferred stock.......................... -- -- Sale of Series D preferred stock.......................... -- -- Conversion of notes payable and interest into Series Z preferred stock................ -- -- Repurchase and cancellation of common stock................... -- (5,865) Net loss......................... (5,118,427) (5,118,427) ------------ ------------ Balance at December 31, 1996....... (12,499,056) (12,363,004) Sale of common stock............. -- 10,072,719 Sale of Series J preferred stock.......................... -- -- Deferred compensation related to stock options.................. -- -- Amortization of deferred compensation................... -- 191,653 Sale of common stock for notes receivable..................... -- -- Repayment of notes receivable.... -- 121,374 Net loss......................... (4,321,686) (4,321,686) ------------ ------------ Balance at December 31, 1997....... (16,820,742) (6,298,944) Amortization of deferred compensation (unaudited)....... -- 110,409 Net loss (unaudited)............. (1,423,576) (1,423,576) ------------ ------------ Balance at March 31, 1998 (unaudited)...................... $(18,244,318) $ (7,612,111) ============ ============
See accompanying notes. F-5 75 COMBICHEM, INC. STATEMENTS OF CASH FLOWS
THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, ---------------------------------------- ------------------------- 1995 1996 1997 1997 1998 ----------- ------------ ----------- ----------- ----------- (UNAUDITED) Cash flows from operating activities: Net loss.................................... $(6,674,558) $ (5,118,427) $(4,321,686) $(1,627,205) $(1,423,576) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation of property and equipment............................ 106,763 310,765 849,285 112,191 330,607 Amortization of premium on short-term investments.......................... -- -- 92,709 26,230 41,214 Deferred rent........................... -- 30,409 60,818 -- 12,636 Deferred revenue........................ -- 2,130,000 (654,248) (790,832) 1,190,914 In-process research and development acquired for convertible notes payable and accrued interest......... 542,676 -- -- -- -- Amortization of deferred compensation... -- -- 191,651 -- 110,409 Stock issued for technology............. 40,000 -- -- -- -- Interest payable converted to preferred stock................................ -- 20,913 -- -- -- Change in operating assets and liabilities: Accounts receivable.................. -- (198,419) (329,214) (89,769) (1,394,288) Prepaid expenses and other current assets............................. (164,995) (154,152) (422,366) 47,884 (19,248) Accounts payable and accrued liabilities........................ 443,095 607,106 1,032,345 (43,954) 25,515 ----------- ------------ ----------- ----------- ----------- Net cash used in operating activities......................... (5,707,019) (2,371,805) (3,500,706) (2,365,455) (1,125,817) Cash flows from investing activities: Purchases of short-term investments......... -- (12,166,132) (6,191,204) -- (2,561,415) Maturities of short-term investments........ -- -- 7,416,825 4,139,760 3,000,000 Purchases of accrued interest on short-term investments............................... -- -- (206,913) -- (107,698) Purchases of property and equipment......... (638,878) (2,575,690) (3,911,307) (150,242) (1,492,794) Deposits and other assets................... 9,923 (102,077) (741,750) 2,481 (149,587) Notes receivable from employees............. (152,866) (66,125) 12,688 -- -- ----------- ------------ ----------- ----------- ----------- Net cash used in investing activities......................... (781,821) (14,910,024) (3,621,661) 3,991,999 (1,311,494) Cash flows from financing activities: Advances on capital lease obligations,...... 693,102 2,337,375 3,257,645 302,656 871,278 Principal repayments on capital lease obligations............................... (108,870) (410,876) (915,816) (182,195) (387,056) Issuance of redeemable convertible preferred stock, net of issuance costs.............. 6,897,749 12,995,390 23,240 -- -- Issuance of common stock, net of repurchased shares ................................... 55,717 16,335 10,072,719 -- -- Payments on note payable.................... (35,000) (100,000) -- -- -- Receipt of payment on note from stockholder............................... -- -- 121,374 -- -- Restricted cash given as collateral for letter of credit.......................... -- (325,000) 62,857 -- -- Proceeds from convertible notes payable..... 750,000 -- -- -- -- Repayments of convertible notes payable..... (250,000) -- -- -- -- ----------- ------------ ----------- ----------- ----------- Net cash provided by financing activities......................... 8,002,698 14,513,224 12,622,019 120,461 484,222 ----------- ------------ ----------- ----------- ----------- Net increase (decrease) in cash and cash equivalents................................. 1,513,858 (2,768,605) 5,499,652 1,747,005 (1,953,089) Cash and cash equivalents at beginning of period...................................... 1,621,730 3,135,588 366,983 366,983 5,866,635 ----------- ------------ ----------- ----------- ----------- Cash and cash equivalents at end of period.... $ 3,135,588 $ 366,983 $ 5,866,635 $ 2,113,988 $ 3,913,546 =========== ============ =========== =========== =========== Supplemental disclosures of cash flow information: Interest paid................................. $ 56,040 $ 124,226 $ 258,109 $ 52,504 $ 120,289 =========== ============ =========== =========== =========== Supplemental schedule of noncash investing and financing activities: Conversion of convertible notes payable and interest payable to redeemable convertible preferred stock............................. $ 502,676 $ 440,000 $ -- $ -- $ -- =========== ============ =========== =========== ===========
See accompanying notes. F-6 76 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and Business CombiChem, Inc. is a computational drug discovery company that is applying its proprietary design technology and rapid synthesis capabilities to accelerate the discovery process for new drugs. The Company believes its approach offers pharmaceutical and biotechnology companies the opportunity to conduct their drug discovery efforts in a more productive and cost-effective manner. Using its Discovery Engine(TM) process, the Company focuses on the generation, evolution and optimization of potential new lead candidates for its collaborative partners, who will then develop, manufacture, market and sell any resulting drugs. CombiChem believes that its process is widely applicable to a variety of disease targets and therapeutic indications. In addition, the Company intends to use its approach on internal programs to discover new lead candidates and then to outlicense them to third parties, retaining a larger economic interest in such candidates. Cash, Cash Equivalents and Short-term Investments Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less when purchased. The Company generally invests its excess cash in U.S. government securities. Short-term investments are recorded at amortized cost which approximates market value. The Company applies Statement of Financial Accounting Standards No. 115, Accounting for Certain Investments in Debt and Equity Securities (SFAS No. 115), to its investments. Under SFAS No. 115, the Company classifies its short-term investments as "Available-for-Sale" and records such assets at estimated fair value in the balance sheet, with unrealized gains and losses, if any, reported in stockholders' equity. As of December 31, 1997, the cost of cash equivalents and short-term investments approximated estimated fair value. Concentration of Credit Risk The Company invests its excess cash in debt instruments of financial institutions and corporations with strong credit ratings. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company historically has not experienced any material losses on its cash equivalents or short-term investments. Property and Equipment Property and equipment are carried at cost. Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining term of the lease. Amortization of equipment under capital leases is reported with depreciation of property and equipment. Impairment of Long-Lived Assets Statement of Financial Accounting Standards No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of (SFAS No. 121), requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the F-7 77 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. SFAS No. 121 also addresses the accounting for long-lived assets that are expected to be disposed. There have not been any impairments of long-lived assets to date. Basic Net Loss Per Share and Pro Forma Basic Net Loss Per Share Effective December 31, 1997, the Company adopted Statement of Financial Accounting Standards No. 128 Earnings Per Share ("SFAS No. 128"). SFAS No. 128 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share, if more dilutive, for all periods presented. In accordance with SFAS No. 128, basic net loss per share has been computed using the weighted-average number of shares of Common Stock outstanding during the period, except that pursuant to Securities and Exchange Commission Staff Accounting Bulletin No. 98, if applicable, common shares issued in each of the periods presented for nominal consideration have been included in the calculation as if they were outstanding for all periods presented. Pro forma basic net loss per share as presented in the Statement of Operations has been computed as described above and also gives effect to the conversion of the convertible Preferred Stock that will occur upon completion of the Company's initial public offering (using the as-if converted method from the original date of issuance.) A reconciliation of shares used in the calculation of basic and pro forma basic net loss per share follows (in thousands, except per share data):
YEAR ENDED DECEMBER 31, THREE MONTHS ----------------------------- ENDED 1995 1996 1997 MARCH 31, 1998 ------- ------- ------- -------------- (UNAUDITED) Net loss............................... $(6,675) $(5,118) $(4,322) $(1,424) ======= ======= ======= ======= Weighted average shares of Common Stock outstanding (shares used in computing basic net loss per share)............ 348 453 1,075 2,447 ======= ======= ======= ======= Basic net loss per share............... $(19.18) $(11.30) $ (4.02) $ (0.58) ======= ======= ======= ======= Shares used in computing basic net loss per share............................ 1,075 2,447 Adjustment to reflect the effect of the assumed conversion of preferred stock................................ 7,729 7,755 ------- ------- Shares used in computing pro forma basic net loss per share............. 8,804 10,202 ======= ======= Pro forma basic net loss per share..... $ (0.49) $ (0.14) ======= =======
Had the Company been in a net income position, diluted earnings per share would have been presented and would have included the shares used in the computation of pro forma basic net loss per share as well as additional potential common shares related to outstanding options and warrants. The diluted EPS computation is not included as all potential common shares are antidilutive. F-8 78 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) New Accounting Standards In June 1997, the Financial Accounting Standards Board issued SFAS No. 130, Reporting Comprehensive Income (SFAS No. 130) and SFAS No. 131, Segment Information (SFAS No. 131). Both of these standards are effective for fiscal years beginning after December 15, 1997. SFAS No. 130 requires that all components of comprehensive income, including net income, be reported in the financial statements in the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income and other comprehensive income, including foreign currency translation adjustments, and unrealized gains and losses on investments, shall be reported, net of their related tax effect, to arrive at comprehensive income. The Company does not believe that comprehensive income or loss will be materially different than net income or loss. SFAS No. 131 amends the requirements for public enterprises to report financial and descriptive information about its reportable operating segments. Operating segments, as defined in SFAS No. 131, are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company in deciding how to allocate resources and in assessing performance. The financial information is required to be reported on the basis that is used internally for evaluating the segment performance. The Company believes it operates in one business and operating segment and does not believe adoption of these standards will have a material impact on the Company's financial statements. Revenues under Collaborative Agreements and Research and Development Costs The Company currently generates revenue primarily through its collaborative agreements, which provide for the analysis of data, design of informative compound libraries and synthesis of compounds utilizing the Company's proprietary technology. Contract research revenue is recognized at the time that research activities are performed under the terms of the research contracts. Contract payments are generally received in advance of the performance of the related research activities. Such payments received in excess of amounts earned are recorded as deferred revenue. Project initiation fees are recognized as revenue upon contract execution. These fees are non-refundable and the Company has no future performance obligations related to such fees. Advance payments received from collaborators, which require future services to be performed by the Company, are recorded as deferred revenue. Such payments are recognized as revenue upon completion by the Company of all related performance obligations, as evidenced by the collaborator's written approval and acceptance. The Company has also received an option payment which is creditable against future project initiation fees, if any, related to the selection of additional targets by the collaborator. Such payment will be recognized as revenue upon the earlier of the collaborator's selection of such additional target or written confirmation of the collaborator's determination that it will not be selecting any such additional targets. The Company's accounts receivable consist of amounts earned, but not yet received, under these agreements. Substantially all of such receivables are expected to be collected within 30 days of the balance sheet date. Research and development costs are expensed as incurred. Costs of services under the Company's collaborative agreements generally approximate the research revenue under such agreements. Project initiation fees and milestone payments do not have associated cost of services. F-9 79 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) The Company's revenues are concentrated among a small number of customers, as follows:
THREE MONTHS YEAR ENDING ENDING DECEMBER 31 MARCH 31 -------------------- ------------ 1995 1996 1997 1997 1998 ---- ---- ---- ---- ---- Elan/Athena................................... -- -- 18% -- 10% ICOS.......................................... -- -- -- -- -- Imclone....................................... -- -- * -- * Roche......................................... -- 67% 30% 68% 57% Sumitomo...................................... -- -- 39% -- 24% Teijin........................................ -- 31% * 32% * Other......................................... -- * -- -- --
- --------------- * Amount earned represents less than 10% of revenues for the period. Stock-Based Compensation As permitted by Statement of Financial Accounting Standards No. 123 (SFAS No. 123), the Company has elected to follow Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25), and related Interpretations in accounting for its employee stock options. Under APB 25, when the exercise price of the Company's employee stock options is not less than the market price of the underlying stock on the date of grant, no compensation expense is recognized. Pro Forma Stockholders' Equity In September 1997, the Board of Directors authorized management of the Company to file a Registration Statement with the Securities and Exchange Commission for the Company to sell shares of its common stock in an initial public offering. If the initial public offering contemplated by this Prospectus is consummated under the terms presently anticipated, all outstanding shares of redeemable convertible preferred stock at March 31, 1998 will convert into 7,754,933 common shares. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Deferred Offering Costs Included in Deposits and other Assets are approximately $903,000 in costs incurred by the Company as of March 31, 1998 in conjunction with the contemplated public offering. These costs will be offset against the proceeds of the public offering. F-10 80 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) Reclassification Reclassifications have been made to certain prior period amounts to conform to the 1997 presentation. 2. BALANCE SHEET INFORMATION Investments There were no realized gains or losses on the sale of securities during the three years ended December 31, 1997 or the three months ended March 31, 1998. Unrealized losses were $2,224, $1,331 and $803 as of December 31, 1996 and 1997 and March 31, 1998, respectively. All debt securities held by the Company at March 31, 1998, have a contractual maturity less than one year. The amortized cost of the debt securities approximates fair value. The fair value of "Available-for-Sale" securities was $12,163,908, $11,053,394 and $10,574,123 at December 31, 1996 and 1997 and March 31, 1998, respectively. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. The Company's short-term investments classified as available for sale are as follows:
DECEMBER 31, ------------------------- MARCH 31, 1996 1997 1998 ----------- ----------- ----------- (UNAUDITED) Corporate bonds...................... $12,166,132 $10,555,534 $10,075,335 Tax exempt municipal bonds........... -- 499,191 499,591 ----------- ----------- ----------- $12,166,132 $11,054,725 $10,574,926 =========== =========== ===========
Property and Equipment Property and equipment consist of the following:
DECEMBER 31, MARCH 31, ----------------------- ------------------------ 1996 1997 1997 1998 ---------- ---------- ---------- ----------- (UNAUDITED) Laboratory and computer equipment...... $1,759,990 $4,131,762 $2,027,728 $ 5,311,824 Leasehold improvements................. 1,373,465 2,524,919 1,224,400 2,913,293 Office furniture, fixtures and equipment............................ 188,174 576,255 219,743 498,079 ---------- ---------- ---------- ----------- 3,321,629 7,232,936 3,471,871 8,723,196 Less accumulated depreciation and amortization......................... (422,474) (1,271,759) (534,665) (1,599,553) ---------- ---------- ---------- ----------- $2,899,155 $5,961,177 $2,937,206 $ 7,123,643 ========== ========== ========== ===========
F-11 81 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) 3. NOTES PAYABLE During 1996, the Company repaid a $100,000 non-interest bearing note with cash and converted two notes payable totaling $440,000 and the related accrued interest into 83,195 shares of Series Z convertible preferred stock. 4. COMMITMENTS Leases The Company leases its facilities in San Diego and Palo Alto under two operating lease agreements that expire in May 2006 and October 2002, respectively. Rent expense was approximately $86,000, $383,000 and $613,000 for the years ended December 31, 1995, 1996 and 1997 and $115,000 and $187,000 for the three months ended March 31, 1997 and 1998, respectively. Lease payments under both agreements are subject to future increases based upon the Consumer Price Index. The Company leases certain equipment under capital lease obligations. Cost and accumulated amortization of equipment under capital leases were $3,054,000 and $349,000 at December 31, 1996, $6,599,000 and $1,140,000 at December 31, 1997 and $7,269,000 and $1,474,000 at March 31, 1998, respectively. Annual future minimum obligations for operating and capital leases as of December 31, 1997 are as follows:
OPERATING CAPITAL YEAR ENDING DECEMBER 31: LEASES LEASES ------------------------ ---------- ----------- 1998............................................ $ 662,795 $ 1,961,928 1999............................................ 683,341 1,722,250 2000............................................ 699,778 1,170,132 2001............................................ 712,106 797,403 2002............................................ 682,799 -- Thereafter......................................... 1,837,189 -- ---------- ----------- Total minimum lease payments......................... $5,278,008 5,651,713 ========== Less amount representing interest.................... (799,143) ----------- Present value of obligations under capital leases.... 4,852,570 Less current portion................................. (1,569,197) ----------- Long-term obligations under capital leases . ........ $ 3,283,373 ===========
Consulting Agreements The Company has entered into various consulting agreements with members of its Scientific Advisory Board and others for aggregate minimum annual fees of approximately $118,000. The agreements are cancelable by either party with limited notice. During the years ended December 31, 1995, 1996 and 1997 and the three months ended March 31, 1997 and 1998, the Company expensed approximately $27,000, $43,000, $61,000, $11,000 and $31,000, respectively, for fees and expense reimbursements paid to these consultants. F-12 82 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) 5. REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Changes in Capitalization In September 1997, the Company reincorporated into Delaware which was accomplished through a merger of the existing California corporation into a new Delaware corporation. The ratio of exchange was one share of the California corporation to one share of the Delaware corporation. The number of authorized shares of the new Delaware corporation is 80,000,000 shares of Common Stock and 63,196,296 shares of Preferred Stock. Subsequent to the reincorporation, the Company effected a one-for-four reverse stock split of the Common Stock. After this reverse stock split of the Common Stock and in accordance with the Company's Certificate of Incorporation, each share of the Preferred Stock is now convertible into one quarter of a share of Common Stock at the option of the holder or automatically on the date specified by written consent or agreement of the holders of at least seventy percent (70%) of the outstanding shares of Preferred Stock. The Company has received such written consent from the holders of greater than seventy percent (70%) of the outstanding shares of Preferred Stock so that the 31,019,635 shares of outstanding shares of Preferred Stock shall be automatically converted into 7,754,933 shares of Common Stock upon the closing of this offering. All share and per share amounts and stock option data have been restated to retroactively give effect to the reincorporation, the reverse stock split of the Common Stock and the related change in shares outstanding. The Company intends to file an Amended and Restated Certificate of Incorporation to become effective immediately prior to the closing of this offering so that the authorized shares of the Company shall be 40,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. Redeemable Convertible Preferred Stock A summary of issued and outstanding preferred stock is as follows:
LIQUIDATION SHARES PREFERENCE ---------- ----------- Redeemable convertible preferred stock: Series A......................................... 1,000,000 $ 500,000 Series B......................................... 2,226,667 1,670,000 Series C......................................... 17,158,486 10,638,261 Series D......................................... 9,869,205 9,869,205 ---------- ----------- 30,254,358 22,677,466 Convertible preferred stock: Series J......................................... 232,500 23,240 Series Z......................................... 532,777 560,913 ---------- ----------- 765,277 584,153 ---------- ----------- 31,019,635 $23,261,619 ========== ===========
In 1994, the Company issued Series A and B redeemable convertible preferred stock for cash at $0.50 and $0.75 per share, respectively. In October 1994, the Company acquired certain intellectual property rights in exchange for 200,000 shares of the Company's Series Z convertible preferred stock valued at $0.50 per share. During 1996, the Company converted two outstanding notes and related accrued interest totalling $460,913 into 332,777 shares of Series Z convertible preferred stock. F-13 83 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) In August 1995, the Company received approximately $6.9 million in net proceeds from the issuance of 11,234,809 shares of Series C redeemable convertible preferred stock at $0.62 per share. Pursuant to the terms of certain promissory notes, the Company converted $502,676 of principal and accrued interest into 810,767 shares of Series C redeemable convertible preferred stock at $0.62 per share. In April 1996, upon the achievement of certain milestones, the Company received an additional $3.1 million in net proceeds from the issuance of an additional 5,112,910 shares of Series C redeemable convertible preferred stock at $0.62 per share. In November 1996, the Company received approximately $9.9 million in net proceeds from the issuance of 9,869,205 shares of Series D redeemable convertible preferred stock at $1.00 per share. At the option of the holder, the shares of Series A, B, C and D redeemable convertible preferred stock and Series J and Z convertible preferred stock are convertible at any time into common stock, subject to certain anti-dilution adjustments. The preferred shares automatically convert into common stock upon the earlier of: 1) the closing of an underwritten public offering of common stock at not less than $16.00 per common share and an aggregate offering price of not less than $12 million or 2) the written election of at least 70% of the preferred stockholders. The preferred stockholders have voting rights equal to the common shares they would own upon conversion. The Company has reserved 7,754,933 shares of common stock for issuance upon conversion of the Series A, B, C, D, J and Z preferred stock. The Company's Certificate of Incorporation provides for redemption of Series A, B, C and D redeemable convertible preferred stock at any time after December 31, 1998, at the request of at least 70% of the holders of such series. The redemption price is equal to the original issue price plus any declared but unpaid dividends. The preferred shareholders are entitled to noncumulative annual dividends of $0.04, $0.06, $0.05, $0.08 and $0.04 per share of Series A, B, C and D redeemable convertible preferred stock and Series Z convertible preferred stock, respectively, if and when such dividends are declared by the Board of Directors. No dividends have been declared to date. In connection with employment agreements, certain employees received options to purchase the Company's Series J convertible preferred stock exercisable upon the achievement of certain milestones. Some of the milestones were met during 1997, and the remainder were met in the first quarter of 1998, and in connection therewith, the Company issued 232,500 shares of Series J convertible preferred stock to the employees. 1995 Stock Option/Stock Issuance Plan In 1995, the Board of Directors adopted the 1995 Stock Option/Stock Issuance Plan (the 1995 Plan), under which 2,355,069 shares of common stock are reserved for issuance upon exercise of options or stock issuances by the Company to certain employees of and consultants to the Company. Under the stock option program, options may be designated as incentive stock options or nonstatutory stock options. Options under the 1995 Plan have a term of up to ten years from the date of grant. The exercise price of incentive stock options must equal at least the fair market value on the date of grant, and the exercise price of nonstatutory stock options may be no less than 85% of the fair market value on the date of grant. Options generally vest over four to five years. F-14 84 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) The Company recorded $1,773,973 of deferred compensation for options granted during the year ended December 31, 1997, representing the difference between the option exercise price and management's estimate of the fair value for financial statement presentation purposes. Management's estimate of fair value of the common stock was based upon the sale of Series D Preferred Stock completed in November 1996 and the sale of common stock to Elan/Athena and ImClone in October 1997. Between the dates of these equity sales, management's estimate of the fair value of common stock was periodically increased as the Company signed collaborative agreements, hired key personnel, and achieved scientific progress on its research programs, including the completion of the Universal Informer Library. The Company is amortizing the deferred compensation over the vesting period of the options. The Company recorded $191,651 of compensation expense during the year ended December 31, 1997 and $110,409 during the three months ended March 31, 1998. Certain employees have elected to purchase the underlying shares prior to vesting. The Company has the option to repurchase, at the original issue price, any unvested shares in the event of termination of service. At March 31, 1998, 779,625 shares were subject to repurchase by the Company. 1997 Stock Incentive Plan The Company's 1997 Stock Incentive Plan (the 1997 Plan) is intended to serve as the successor equity incentive program to the Company's 1995 Plan. The 1997 Plan was adopted by the Board of Directors and the stockholders on October 7, 1997 and will become effective upon completion of the initial public offering contemplated by this Prospectus. A total of 1,072,170 shares of Common Stock have been authorized for issuance under the 1997 Plan. Under the 1997 Plan, options may be designated as incentive stock options or nonstatutory stock options. Options under the 1997 Plan have a term of up to 10 years from the date of grant. The exercise price of options shall be fixed by the plan administrator, but shall not be less than 100% of the fair market value per share of common stock on the option grant dates. Under the 1997 Plan, selected employees and consultants may be issued shares of common stock at no less than 100% of the fair market value on the date of grant. The vesting schedule for each share issuance is determined by the Board of Directors as Plan Administrator. 1997 Employee Stock Purchase Plan The 1997 Employee Stock Purchase Plan (the Purchase Plan) was adopted by the Board of Directors and the stockholders on October 7, 1997 and will become effective upon completion of the initial public offering contemplated by this Prospectus. A total of 150,000 shares of Common Stock have been authorized for issuance under the Purchase Plan. The Purchase Plan permits eligible employees of the Company to purchase shares of Common Stock, at semi-annual intervals, through periodic payroll deductions. Payroll deductions may not exceed 10% of the participant's base salary, and the purchase price will not be less than 85% of the lower of the fair market value of the stock at either the beginning or the end of the semi-annual intervals. F-15 85 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) Information with respect to the 1995 Plan is as follows:
WEIGHTED AVERAGE SHARES EXERCISE PRICE ---------- -------------- Granted........................................... 562,980 $0.30 Exercised....................................... -- -- Canceled........................................ -- -- ---------- Balance at December 31, 1995...................... 562,980 0.30 Granted......................................... 531,479 0.30 Exercised....................................... (72,589) 0.30 Canceled........................................ (12,536) 0.30 ---------- Balance at December 31, 1996...................... 1,009,334 0.30 Granted......................................... 721,543 2.79 Exercised....................................... (1,210,310) 0.45 Canceled........................................ (32,471) 0.34 ---------- Balance at December 31, 1997...................... 488,096 3.56 ---------- Granted......................................... 47,500 8.00 Exercised....................................... -- -- Canceled........................................ -- -- ---------- ----- Balance at March 31, 1998......................... 535,596 $3.95 ========== =====
At March 31, 1998, options to purchase 535,596 shares were exercisable and 536,574 shares remain available for grant. Following is a further breakdown of the options outstanding as of March 31, 1998:
WEIGHTED AVERAGE WEIGHTED WEIGHTED EXERCISE RANGE OF AVERAGE AVERAGE PRICE OF EXERCISE OPTIONS REMAINING EXERCISE OPTIONS OPTIONS PRICES OUTSTANDING LIFE IN YEARS PRICE EXERCISABLE EXERCISABLE -------- ----------- ------------- -------- ----------- ----------- $0.30 -- $0.40 88,250 7.95 $0.33 88,250 $0.33 $1.00 27,500 9.30 1.00 27,500 1.00 $2.00 -- $3.00 16,875 7.56 2.74 16,875 2.74 $4.00 -- $5.00 315,716 6.15 4.16 315,716 4.16 $8.00 87,255 9.71 8.00 87,255 8.00 ------- ---- ----- ------- ----- 535,596 7.09 $3.95 535,596 $3.95 ======= ==== ===== ======= =====
Adjusted pro forma information regarding net loss and net loss per share is required by SFAS No. 123, and has been determined as if the Company had accounted for its employee stock options and stock purchase plan under the fair value method of SFAS No. 123. The fair value for these options was estimated at the date of grant using the "Minimum Value" method for option pricing with the following assumptions for 1995, 1996 and 1997: risk-free interest rates of 6.50%; dividend yield of 0%; and a weighted-average expected life of the options of five years. F-16 86 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) For purposes of adjusted pro forma disclosures, the estimated fair value of the options are amortized to expense over the vesting period. The Company's adjusted pro forma information is as follows:
THREE MONTHS ENDED YEAR ENDED DECEMBER 31, MARCH 31, --------------------------------------- ----------- 1995 1996 1997 1998 ----------- ----------- ----------- ----------- Adjusted pro forma net loss........ $(6,678,067) $(5,137,253) $(4,376,686) $(1,456,366) Adjusted pro forma basic net loss per share........................ $ (2.93) $ (0.92) $ (0.50) $ (0.14)
The weighted-average fair value of options granted during 1995, 1996 and 1997 was $0.08, $0.08, and $0.72, respectively and for the first three months of 1998 was $8.00. The pro forma effect on net loss for 1995, 1996, 1997 and 1998 is not likely to be representative of the pro forma effects on reported net income or loss in future years because these amounts reflect less than four years of vesting. Warrants At March 31, 1998, the Company has issued warrants to purchase an aggregate of 130,728 shares of redeemable convertible preferred stock at prices ranging from $2.00 to $2.48 per share. The warrants are exercisable in whole or in part through various dates. The Company also has issued warrants to purchase 8,750 shares of common stock at $0.30 per share. The warrants are exercisable in whole or in part at any time at or prior to June 2000. 6. NOTES RECEIVABLE FROM EMPLOYEE/STOCKHOLDERS During 1995, the Company lent $150,000 to an employee and stockholder for the purchase of a residence in connection with the individual's employment agreement. The note bears interest at approximately 5.8% and matures on the earlier of (i) September 5, 2000, (ii) 30 days following cessation of employment, (iii) 180 days following the date at which the Company completes a successful initial public offering of shares of its common stock, or (iv) the date on which more than 50% of the Company's outstanding shares of common stock are acquired by a single purchaser or a group of purchasers. The note is secured by 87,500 shares of the Company's common stock owned by the employee at the date of the note, plus any capital stock thereafter acquired. In August 1996, the Company lent $66,125 to an employee for relocation in connection with employment, which is secured by a deed of trust. The loan is represented by a promissory note which is due and payable on the earlier of August 28, 1999 or the occurrence of certain events, such as expiration of the 30-day period following the date the individual ceases to be a full time employee of the Company. The loan bears no interest, and principal payments of $22,000 have been made to date. During 1997, the Company instituted an employee loan program whereby the proceeds of the loan are used to purchase common stock from the exercise of the employee's stock options. Under the program, the employee pays 25% of the total exercise price, and the Company loans the employee the F-17 87 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) remaining 75% of the purchase price. The loans bear interest at an adjustable rate that is the minimum rate allowable by the Internal Revenue Service, subject to quarterly adjustments by the Company. The loans will be repaid through 3 equal payments on the first three anniversary dates of the loan. The Company has $419,061 in loans outstanding at December 31, 1997 and March 31, 1998. 7. COLLABORATIVE AGREEMENTS Athena Neurosciences, Inc., a wholly owned subsidiary of Elan Corporation, plc In October 1997, the Company entered into a multiple project collaborative agreement with Athena Neurosciences, Inc., a wholly owned subsidiary of Elan Corporation, plc (Elan/Athena) providing for a three-year research program to discover novel therapeutic compounds for treatment of central nervous system conditions. The first project was initiated upon signing of this collaboration agreement, with a second project authorized in March 1998, for which Elan/Athena has agreed to provide additional research funding. The agreement provides for Elan/Athena's access to the Universal Informer Library as deemed necessary by the research management committee composed of Elan/Athena and CombiChem representatives. Under the agreement, Elan/Athena paid a project initiation fee and agreed to provide research funding and milestone payments upon the achievement of pre-determined objectives. Elan/Athena will also make royalty payments on worldwide sales of products resulting from the collaboration. The agreement may be terminated by either party 90 days following an uncured material breach or by Elan/Athena after the one-year anniversary upon 90 days prior written notice. Additionally, in March 1998, Elan/Athena purchased an option for an undisclosed fee creditable against future project initiation fees, if any, covering an additional target (for a potential future project) not previously covered by the initial collaborative agreement. In connection with the initial collaborative agreement, Elan International Services Ltd., an affiliate of Elan/Athena, purchased 1,000,000 shares of Common Stock for $8.0 million. In addition, Elan International Services Ltd., a stockholder of CombiChem, and a wholly owned subsidiary of Elan Corporation, plc (whose wholly owned subsidiary, Athena Neurosciences, Inc. is a collaborative partner of CombiChem), has expressed an interest in acquiring approximately $2 million of the shares of Common Stock offered hereby at the initial public offering price. ImClone Systems Incorporated In October 1997, the Company entered into a collaborative agreement with ImClone Systems Incorporated (ImClone) providing for a two-year research program to identify and characterize novel small molecule inhibitors to multiple targets for development in oncology. The agreement provides for ImClone's access to the Company's Universal Informer Library and Virtual Library under the supervision of the research management committee composed of representatives of the Company and ImClone. Under the terms of the agreement, ImClone will provide the Company with research support payments, milestone payments upon the achievement of certain program objectives and royalties on worldwide product sales of therapeutic products that may arise out of the collaboration. The agreement may be terminated by either party 90 days following an uncured material breach or by ImClone within 30 days prior to the one-year anniversary by providing 90 days' prior written notice. In connection with the collaborative agreement, ImClone purchased 250,000 shares of Common Stock for $2.0 million. F-18 88 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) Roche Bioscience, a division of Syntex (U.S.A.) Inc. In October 1996, the Company entered into a collaborative agreement with Roche Bioscience providing for a broad two-year research program to perform research against three initial targets, including a protein-protein interaction, an enzyme and a receptor, with an option to add additional targets. Roche Bioscience can elect one of the approaches -- lead generation, lead evolution or lead optimization -- for each research program against each collaboration target. A program may be initiated at any time during the term of the collaboration, thereby extending the term to allow for completion of each program. Under the agreement, Roche Bioscience paid a project initiation fee to CombiChem and agreed to provide research funding and to make milestone payments upon the achievement of certain preclinical and clinical milestones. Roche Bioscience will make royalty payments on worldwide sales of products resulting from the collaboration. Upon completion of the first year of the agreement, Roche Bioscience may terminate the collaboration at any time upon six months' prior written notice. Certain special conditions could also allow Roche Bioscience to terminate with 45 days' prior written notice. Sumitomo Pharmaceuticals Co., Ltd. In August 1997, the Company entered into a collaborative agreement with Sumitomo Pharmaceuticals Co. Ltd. (Sumitomo) providing for a two-year lead evolution program on a target that is believed to play a fundamental role in osteoarthritis and rheumatoid arthritis. Under the agreement, Sumitomo paid a project initiation fee and agreed to provide research funding and milestone payments upon the achievement of certain preclinical and clinical milestones. Sumitomo will make royalty payments on worldwide sales of products resulting from the collaboration. Sumitomo may extend the research period for up to four successive six-month periods upon mutual agreement. The agreement may be terminated by either party 90 days following an uncured material breach. Teijin Limited In March 1996, the Company entered into a collaborative agreement with Teijin Limited (Teijin) providing for a one-year research program on a G-protein coupled receptor target. In March 1997, the Company and Teijin amended their agreement to extend the research phase of the collaborative agreement for an additional year. While the initial focus of the collaboration was lead optimization, the effort was redirected to lead evolution during the course of the research. Under the agreement, Teijin paid a project initiation fee to CombiChem and agreed to provide research funding and milestone payments upon the achievement of certain preclinical and clinical milestones. Teijin also committed internal resources to the discovery effort. Teijin will make royalty payments on products resulting from the collaboration. CombiChem retains the rights to the compounds arising under this collaboration in North and South America; Teijin has rights to these compounds in Asia and Europe with a right of first negotiation to acquire CombiChem's rights. Under the original agreement, either party may terminate the agreement in the event of a material breach remaining uncured for 60 days. As of March 31, 1998, the Company has successfully concluded its research phase and delivered lead candidates to Teijin for further development. As this development process continues, CombiChem expects to receive additional payments from Teijin if certain milestones are met. F-19 89 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) 8. BENEFIT PLAN The Company sponsors a benefit plan which covers employees who meet certain age and service requirements. Employees may contribute a portion of their earnings each plan year subject to certain Internal Revenue Service limitations. The Company made no discretionary contributions to the plan for the years ended December 31, 1995, 1996 and 1997 or the three months ended March 31, 1998. 9. INCOME TAXES At December 31, 1997, the Company had federal and California income tax net operating loss carryforwards of approximately $15,411,000 and $15,517,000, respectively. The federal and California tax loss carryforwards will begin to expire in 2009 and 2002, respectively, unless previously utilized. The Company also has federal and California research tax credit carryforwards of approximately $379,000 and $275,000, respectively, which will begin to expire in 2010 unless previously utilized. The Company also has a federal foreign tax credit carryforward of approximately $200,000, which will expire in 2002 unless previously utilized. Pursuant to Sections 382 and 383 of the Internal Revenue Code, annual use of approximately $7 million and $200,000 of the Company's net operating loss and credit carryforwards, respectively, may be limited because of cumulative changes in ownership of more than 50% which occurred during 1995. However, annual limitation will not prevent the entire amount of the net operating loss and credit carryforwards from being used during the carryforward period. Therefore, the Company does not believe such limitation will have a material effect upon the utilization of these carryforwards. Significant components of the Company's deferred tax assets are shown below. A valuation allowance, which was increased by $2,211,000 in 1997, has been recognized to offset the deferred tax assets as of December 31, 1996 and 1997 as realization of such assets is uncertain.
DECEMBER 31, ----------------------------------------- 1995 1996 1997 ----------- ----------- ----------- Deferred tax assets: Net operating loss carryforwards.................. $ 2,651,000 $ 4,792,000 $ 6,325,000 Research and development credits........................ 179,000 198,000 558,000 Foreign tax credit................ -- -- 200,000 Other, net........................ 29,000 122,000 240,000 ----------- ----------- ----------- Total deferred tax assets.................. 2,859,000 5,112,000 7,323,000 Valuation allowance for deferred tax assets............................ (2,859,000) (5,112,000) (7,323,000) ----------- ----------- ----------- Net deferred tax assets............. $ -- $ -- $ -- =========== =========== ===========
The Company recorded foreign tax expense of $200,000 for the year ended December 31, 1997 for taxes payable to a Japanese tax authority resulting from the revenue recognized on the Sumitomo collaboration. F-20 90 COMBICHEM, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 1997 (Information subsequent to December 31, 1997 and pertaining to March 31, 1998 and the three-month periods ended March 31, 1997 and 1998 is unaudited) 10. SUBSEQUENT EVENTS New Collaborative Agreement In March 1998, the Company entered into a collaborative agreement with ICOS Corporation (ICOS) providing for a lead evolution project on an identified, undisclosed target. Under the agreement, ICOS receives exclusive global rights to develop and market any products resulting from the collaboration. ICOS agreed to pay CombiChem an advance payment of $350,000, due in April 1998, research funding, payments upon achievement of certain clinical milestones and royalty payments on any product sales. The advance payment has been recorded as deferred revenue and will be recognized when the Company's performance obligations have been met. The lead evolution project terminates on August 31, 2000. The agreement may be terminated by either party 90 days following an uncured material breach. Feasibility Study In March 1998, the Company entered into an agreement with an unnamed pharmaceutical company to allow the pharmaceutical company to perform a feasibility study, which could lead to a collaborative agreement, in exchange for an advance payment of $300,000 due in April 1998. The advance payment has been recorded as deferred revenue and will be recognized when the Company's performance obligations have been met. F-21 91 [DEPICTIONS OF ACTIVE SITES AND COMPOUNDS] Using only the structures of compounds screened against a known HIV protease target, CombiChem's Discovery Engine(TM) has generated a hypothesis (a computational model), as depicted here, which illustrates potentially important characteristics of the HIV protease active binding site. X-ray crystallography has determined the actual three-dimensional structure of the active binding site of the HIV protease target, as shown here. In this example, CombiChem's computer-generated hypothesis has identified certain important characteristics of the HIV protease active binding site as demonstrated by the lock-and-key structural fit depicted in this overlay. 92 [CombiChem Logo] 93 PART II INFORMATION NOT REQUIRED IN PROSPECTUS ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. The following table sets forth all expenses, other than underwriting discounts and commissions, payable by the Registrant in connection with the sale of the Common Stock being registered. All the amounts shown are estimates, except for the registration fee, the Nasdaq National Market filing fee and the NASD fee. Registration fee............................................ $ 10,194 Nasdaq National Market fee.................................. 87,000 NASD fee.................................................... 3,864 Blue Sky fees and expenses.................................. 10,000 Printing and engraving expenses............................. 230,000 Legal fees and expenses..................................... 335,000 Accounting fees and expenses................................ 190,000 Transfer Agent and Registrar fees........................... 5,000 Miscellaneous expenses...................................... 128,942 ---------- TOTAL............................................. $1,000,000 ==========
ITEM 14. INDEMNIFICATION OF OFFICERS AND DIRECTORS. Section 145 of the Delaware General Corporation Law permits indemnification of officers and directors of the Company under certain conditions and subject to certain limitations. Section 145 of the Delaware General Corporation Law also provides that a corporation has the power to purchase and maintain insurance on behalf of its officers and directors against any liability asserted against such person and incurred by him or her in such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such liability under the provisions of Section 145 of the Delaware General Corporation Law. Article VII, Section 1 of the Restated Bylaws of the Company provides that the Company shall indemnify its directors and executive officers to the fullest extent not prohibited by the Delaware General Corporation Law. The rights to indemnity thereunder continue as to a person who has ceased to be a director, officer, employee or agent and inure to the benefit of the heirs, executors and administrators of the person. In addition, expenses incurred by a director or executive officer in defending any civil, criminal, administrative or investigative action, suit or proceeding by reason of the fact that he or she is or was a director or officer of the Company (or was serving at the Company's request as a director or officer of another corporation) shall be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Company as authorized by the relevant section of the Delaware General Corporation Law. As permitted by Section 102(b)(7) of the Delaware General Corporation Law, Article V, Section (A) of the Company's Certificate of Incorporation provides that a director of the Company shall not be personally liable for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or acts or omissions that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law or (iv) for any transaction from which the director derived any improper personal benefit. The Company has entered into indemnification agreements with each of its directors and executive officers. Generally, the indemnification agreements attempt to provide the maximum II-1 94 protection permitted by Delaware law as it may be amended from time to time. Moreover, the indemnification agreements provide for certain additional indemnification. Under such additional indemnification provisions, however, an individual will not receive indemnification for judgments, settlements or expenses if he or she is found liable to the Company (except to the extent the court determines he or she is fairly and reasonably entitled to indemnity for expenses), for settlements not approved by the Company or for settlements and expenses if the settlement is not approved by the court. The indemnification agreements provide for the Company to advance to the individual any and all reasonable expenses (including legal fees and expenses) incurred in investigating or defending any such action, suit or proceeding. In order to receive an advance of expenses, the individual must submit to the Company copies of invoices presented to him or her for such expenses. Also, the individual must repay such advances upon a final judicial decision that he or she is not entitled to indemnification. The Company has purchased directors' and officers' liability insurance. The Company intends to enter into additional indemnification agreements with each of its directors and executive officers to effectuate these indemnity provisions. The Underwriting Agreement (Exhibit 1.1 hereto) contains provisions by which the Underwriters have agreed to indemnify the Company, each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, each director of the Company, and each officer of the Company who signs this Registration Statement, with respect to information furnished in writing by or on behalf of the Underwriters for use in the Registration Statement. ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES: Since September 30, 1994, the Company has sold and issued the following unregistered securities (adjusted to give effect to the reverse stock split in October 1997): (1) From September 30, 1994 to March 31, 1998, the Company issued an aggregate of 1,863,502 options to purchase Common Stock with exercise prices ranging from $.248 to $8.00 per share under the Predecessor Plan and an aggregate of 1,282,899 shares of Common Stock were issued through the exercise of options granted under the Predecessor Plan for an aggregate exercise price of $527,216. For additional information concerning these transactions, reference is made to the information contained under the caption "Management -- Benefit Plans" in the form of the Prospectus included herein. (2) On October 14, 1994, the Company issued 50,000 shares of Series Z Preferred Stock to Sydney Brenner for an aggregate consideration of $100,000. (3) On October 18, 1994, the Company issued 125,000 shares of Common Stock to Robert A. Curtis, former Chief Executive Officer of the Company, at $0.04 per share, of which 57,290 were vested as of the date of the termination of his employment in October 1995. (4) On October 18, 1994, the Company issued an aggregate of 625 shares of Common Stock to one investor for an aggregate consideration of $25. (5) On November 1, 1994, the Company issued an aggregate of 100,000 shares of Series A Preferred Stock to certain funds advised by Sequoia Capital for an aggregate consideration of $200,000. (6) On November 1, 1994, the Company issued an aggregate of 25,000 shares of Common Stock to certain venture funds advised by Sequoia Capital for an aggregate consideration of $5,000. (7) On November 8, 1994, the Company issued an aggregate of 43,750 shares of Common Stock to one investor for an aggregate consideration of $8,750. (8) On November 18, 1994, the Company issued an aggregate of 2,500 shares of Common Stock to one investor for an aggregate consideration of $500. II-2 95 (9) From November 23, 1994 through January 15, 1995, the Company issued an aggregate of 556,669 shares of Series B Preferred Stock to certain funds advised by Sequoia Capital, Forward Ventures II, L.P. and an individual investor for an aggregate consideration of $1,670,000. (10) In December 1994, the Company issued a warrant to purchase 20,914 shares of Series Z Preferred Stock to Comdisco, Inc. at an exercise price of $2.00 per share in connection with an equipment lease financing. (11) From January 1, 1995 through April 24, 1995, the Company issued an aggregate of 32,500 shares of Common Stock to eight investors for an aggregate consideration of $9,750. (12) On March 20, 1995, the Company issued an aggregate of 100,000 shares of Common Stock to The Scripps Research Institute for an aggregate consideration of $40,000. (13) From April 25, 1995 through July 30, 1995, the Company issued an aggregate of 162,500 shares of Common Stock to three investors for an aggregate consideration of $48,750. (14) On June 15, 1995, the Company issued a warrant to purchase 8,750 shares of Common Stock to LJL BioSystems, Inc. at an exercise price of $0.30. (15) In connection with an asset purchase agreement dated August 4, 1995, the Company issued an aggregate of 83,195 shares of Series Z Preferred Stock to Molecular Simulations, Inc. from June 1996 through July 1996 in consideration for certain technology rights. (16) On August 5, 1995, the Company issued 1,500 shares of Common Stock to Ken Rubenstein at $0.30 per share in connection with a consulting agreement. (17) On August 17, 1995, August 25, 1995 and September 11, 1995, the Company issued an aggregate of 3,011,402 shares of Series C Preferred Stock to various venture capital funds and certain other investors for an aggregate consideration of $7,468,257. (18) On August 17, 1995, the Company issued warrants to purchase 30,244 shares of Series C Preferred Stock at an exercise price of $2.48 per share. (19) On September 7, 1995, the Company issued 2,017 shares of Series C Preferred Stock to one investor for an aggregate consideration of $5,000. (20) In December 1995, the Company issued an aggregate of 58,125 shares of Series J Preferred Stock to three employees upon the exercise of options to purchase Series J Preferred Stock at an exercise price of $0.40. (21) On April 9, 1996, the Company issued an aggregate of 1,276,215 shares of Series C Preferred Stock to various venture capital funds and certain other investors for an aggregate consideration of $3,165,003. (22) In April 1996 and June 1996, the Company issued warrants to purchase an aggregate of 60,082 shares of Series C Preferred Stock to Comdisco, Inc. at an exercise price of $2.48 per share in connection with an equipment lease financing. (23) In May 1996, the Company issued warrants to purchase an aggregate of 28,227 shares of Series Z Preferred Stock to Silicon Valley Bank and MMC/GATX Partnership No. 1 at an exercise price of $2.48 per share in connection with an equipment lease financing. (24) On November 15, 1996, the Company issued an aggregate of 2,467,310 shares of Series D Preferred Stock to various venture capital funds and certain other investors for an aggregate consideration of $9,869,205. (25) On January 23, 1997, the Company issued an aggregate of 1,250 shares of Common Stock to one investor at $0.40 per share pursuant to a Restricted Stock Issuance Agreement for an aggregate consideration of $500. II-3 96 (26) On June 11, 1997, the Company issued an aggregate of 10,000 shares of Common Stock to one investor at $0.30 per share for an aggregate consideration of $4,000. (27) On July 1, 1997, the Company issued an aggregate of 11,250 shares of Common Stock to the University of Pittsburgh for technology rights valued at $11,250. (28) On October 7, 1997, the Company issued an aggregate of 12,500 shares of Common Stock to two investors for past services rendered to the Company. (29) On October 10, 1997, the Company issued an aggregate of 250,000 shares of Common Stock to ImClone Systems Incorporated in conjunction with a collaboration agreement. (30) On October 15, 1997, the Company issued an aggregate of 1,000,000 shares of Common Stock to Elan International Services Ltd., in conjunction with a collaboration agreement. The sales and issuances of securities in the above transactions were deemed to be exempt under the Act by virtue of Section 4(2) thereof and/or Regulation D and Rule 701 promulgated thereunder as transactions not involving any public offering. The purchasers in each case represented their intention to acquire the securities for investment only and not with a view to the distribution thereof. Appropriate legends were affixed to the stock certificates issued in such transactions. Similar representations of investment intent were obtained and similar legends imposed in connection with any subsequent transfers of any such securities. The Company believes that all recipients had adequate access, through employment or other relationships, to information about the Company to make an informed investment decision. ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. (a) Exhibits.
EXHIBIT NUMBER DESCRIPTION - -------- ----------- 1.1++ Form of Underwriting Agreement. 3.1++ Certificate of Incorporation of the Company, as amended. 3.2++ Form of Amended and Restated Certificate of Incorporation of the Company to become effective immediately prior to the Offering. 3.3++ Bylaws of the Company, as amended. 3.4++ Form of Restated Bylaws of the Company to be effective upon completion of the Offering. 4.1++ Form of Certificate for Common Stock. 5.1++ Opinion of Brobeck, Phleger & Harrison LLP with respect to the Common Stock being registered. 10.1++ Preferred Stock Purchase Agreement for Series A Preferred Stock between the Company and Forward Ventures II, L.P., dated August 26, 1994. 10.2++ Preferred Stock Purchase Agreement for Shares of Series Z Preferred Stock between the Company and Sydney Brenner, dated October 14, 1994. 10.3++ Stock Purchase Agreement for Shares of Series A Preferred Stock and Common Stock between the Company and the investors listed on Exhibit A thereto, dated November 1, 1994. 10.4++ Stock Purchase Agreement Series B Preferred Stock between the Company and the purchasers listed on Exhibit A thereto, dated November 29, 1994. 10.5++ Series C Preferred Stock Purchase Agreement between the Company and the purchasers listed on Schedule A thereto, dated August 17, 1995. 10.6++ Stock Purchase Agreement for Series C Preferred Stock between the Company and Todd Schmidt dated September 7, 1995.
II-4 97
EXHIBIT NUMBER DESCRIPTION - -------- ----------- 10.7*++ Supplemental Purchase Agreement between the Company and the purchasers on Schedule A thereto, dated April 8, 1996. 10.8*++ Series D Preferred Stock Purchase Agreement between the Company and the purchasers listed on Schedule A thereto, dated November 15, 1996. 10.9++ Amended and Restated Investors' Rights Agreement between the Company and the stockholders listed on Schedule A thereto, dated November 15, 1996. 10.10++ Series J Preferred Stock Purchase Agreement between the Company and Steve Teig, dated June 10, 1997. 10.11++ Series J Preferred Stock Purchase Agreement between the Company and Jonathan Greene, dated June 11, 1997. 10.12++ Series J Preferred Stock Purchase Agreement between the Company and Andrew Smellie, dated June 11, 1997. 10.13++ Warrant Agreement to Purchase Shares of the Series Z Preferred Stock, as amended between the Company and Comdisco, Inc., dated December 20, 1994. 10.14++ Common Stock Purchase Warrant between the Company and LJL BioSystems, Inc., dated June 15, 1995. 10.15++ Form of Warrant to Purchase Shares of Series C Preferred Stock between the Company and the purchasers listed on Schedule A thereto, dated August 17, 1995. 10.16++ Form of Warrant Agreement to Purchase Shares of Series C Preferred Stock of the Company, between the Company and Comdisco, Inc. in the amounts listed on Schedule A thereto. 10.17++ Form of Warrant to Purchase Shares of Series Z Preferred Stock between the Company and the purchasers listed on Schedule A thereto, dated May 20, 1996. 10.18++ Master Lease Agreement with the Company and Comdisco Inc., dated November 6, 1994, Schedule VL-1, dated November 11, 1994, Schedule VL-2 dated April 15, 1996 and Schedule VL-3 dated April 15, 1996. 10.19*++ Collaboration Agreement between the Company and Teijin Limited, dated March 29, 1996, as amended. 10.20*++ Collaborative Research and License Agreement between the Company and Roche Bioscience, dated October 25, 1996. 10.21*++ Research and Technology Development Agreement between the Company and Sumitomo Pharmaceuticals Co., Ltd., dated August 18, 1997. 10.22* Collaborative Research and License Agreement between the Company and ImClone Systems Incorporated, dated October 10, 1997. 10.23*++ Collaborative Research and License Agreement between the Company and Athena Neurosciences, Inc., dated October 15, 1997, as amended. 10.24++ Full Recourse Secured Promissory Note and Stock Pledge Agreement between the Company and Peter Myers, dated September 5, 1995. 10.25++ Promissory Note Secured by Deed of Trust between the Company and John Saunders, dated August 30, 1996. 10.26++ Promissory Note between the Company and Vicente Anido, Jr., dated February 24, 1997. 10.27++ Pledge Agreement between the Company and Vicente Anido, Jr., dated February 24, 1997. 10.28++ Promissory Note Secured by Stock Pledge Agreement between the Company and Vicente Anido, Jr., dated June 6, 1997 10.29++ Stock Pledge Agreement between the Company and Vicente Anido, Jr., dated June 6, 1997. 10.30++ Employment Agreement with Peter Myers, dated March 1, 1995.
II-5 98
EXHIBIT NUMBER DESCRIPTION - -------- ----------- 10.31++ Employment Agreement with John Saunders, dated January 1, 1996. 10.32++ Employment Agreement with Steven Teig, dated July 1, 1995. 10.33++ Employment Agreement with Vicente Anido, Jr., dated March 14, 1996. 10.34++ Employment Agreement with Lee R. McCracken, dated May 13, 1996. 10.35++ Employment Letter with Karin Eastham, dated March 14, 1997. 10.36++ Standard Industrial/Commercial Single-Tenant Lease between the Company and Campson Corporation, dated December 22, 1995. 10.37++ Standard Office Lease-Full Service between the Company and Nearon Enterprises, LLC, dated October 24, 1996. 10.38++ Lease Agreement between Harbor Investment Partners and the Company, dated October 6, 1997. 10.39++ 1995 Stock Option/Stock Issuance Plan. 10.40++ 1995 Stock Option/Stock Issuance Plan Form of Notice of Grant. 10.41++ 1995 Stock Option/Stock Issuance Plan Form of Stock Option Agreement. 10.42++ 1995 Stock Option/Stock Issuance Plan Form of Stock Purchase Agreement. 10.43++ 1995 Stock Option/Stock Issuance Plan Form of Restricted Stock Issuance Agreement. 10.44++ 1997 Stock Incentive Plan. 10.45++ 1997 Employee Stock Purchase Plan. 10.46++ Form of Indemnification Agreement between the Company and each of its directors. 10.47++ Form of Indemnification Agreement between the Company and each of its officers. 10.48++ 1997 Stock Incentive Plan Form of Notice of Grant of Stock Option 10.49++ 1997 Stock Incentive Plan Form of Stock Option Agreement 10.50++ 1997 Stock Incentive Plan Form of Addendum to Stock Option Agreement (Involuntary Termination Following Corporate Transaction/Change in Control) 10.51++ 1997 Stock Incentive Plan Form of Addendum to Stock Option Agreement (Limited Stock Appreciation Right) 10.52++ 1997 Stock Incentive Plan Form of Stock Issuance Agreement 10.53++ 1997 Stock Incentive Plan Form of Addendum to Stock Issuance Agreement (Involuntary Termination Following Corporate Transaction/Change in Control) 10.54++ 1997 Stock Incentive Plan Form of Notice of Grant of Automatic Stock Option (Initial Grant) 10.55++ 1997 Stock Incentive Plan Form of Notice of Grant of Automatic Stock Option (Annual Grant) 10.56++ 1997 Stock Incentive Plan Form of Automatic Stock Option Agreement 10.57++ 1997 Employee Stock Purchase Plan Form of Stock Purchase Agreement 10.58* Collaborative Research and License Agreement between the Company and ICOS Corporation, dated March 30, 1998. 11.1++ Statement of Computation of pro forma net loss per share. 23.1++ Consent of Brobeck, Phleger & Harrison LLP (contained in their opinion filed as Exhibit 5.1). 23.2 Consent of Ernst & Young LLP, Independent Auditors. 24.1++ Power of Attorney (see page II-8). 27.1++ Financial Data Schedule.
- --------------- ++ Previously filed with the Commission. II-6 99 * Certain confidential portions of this Exhibit were omitted by means of redacting a portion of the text (the "Mark"). This Exhibit has been filed separately with the Secretary of the Commission without the Mark pursuant to the Company's Application Requesting Confidential Treatment under Rule 406 under the Securities Act. (b) Financial Statement Schedules included separately in the Registration Statement. All other schedules are omitted because they are not required, are not applicable or the information is included in the Financial Statements or Notes thereto. ITEM 17. UNDERTAKINGS. The undersigned hereby undertakes to provide to the Underwriters at the closing specified in the Underwriting Agreement certificates in such denominations and registered in such names as required by the Underwriters to permit prompt delivery to each purchaser. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the provisions described in Item 14, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. The undersigned registrant hereby undertakes that: (1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. (2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. II-7 100 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Company has duly caused this Amendment No. 9 to this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, County of San Diego, State of California, on the 7th day of May, 1998. COMBICHEM, INC. By: /s/ VICENTE ANIDO, JR. ------------------------------------ Vicente Anido, Jr. President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
SIGNATURE TITLE DATE --------- ----- ---- /s/ VICENTE ANIDO, JR. President, Chief Executive Officer and May 7, 1998 - -------------------------------------- Director (Principal Executive Officer) (Vicente Anido, Jr.) Vice President of May 7, 1998 /s/ KARIN EASTHAM Finance and Administration and Chief - -------------------------------------- Financial Officer (Principal Financial (Karin Eastham) and Accounting Officer) * Chairman of the Board and Director May 7, 1998 - -------------------------------------- (Pierre Lamond) * Director May 7, 1998 - -------------------------------------- (Peter L. Myers) * Director May 7, 1998 - -------------------------------------- (Philippe O. Chambon) * Director May 7, 1998 - -------------------------------------- (Arthur Reidel) * Director May 7, 1998 - -------------------------------------- (William Scott)
By: /s/ VICENTE ANIDO, JR. ---------------------------------- Vicente Anido, Jr., Attorney-in-fact II-8 101 EXHIBIT INDEX
SEQUENTIALLY EXHIBIT NUMBERED NUMBER DESCRIPTION PAGE - -------- ----------- ------------ 1.1++ Form of Underwriting Agreement. 3.1++ Certificate of Incorporation of the Company, as amended. 3.2++ Form of Amended and Restated Certificate of Incorporation of the Company to become effective immediately prior to the Offering. 3.3++ Bylaws of the Company, as amended. 3.4++ Form of Restated Bylaws of the Company to be effective upon completion of the Offering. 4.1++ Form of Certificate for Common Stock. 5.1++ Opinion of Brobeck, Phleger & Harrison LLP with respect to the Common Stock being registered. 10.1++ Preferred Stock Purchase Agreement for Series A Preferred Stock between the Company and Forward Ventures II, L.P., dated August 26, 1994. 10.2++ Preferred Stock Purchase Agreement for Shares of Series Z Preferred Stock between the Company and Sydney Brenner, dated October 14, 1994. 10.3++ Stock Purchase Agreement for Shares of Series A Preferred Stock and Common Stock between the Company and the investors listed on Exhibit A thereto, dated November 1, 1994. 10.4++ Stock Purchase Agreement Series B Preferred Stock between the Company and the purchasers listed on Exhibit A thereto, dated November 29, 1994. 10.5++ Series C Preferred Stock Purchase Agreement between the Company and the purchasers listed on Schedule A thereto, dated August 17, 1995. 10.6++ Stock Purchase Agreement for Series C Preferred Stock between the Company and Todd Schmidt dated September 7, 1995. 10.7*++ Supplemental Purchase Agreement between the Company and the purchasers on Schedule A thereto, dated April 8, 1996. 10.8*++ Series D Preferred Stock Purchase Agreement between the Company and the purchasers listed on Schedule A thereto, dated November 15, 1996. 10.9++ Amended and Restated Investors' Rights Agreement between the Company and the stockholders listed on Schedule A thereto, dated November 15, 1996. 10.10++ Series J Preferred Stock Purchase Agreement between the Company and Steve Teig, dated June 10, 1997. 10.11++ Series J Preferred Stock Purchase Agreement between the Company and Jonathan Greene, dated June 11, 1997. 10.12++ Series J Preferred Stock Purchase Agreement between the Company and Andrew Smellie, dated June 11, 1997. 10.13++ Warrant Agreement to Purchase Shares of the Series Z Preferred Stock, as amended between the Company and Comdisco, Inc., dated December 20, 1994. 10.14++ Common Stock Purchase Warrant between the Company and LJL BioSystems, Inc., dated June 15, 1995. 10.15++ Form of Warrant to Purchase Shares of Series C Preferred Stock between the Company and the purchasers listed on Schedule A thereto, dated August 17, 1995.
102
SEQUENTIALLY EXHIBIT NUMBERED NUMBER DESCRIPTION PAGE - -------- ----------- ------------ 10.16++ Form of Warrant Agreement to Purchase Shares of Series C Preferred Stock of the Company, between the Company and Comdisco, Inc. in the amounts listed on Schedule A thereto. 10.17++ Form of Warrant to Purchase Shares of Series Z Preferred Stock between the Company and the purchasers listed on Schedule A thereto, dated May 20, 1996. 10.18++ Master Lease Agreement with the Company and Comdisco Inc., dated November 6, 1994, Schedule VL-1, dated November 11, 1994, Schedule VL-2 dated April 15, 1996 and Schedule VL-3 dated April 15, 1996. 10.19*++ Collaboration Agreement between the Company and Teijin Limited, dated March 29, 1996, as amended. 10.20*++ Collaborative Research and License Agreement between the Company and Roche Bioscience, dated October 25, 1996. 10.21*++ Research and Technology Development Agreement between the Company and Sumitomo Pharmaceuticals Co., Ltd., dated August 18, 1997. 10.22* Collaborative Research and License Agreement between the Company and ImClone Systems Incorporated, dated October 10, 1997. 10.23*++ Collaborative Research and License Agreement between the Company and Athena Neurosciences, Inc., dated October 15, 1997, as amended. 10.24++ Full Recourse Secured Promissory Note and Stock Pledge Agreement between the Company and Peter Myers, dated September 5, 1995. 10.25++ Promissory Note Secured by Deed of Trust between the Company and John Saunders, dated August 30, 1996. 10.26++ Promissory Note between the Company and Vicente Anido, Jr., dated February 24, 1997. 10.27++ Pledge Agreement between the Company and Vicente Anido, Jr., dated February 24, 1997. 10.28++ Promissory Note Secured by Stock Pledge Agreement between the Company and Vicente Anido, Jr., dated June 6, 1997 10.29++ Stock Pledge Agreement between the Company and Vicente Anido, Jr., dated June 6, 1997. 10.30++ Employment Agreement with Peter Myers, dated March 1, 1995. 10.31++ Employment Agreement with John Saunders, dated January 1, 1996. 10.32++ Employment Agreement with Steven Teig, dated July 1, 1995. 10.33++ Employment Agreement with Vicente Anido, Jr., dated March 14, 1996. 10.34++ Employment Agreement with Lee R. McCracken, dated May 13, 1996. 10.35++ Employment Letter with Karin Eastham, dated March 14, 1997. 10.36++ Standard Industrial/Commercial Single-Tenant Lease between the Company and Campson Corporation, dated December 22, 1995. 10.37++ Standard Office Lease-Full Service between the Company and Nearon Enterprises, LLC, dated October 24, 1996. 10.38++ Lease Agreement between Harbor Investment Partners and the Company, dated October 6, 1997. 10.39++ 1995 Stock Option/Stock Issuance Plan. 10.40++ 1995 Stock Option/Stock Issuance Plan Form of Notice of Grant.
103
SEQUENTIALLY EXHIBIT NUMBERED NUMBER DESCRIPTION PAGE - -------- ----------- ------------ 10.41++ 1995 Stock Option/Stock Issuance Plan Form of Stock Option Agreement. 10.42++ 1995 Stock Option/Stock Issuance Plan Form of Stock Purchase Agreement. 10.43++ 1995 Stock Option/Stock Issuance Plan Form of Restricted Stock Issuance Agreement. 10.44++ 1997 Stock Incentive Plan. 10.45++ 1997 Employee Stock Purchase Plan. 10.46++ Form of Indemnification Agreement between the Company and each of its directors. 10.47++ Form of Indemnification Agreement between the Company and each of its officers. 10.48++ 1997 Stock Incentive Plan Form of Notice of Grant of Stock Option 10.49++ 1997 Stock Incentive Plan Form of Stock Option Agreement 10.50++ 1997 Stock Incentive Plan Form of Addendum to Stock Option Agreement (Involuntary Termination Following Corporate Transaction/Change in Control) 10.51++ 1997 Stock Incentive Plan Form of Addendum to Stock Option Agreement (Limited Stock Appreciation Right) 10.52++ 1997 Stock Incentive Plan Form of Stock Issuance Agreement 10.53++ 1997 Stock Incentive Plan Form of Addendum to Stock Issuance Agreement (Involuntary Termination Following Corporate Transaction/Change in Control) 10.54++ 1997 Stock Incentive Plan Form of Notice of Grant of Automatic Stock Option (Initial Grant) 10.55++ 1997 Stock Incentive Plan Form of Notice of Grant of Automatic Stock Option (Annual Grant) 10.56++ 1997 Stock Incentive Plan Form of Automatic Stock Option Agreement 10.57++ 1997 Employee Stock Purchase Plan Form of Stock Purchase Agreement 10.58* Collaborative Research and License Agreement between the Company and ICOS Corporation, dated March 30, 1998. 11.1++ Statement of Computation of pro forma net loss per share. 23.1++ Consent of Brobeck, Phleger & Harrison LLP (contained in their opinion filed as Exhibit 5.1). 23.2 Consent of Ernst & Young LLP, Independent Auditors. 24.1++ Power of Attorney (see page II-8). 27.1++ Financial Data Schedule.
- --------------- ++ Previously filed with the Commission. * Certain confidential portions of this Exhibit were omitted by means of redacting a portion of the text (the "Mark"). This Exhibit has been filed separately with the Secretary of the Commission without the Mark pursuant to the Company's Application Requesting Confidential Treatment under Rule 406 under the Securities Act. EX-10.22 2 EXHIBIT 10.22 1 EXHIBIT 10.22 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN COMBICHEM, INC. AND IMCLONE SYSTEMS INCORPORATED October 10, 1997 2 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the "Agreement") is entered into and made effective as of October 10, 1997 (the "Effective Date"), by and between COMBICHEM, INC., a Delaware corporation having its principal offices at 9050 Camino Santa Fe, San Diego, California ("CombiChem"), and IMCLONE SYSTEMS INCORPORATED, a Delaware corporation having its principal offices located at 180 Varick Street, 7th Floor, New York, New York ("ImClone"). WHEREAS, CombiChem has developed and owns certain drug discovery technology and intellectual property rights, including but not necessarily limited to chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for biological screening assays and medicinal chemistry (collectively, "CombiChem Technology"); WHEREAS, ImClone desires to utilize CombiChem Technology for its drug discovery activities under ImClone know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of human disease in the area of oncology; WHEREAS, the parties wish to collaborate in a Research Program against Collaboration Target(s) ("Collaboration"); WHEREAS, for purposes of the Collaboration, the Parties intend to focus on up to *** Collaboration Targets per *** related to ImClone's Areas of Interest; NOW, THEREFORE, the Parties agree as follows: 1. DEFINITIONS 1.1 "Abandoned Compound" shall have the meaning set forth in Section 3.1. 1.2 "Abandoned Target" shall have the meaning set forth in Section 3.1. 1.3 "Active Compound(s)" means a compound (or compounds) which (a) (i) is selected by either Party under the Research Program from Collaboration Compounds, or (ii) is derived from a Collaboration Compound; and (b) shows In Vitro Activity. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 1 3 1.4 "Additional Target(s)" means a Target that is added to the Collaboration in accordance with Section 4.2. 1.5 "Affiliate" of a Party means any corporation or other business entity controlled by, controlling or under common control with, such Party. For this purpose "control" shall mean direct or indirect beneficial ownership of more than fifty percent (50%) of the voting securities or income interest in such corporation or other business, or if not meeting the preceding requirements, any company owned or controlled by or owning or controlling such Party at the maximum control or ownership right permitted in the country where such company exists. 1.6 "Areas of Interest" shall include *** *** . 1.7 "Collaboration" has the meaning set forth in the preamble. 1.8 "Collaboration Compound(s)" means a compound (or compounds) which (a) is synthesized following the Effective Date for screening against a Collaboration Target under the Research Program, (b) is a pre-existing CombiChem Compound which CombiChem desires to designate as a Collaboration Compound, or (iii) is a pre-existing ImClone Compound which ImClone desires to designate as a Collaboration Compound. 1.9 "Collaboration Target(s)" means either an Initial Target or an Additional Target. 1.10 "CombiChem Compound" means a chemical compound that is proprietary to CombiChem, or whose use or manufacture is proprietary to CombiChem. 1.11 "CombiChem Technology" has the meaning set forth in the preamble. 1.12 "Confidential Information" includes, but is not limited to, (a) all information and materials received by either Party from the other Party pursuant to this Agreement; (b) all information and materials developed in the course of the Collaboration; and (c) the material financial terms of this Agreement. 1.13 "Development Compound(s)" means a compound ( or compounds) which (a) (i) is a Lead Compound or (ii) is derived from a Lead Compound; and *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 2 4 (b) are determined by ImClone to be appropriate for preclinical studies for the purpose of IND filing by ImClone. 1.14 "Due Diligence" means the use of the resources of ImClone or its licensees or CombiChem in a manner which is consistent with the exercise of prudent scientific and business judgment as applied to other programs of ImClone or CombiChem, as the case may be, targeting products aimed at markets or patient groups of similar sizes and of similar scientific and commercial potential. With respect to any Development Compound, "Due Diligence" shall also require ImClone or its licensees to conduct all necessary preclinical studies and to file an IND for such Development Compound within *** from the date upon which ImClone has designated such Development Compound from any Lead Compound or its derivatives. 1.15 "Exclusivity Period" means the Research Period plus twelve (12) months. 1.16 "Field" means all therapeutic indications of human disease for the Collaboration Target. 1.17 "First Commercial Sale" of a Product shall mean the first sale for use or consumption of such Product in a country after required marketing and pricing approval has been granted by the governing health regulatory authority of such country. Sale to an Affiliate or licensee shall not constitute a First Commercial Sale unless the Affiliate or licensee is the end user of the Product. 1.18 "FTE" means full time equivalent with respect to employees of CombiChem. 1.19 "ImClone Compound" means a chemical compound that is proprietary to ImClone, or whose use or manufacture is proprietary to ImClone. 1.20 "Inactive Compound(s)" means a Collaboration Compound(s) which does not have the In Vitro Activity required for an Active Compound. 1.21 "In Vitro Activity" shall mean the observation of *** *** . 1.22 "Initial Target" shall have the meaning set forth in Section 4.1 hereof. 1.23 "Lead Compound(s)" means a compound (or compounds) which (a) is selected from an Active Compound(s) by the RMC under the Research Program, or (b) is derived from Active Compound(s) and is selected by the RMC. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 3 5 1.24 "Net Sales" means the gross sales invoiced by ImClone or its Affiliates or licensees for Products to non-Affiliated Third Parties less actual deductions of returns (including withdrawals and recalls), rebates (price reductions, including Medicaid and similar types of rebates e.g. chargebacks), volume (quantity) discounts, discounts granted at the time of invoicing, the cost of transport, insurance, delivery, sales taxes and other taxes (other than income taxes) directly linked to and included in the gross sales amount, as computed on a product-by-product basis for the countries concerned, whereby the amount of such sales in foreign currencies is converted into United States dollars at the exchange rate of the last business day for each calendar month as reported by Citibank, N.A. (New York). 1.25 "Patent" means, (a) valid and enforceable Letters Patent, including any extension (including Supplemental Protection Certificate), registration, confirmation, reissue, continuation, divisionals, continuation-in-part, reexamination or renewal thereof, or (b) pending applications for any of the foregoing. 1.26 "Payments" shall have the meaning set forth in Section 9.3 1.27 "Party" means CombiChem or ImClone, as the case may be, including their respective Affiliates, permitted successors and assigns. 1.28 "Product(s)" means any product containing a Development Compound with such compound as the active ingredient and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field. 1.29 "Project Team" shall have the meaning set forth in Section 2.1(c). 1.30 "Research Management Committee" or" RMC" has the meaning set forth in Article 6 below. 1.31 "Research Period" means the initial twenty-four (24) month term of the Collaboration, which can be extended in accordance with Section 7.1 below. 1.32 "Research Plan" means the mutually-agreed research plan for the Collaboration attached hereto as Appendix A. 1.33 "Research Program" means the research to be conducted as part of the Collaboration under the Research Plan, and shall include, without limitation, the activities and items set forth in Sections 2.1 and 2.2 of this Agreement. 1.34 "Returned Compound" shall have the meaning set forth in Section 9.2. 4 6 1.35 "Royalty Term" means, in the case of any Product, in any country, the period of time commencing on the First Commercial Sale and ending upon the later of (a) fifteen (15) years from the date of First Commercial Sale in such country; or (b) the expiration of the last-to-expire Patent resulting from the Research Program filed in the Field with claims covering that Product in the relevant country. 1.36 "Target" means a biomolecular entity that a small molecule is screened against in order to determine whether the small molecule demonstrates relevant activity. 1.37 "Territory" means the entire world. 1.38 "Third Party" means an entity other than CombiChem or ImClone or their respective Affiliates. 1.39 "Universal Informer Library" shall mean CombiChem's proprietary Universal Informer Library of compounds. 2. RESEARCH COLLABORATION 2.1 CombiChem Responsibilities. CombiChem shall with Due Diligence conduct the following activities under the Research Program in accordance with the terms of this Agreement and as more fully described in the Research Plan: (a) During the Research Period, CombiChem shall (i) review data and information regarding the Collaboration Targets provided by ImClone; (ii) based on such data and information and using the CombiChem Technology, design informative compound libraries; and (iii) supply all lead chemistries and synthesize compounds as provided in Section 5.3 below. (b) During the Research Period, CombiChem shall keep ImClone informed of its activities performed in connection with the Collaboration, including, without limitation, providing ImClone with data and information regarding Collaboration Compounds prior to the meetings of the Research Management Committee. (c) Subject to Article 4 and at all times during the Research Period, CombiChem shall dedicate a project team of five (5) FTEs comprised of synthetic and analytical chemists, compound control scientists, and a computational scientist (the "Project Team") to conduct all of its activities in connection with the Collaboration; provided, however, that the RMC may at any time during the Research Period substitute employees for the FTEs described above; provided, further, that 5 7 ImClone may request that CombiChem expand its Project Team by adding additional FTEs to work on the Collaboration at the rate and in the manner specified in Section 8.2(b). 2.2 ImClone Responsibilities. ImClone shall with Due Diligence provide CombiChem with the following resources under the Research Program as more fully described in the Research Plan: (a) ImClone shall provide CombiChem with support and assistance useful or necessary for the conduct of the Research Program, including providing data and information (including leads and/or screening hits to the extent available) relating to Collaboration Targets, certain chemistries useful in compound synthesis, information concerning assay methods and screening data. (b) During the Research Period, ImClone shall provide CombiChem with data and information regarding Collaboration Compounds and the Collaboration Target assays developed by ImClone under the Research Program prior to the meetings of the Research Management Committee. (c) During the Exclusivity Period and with Due Diligence, ImClone shall screen Collaboration Compounds for In Vitro and, where appropriate, in vivo activity against the Collaboration Target. (d) During the Exclusivity Period and with Due Diligence, ImClone shall (i) screen Lead Compounds, (ii) endeavor to determine Development Compounds, and (iii) develop Products. 2.3 Research Plan. The Parties hereby agree that the Research Program shall be carried out in accordance with the Research Plan which is attached hereto as Appendix A. At the direction of the RMC, the Research Program shall involve the use of CombiChem's Universal Informer Library in order to initiate CombiChem's discovery process with the objective of identifying Lead Compounds with respect to a specific Collaboration Target. The Research Management Committee shall review the Research Plan on an ongoing basis and may make changes to the Research Plan so long as such changes are mutually agreed to by CombiChem and ImClone. 2.4 Annual Reports. Following the first IND filing through First Commercial Sale, ImClone shall provide CombiChem with an annual report summarizing ImClone's activities in developing Development Compounds. 6 8 2.5 Third Party Licenses. Each Party shall be solely responsible for any Third Party license fees required to perform its obligations under this Agreement subject to Section 8.4. Any agreements between a Party and a Third Party shall in all material respects permit performance under this Agreement. 3. EXCLUSIVITY 3.1 Collaboration Target Exclusivity. So long as ImClone or its licensee is proceeding with Due Diligence, CombiChem shall not work on a Collaboration Target with any Third Parties. In the event that ImClone or its licensee fails to exercise Due Diligence with respect to, or notifies CombiChem that it has abandoned work on, any Collaboration Target (an "Abandoned Target") and any Collaboration Compound, other than an ImClone Compound which is subject to the rights of a Third Party licensor, associated with such Collaboration Target (together with all derivatives of such Collaboration Compound, an "Abandoned Compound"), then, (a) such Abandoned Target shall not be subject to any provision hereunder, and (b) such Abandoned Compound shall be available to CombiChem for any purpose thereafter. 3.2 Active Compounds. (a) Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to ImClone during the Research Period. Following the expiration of the Research Period, Active Compounds with respect to which ImClone fails to proceed with Due Diligence shall be deemed to be Inactive Compounds for all purposes hereunder; provided, that any Active Compound which is the subject of claim(s) under a pending Patent shall continue to be treated as an Active Compound during the Exclusivity Period so long as ImClone exercises Due Diligence with respect to any Collaboration Compound. (b) Prior to the existence of Patent(s) in accordance with Section 5.2, ImClone shall have exclusive rights in all intellectual property relating to Active Compounds, their use, and method of manufacture so long as ImClone continues to show Due Diligence under this Agreement; provided, however, that ImClone acknowledges and agrees that CombiChem reserves the right to assign or grant exclusive rights, including rights to Active Compounds, to a third party collaborator who first identifies a novel compound, a novel use of a compound, or a novel method of manufacturing a compound, to the extent CombiChem is obligated to do so under its existing contractual obligations. Upon notice by ImClone that it intends to file a Patent application with respect to any Active Compound, Lead Compound, Development Compound or Product, CombiChem shall promptly inform ImClone whether CombiChem has the power to grant the exclusive rights in accordance with this Section 3.2 and the assignments in accordance with Section 5.2; provided, however, that under no circumstances CombiChem will grant assurances to ImClone to the effect that any Active Compound, Lead Compound, Development Compound or Product is not covered under the patent claims of Third Parties wherein such claims are not the direct result of a collaboration between the Third Party and CombiChem. 7 9 3.3 Inactive Compounds/Returned Compounds. Subject to Section 9.4, Inactive Compounds and Returned Compounds shall be available to both Parties for any purpose. 4. TARGETS 4.1 Initial Targets. During the Research Period, ImClone may designate up to *** Collaboration Targets per *** under the Research Program. During the initial *** *** of the Research Program, subject to the Research Plan it is anticipated that the Collaboration shall initially focus on up to *** Targets as follows: **** *** (collectively, the "Initial Targets"). With respect to Collaboration Targets, the RMC will determine whether to continue to pursue work against designated Collaboration Targets and will prioritize the activities of the Project Team against such Collaboration Targets. In the event that the results of the initial screening activities of ImClone with respect to the Initial Targets specified in Section 4.1 *** *** which shall determine whether such Targets are suitable for designation as Additional Targets. Subject to the dispute resolution mechanism provided for in Article 6, ImClone shall have the right to make a final determination as to whether to continue or pursue work against any Collaboration Target if the respective Chief Executive Officers of CombiChem and ImClone are unable to resolve any dispute concerning the same. In addition, ImClone's right to designate or substitute a Target (including those Additional Targets set forth in Section 4.2) relating to ImClone's Areas of Interest shall be subject to the written notice and approval requirements specified in Section 4.2(b). 4.2 Additional Targets. (a) Within ninety (90) days prior to the commencement of the second 12-month period of the Research Program, ImClone may add up to *** relating to ImClone's Areas of Interest to the Collaboration by notifying CombiChem in writing that it wishes to designate such Target(s) as Additional Target(s); it being understood that the Project Team shall be obligated to simultaneously work on no more than *** Collaboration Targets as directed by the RMC. (b) If CombiChem has already committed to working on a proposed Additional Target or has delivered a term sheet to any Third Party and remains in discussions to enter into a binding agreement with such Third Party with respect to the proposed Target at the time of notification, CombiChem shall inform ImClone that such proposed Additional Target is not available. Otherwise, the RMC shall establish the specific scientific achievements (to be mutually agreed between CombiChem and ImClone) for such Target and the same shall be designated as an Additional Target for the Collaboration and subject to the terms (including the commercial terms) of this Agreement. 4.3 Expansion of Project Team. Notwithstanding the provisions of Sections 4.1 and 4.2, ImClone may request that CombiChem expand its Project Team during the Research Period *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 8 10 in order to accelerate work on Collaboration Targets and/or to add additional Target(s). In such event, the RMC shall promptly confer as to the appropriate number of FTEs to be added to Project Team to work on the Collaboration at a cost to ImClone as specified in Section 2.1(c). 5. COLLABORATION COMPOUNDS 5.1 Pre-Existing Compounds. ImClone shall have no rights to any pre-existing CombiChem Compound unless and until such compound is designated as a Collaboration Compound by CombiChem. Additionally, CombiChem may decline to synthesize a particular compound or library of compounds by reason of existing Patents or contractual obligations. CombiChem shall have no rights to any pre-existing ImClone Compound which is not utilized in the Research Program. 5.2 Intellectual Property Rights; Assignment to ImClone. Subject to Section 3.2(b) above, ImClone shall have the right and responsibility at ImClone's expense to file, maintain and prosecute Patents relating to Active Compounds, Lead Compounds, Development Compounds and Products, their use, and their methods of manufacture. At ImClone's request, CombiChem shall assign all its right, title and interest in such Patents to ImClone. If ImClone fails to so file, maintain or prosecute such Patent, CombiChem shall have the right to request ImClone to do so. If ImClone elects not to file, maintain or prosecute such Patent, CombiChem shall have the right to take over such filing, maintenance or prosecution of such Patent, at its sole expense, and ImClone shall assign all intellectual property rights it may have in the Active Compound, Lead Compound, Development Compound or Product to CombiChem. 5.3 Supply of Collaboration Compounds. Aliquots of *** of any Collaboration Compound that has been synthesized will be prepared and given to ImClone. CombiChem shall replenish that amount upon ImClone's reasonable request. CombiChem shall maintain aliquots of any Collaboration Compound that has been synthesized by CombiChem. CombiChem shall also provide ImClone with additional requirements of samples at CombiChem's cost. 6. RESEARCH MANAGEMENT COMMITTEE The design, review and conduct of the Research Program will be coordinated by the Research Management Committee, which will meet regularly on a mutually-agreeable schedule. The Research Management Committee may establish and amend or revise the Research Plan as necessary to reflect the scientific progress and work performed under the Research Program, such amendments to be mutually agreed to by ImClone and CombiChem. The Research Management Committee will consist of an equal number of members from ImClone and CombiChem and will include appropriate representatives from ImClone and CombiChem as mutually agreed. The co-chairs of the Research Management Committee will initially be the Vice President, Chemistry of CombiChem and the Vice President for Research of ImClone and subsequently may change as mutually-agreed upon by the Parties. Decisions of the Research Management Committee shall be by *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 9 11 consensus. If a decision is not reached by the RMC with respect to management of the Research Program, the dispute will be referred to the co-chairs of the RMC. If the co-chairs of the RMC are unable to resolve the dispute, the dispute will be referred to the respective Chief Executive Officers of CombiChem and ImClone. 7. RESEARCH PERIOD; TERMINATION OF RESEARCH PROGRAM 7.1 Research Period: Option to Extend the Research Period. The initial term of the Collaboration shall be the Research Period, subject to extension upon mutual agreement. To extend the Research Period, ImClone must notify CombiChem no later than ninety (90) days prior to the then-current expiration date and the Parties shall negotiate in good faith the terms and conditions of any such extension. 7.2 Termination of Research Program. (a) The Research Program may be terminated by a Party for the material breach by the other Party of obligations under the Research Program by giving the breaching party notice of the breach and of the intent of the non-breaching Party to terminate the Research Program unless the breach is cured within ninety (90) days of notification. The non-breaching Party may terminate the Research Program following such ninety (90) day period by providing the breaching party with ninety (90) days' prior written notice that the Research Program is terminated, and the Research Program shall be terminated on the 90th day following such date. (b) Within thirty (30) days prior to the one (1) year anniversary of this Agreement, ImClone and CombiChem senior and scientific management personnel shall meet to review the status of the Collaboration. If, based upon such review, the status of the Collaboration is satisfactory to ImClone, ImClone shall make the Second Research Payment described in Section 8.2 to CombiChem on or before the one (1) year anniversary of this Agreement; provided, however, that ImClone may, in its discretion, make such Second Research Payment at any time prior to the date which is the one (1) year anniversary of this Agreement. If however, based upon such review, the status of the Collaboration is unsatisfactory to ImClone, ImClone may terminate the Research Program by providing 90-days' prior written notice to CombiChem that the Research Program shall be terminated. Upon receipt of such notice by CombiChem, ImClone shall have no further obligation to make the Second Research Payment to CombiChem (if such payment has not already been made to CombiChem), and the Research Program shall be terminated on the 90th day following such date. (c) CombiChem shall, within thirty (30) days following the effective date of termination under Section 7.2(a) or 7.2(b), pay to ImClone such amount as is calculated by taking *** *** *** shall be based upon *** . Any amount due by CombiChem under this Section 7.2(c) may be in the form, at CombiChem's discretion, of *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 10 12 *** *** *** . 8. CONSIDERATION 8.1 Equity Purchase. Upon execution of this Agreement, ImClone shall purchase 1,000,000 shares (on a pre-split basis and subject to adjustment) of Common Stock of CombiChem at a per share purchase price equal to $2.00 per share for an aggregate purchase price of U.S. $2 million, pursuant to the terms of that certain Common Stock Purchase Agreement, dated as of the Effective Date, by and between CombiChem and ImClone (together with all ancillary agreements thereto, the "Stock Purchase Agreement"). In the event that CombiChem closes an initial public offering of its common stock at a sales price per share to the public (the "IPO Price") which is less than $2.50 per share (on a pre-split basis), then, upon the closing of such initial public offering, CombiChem shall issue to ImClone, without further consideration other than the purchase price paid by ImClone pursuant to the Stock Purchase Agreement, such additional number of shares of CombiChem common stock equal to: 2,000,000 -------------- -1,000,000 Adjusted Price wherein the "Adjusted Price" = the IPO Price X .80 if the IPO Price is less than $2.50 per share. All shares of CombiChem common stock issued pursuant to this Section 8.1 shall be deemed to be "Shares" within the meaning of the Stock Purchase Agreement. 8.2 Program Funding. (a) ImClone shall support CombiChem's efforts in conducting the Research Program by making a payment upon the execution of this Agreement in the sum of U.S. $0.5 million as direct research support.. In addition, subject to Section 7.2(b), ImClone shall make a payment (the "Second Research Payment") to CombiChem prior to October 10, 1998 in the amount of U.S. $0.5 million in the form either, at ImClone's discretion, of (i) cash, or (ii) stock equal to the quotient obtained by dividing (i) U.S. $0.5 million by (ii) the average of the last reported sales price of the ImClone common stock as quoted on the National Market System of the National Association of Securities Dealer's Automated Quotation System during the thirty (30) consecutive trading days ending on the day prior to delivery of such shares (the "ImClone Price Per Share"). (b) In the event that the Project Team is expanded in accordance with Section 4.3, ImClone shall make payments, in cash, to CombiChem, at a per annum rate of U.S. *** payable quarterly in advance of the work to be performed by such additional FTE(s). (c) Any shares of ImClone common stock issued to CombiChem under this Section 8.2 shall be restricted securities under the Securities Act of 1933, as amended, and shall *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 11 13 be issued pursuant to a stock issuance agreement between ImClone and CombiChem which shall contain provisions for representations and warranties equivalent to, and registration rights and indemnification (and such other relevant provisions) with respect to the shares of ImClone common stock issued thereunder no less favorable than, those contained in the Stock Purchase Agreement. 8.3 Milestone Payments. Within thirty (30) days of the occurrence of a development milestone triggered by the activities of ImClone as shown on Appendix B, ImClone shall pay CombiChem the related milestone payment in U.S. dollars as set forth on Appendix B. Alternatively, in the event that ImClone shall outlicense the Patents covering any Product, CombiChem shall be entitled to the payments set forth in Section 9.3 in lieu of any payments pursuant to this Section 8.3. 8.4 Royalties. (a) Direct Sales by ImClone (i) Subject to Section 8.4(c), during the Royalty Term, ImClone will pay CombiChem a running royalty of *** of Net Sales of Products sold by ImClone or its Affiliates in all countries in the Territory. Each payment of royalties shall be accompanied by a report of Net Sales of Products in sufficient detail to permit confirmation of the accuracy of the royalty payment made. (ii) The royalties owed under Section 8.4(a)(i) shall not be reduced in accordance with Sections 8.4(c)(i) through 8.4(c)(iii) in an amount which results in a royalty payable to CombiChem of less than *** of Net Sales for Products sold directly by ImClone or its Affiliate. (b) Sales by ImClone's Licensees In the event that ImClone outlicenses Active Compounds, Lead Compounds, Development Compounds and resulting Products are sold by ImClone's licensees in any country in the Territory, ImClone's royalty payable to CombiChem shall be as follows: ImClone Royalty from Outlicensing CombiChem Royalty due to Outlicensing - ----------------------------------- ------------------------------------- Greater than *** (1) *** of ImClone royalty, but no greater than *** (2) Subject to reduction as outlined in Sections 8(c)(i) through 8(c)(iii), but such reductions shall not reduce CombiChems royalty below *** except as otherwise provide in Section 8.4(c)(iii). *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 12 14 Less than or equal to *** (1) *** of ImClone royalty and not subject to reduction as outlined in Sections 8(c)(i) and and 8(c)(ii). (c) Royalty Reductions (i) In any country in which Patents do not include a valid issued patent covering a Product sold by ImClone or its licensee, and/or where a generic equivalent has been approved for sale and is being sold in such country, the royalty provided for in Section 8.4(a)(i) and in Section 8.4(b), as indicated therein, shall be reduced by *** . (ii) In any country in which ImClone pays a Third Party royalty for patents and related technology in order to sell a Product, *** of such Third Party royalty shall be *** the royalty payment owed by ImClone to CombiChem in accordance with Section 8.4(a)(i) and Section 8.4(b), as indicated therein. During the Research Period, the RMC will make the determination whether to include any Third Party royalty-bearing patents and related technology in the Collaboration. After the Research Period, ImClone shall, in its discretion, make the determination whether to enter into any agreements with respect to Third Party royalty-bearing patents and related technology for purposes of this Agreement. (iii) In any country in which CombiChem receives any Additional Payments in respect of payments received by ImClone which are treated as an advance against royalties due ImClone from its licensee, such Additional Payments shall be *** the royalties provided for in Section 8.4(b) that are derived from such licensee. 8.5 Manner and Place of Payment. Royalty payments and reports for Net Sales of Products shall be calculated in local currencies and reported for each calendar quarter. All royalty payments owed under this Agreement shall be made by wire transfer to the bank account to be designated by CombiChem within thirty (30) days following the end of each such calendar quarter. 8.6 Records and Audit. During the term of this Agreement and for a period of five (5) years thereafter, ImClone shall keep complete and accurate records pertaining to the sale or other disposition of Products in sufficient detail to permit CombiChem to confirm the accuracy of all payments due hereunder. CombiChem shall have the right to cause an independent certified public accounting firm reasonably acceptable to ImClone to audit such records to confirm ImClone's Net Sales for the preceding year. Any information obtained during such audit shall be treated as Confidential Information. Such audits may be exercised during normal business hours of ImClone no more than once each year. CombiChem shall bear the full cost of such audit unless such audit discloses a variance of more than five percent (5%) in ImClone's favor from the amount of the Net Sales reported by ImClone for such audited period. In such case, ImClone shall bear the fill cost of such audit. 8.7 Taxes. All income and other taxes levied on account of the royalties and other payments accruing to CombiChem under this Agreement shall be paid by CombiChem, *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 13 15 including taxes levied thereon as income to CombiChem. If provision is made in law or regulation for withholding, such tax shall be deducted from the royalty or other payment made by ImClone to the proper taxing authority and a receipt of payment of the tax secured and promptly delivered to CombiChem. Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under any double taxation or similar agreement or treaty from time to tune in force. 9. LICENSE GRANTS; OUTLICENSE 9.1 CombiChem License Grant to ImClone. Subject to the terms and conditions of this Agreement, CombiChem hereby grants to ImClone an exclusive worldwide license, with the right to sublicense, to use such CombiChem Technology as is necessary to make, have made, use, have used, sell, have sold and import Collaboration Compounds or Products in the Territory. Such license shall remain exclusive in relation to each Collaboration Compound and/or Product so long as ImClone or its licensee continues to develop and commercialize such Collaboration Compound and/or Product containing such Collaboration Compound against a Collaboration Target with Due Diligence. 9.2 ImClone License Grant to CombiChem. Subject to the terms and conditions of this Agreement and following the failure of ImClone or its licensee to develop and commercialize with Due Diligence a Lead Compound, a Development Compound or Product, as the case may be, (collectively, and together with all Abandoned Compounds, "Returned Compound"), ImClone shall grant to CombiChem an exclusive license (exclusive even as to ImClone and its Affiliates), with the right to sublicense, under those ImClone Patents and know-how which are resulting from the Research Program and related exclusively to the Returned Compound to make, have made, use, have used, sell, have sold and import such Returned Compound in the Territory. 9.3 ImClone Outlicense. ImClone shall have a right to outlicense the Patents covering the Product to a Third Party subject to CombiChem's right to receive (a) royalties as provided in Section 8.4(b), and (b) additional payments ("Additional Payments") such that CombiChem has received, as of each Payment Date, the greater of (i) the cumulative amount due CombiChem by ImClone upon the attainment of the milestones set forth in Appendix B by ImClone' s licensee, or (ii) the cumulative amount equal to *** of the *** *** *** *** *** but excluding, to the extent reasonable and customary, all *** *** (collectively, the royalties described in clause (a and the payments described in clause (b) of this sentence, the "Payments") received by ImClone from such Third Party in connection with such license. The royalty Payments described in clause (a) of the preceding sentence shall be remitted to CombiChem within thirty (30) days after receipt by ImClone *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 14 16 of such Payments from its licensee. The Additional Payments described in clause (b) of the preceding sentence shall be paid to CombiChem within thirty (30) days following each date (a "Payment Date") upon which any milestone designated in Appendix B is achieved and/or ImClone receives a payment (as described above) from its licensee. As an express condition of any such outlicense, any such licensee shall be required to agree in writing to be bound by royalty reporting and recordkeeping and inspection provisions consistent with those contained in this Agreement. In addition, CombiChem shall have the right to receive all audit reports relating to sales of Products of ImClone's licensees, and to cause ImClone or its successor to have an independent certified public accounting firm audit such licensees records on the same terms as those specified in Section 8.6. All payments shall be made by wire transfer to such bank account designated by CombiChem. Failure of such licensee to make any milestone or royalty payment in respect of such Product shall not relieve ImClone of its obligations to make royalty and milestone payments to CombiChem hereunder. 9.4 Rights to Inactive Compounds/Returned Compounds. No provision of this Agreement shall prevent either Party from making, having made, using, having used, selling, having sold, or importing Inactive Compounds, products containing Inactive Compounds, Returned Compounds or products containing Returned Compounds or screening Inactive Compounds and Returned Compounds against any target other than the Collaboration Targets. In the event that either ImClone or CombiChem (the "Contracting Party") shall enter into a binding agreement with a Third Party to develop, market and/or sell any product containing any Inactive Compound or Returned Compound as an active ingredient (a "Third Party Transaction"), then the other Party hereto (the "Other Party") shall be entitled to *** of *** by the Contracting Party from such Third Party in respect of such Third Party Transactions. All such payments shall be sent by wire transfer to such bank account designated by the Other Party within thirty (30) days after the Contracting Party's receipt of such payments and shall be subject to the recording and auditing provisions of Section 8.6. 9.5 Miscellaneous License. In addition to any other rights granted by either Party in accordance with this Article 9, each Party grants to the other party a non-exclusive license without the right to grant sublicenses, under any intellectual property rights the granting Party has the power to grant in order for the other Party to carry out its rights and obligations under this Agreement including, but not necessarily limited to, conducting the Research Program and manufacturing, developing, selling and importing Products. 10. TERM AND TERMINATION 10.1 Term. The term of this Agreement shall commence upon the Effective Date of this Agreement, and shall expire on the expiration of the last royalty obligation under this Agreement, except as provided hereunder. 10.2 Termination by ImClone or CombiChem. Subject to Section 7.2, if either Party materially breaches this Agreement and fails to remedy that breach within ninety (90) days of receiving written notice thereof from the other Party, or enters into any arrangement of composition *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 15 17 with its creditors or goes into liquidation, insolvency, bankruptcy, receivership or reorganization proceedings, whether voluntarily or compulsorily which is not dismissed within ninety (90) days, then the other Party may at any time, by notice in writing or by telefax, terminate this Agreement. 10.3 After Termination. (a) Upon any termination of the Research Program under Section 7.2(a) due to a material breach of this Agreement by ImClone, ImClone's rights pursuant to Sections 3.1, 3.2, 5.3, 9.1, 9.3 and 9.5 shall immediately cease, and all rights granted hereunder with respect to Targets and Collaboration Compounds, Active Compounds, Lead Compounds, Development Compounds, or Products shall immediately revert to CombiChem without further obligation to ImClone. ImClone's rights pursuant to Section 5.2 and 9.3 above that accrue prior to such termination shall be retained by ImClone. ImClone may make, use, sell and import Active Compounds, Lead Compounds, Development Compounds or Products under rights retained by ImClone pursuant to this Section 10.3(a) so long as ImClone continues to satisfy all of its royalty, milestone, and Payment obligations in accordance with Sections 8.3, 8.4, 9.3 and 9.4. (b) Upon any termination of the Research Program under Section 7.2(a) due to a material breach of this Agreement by CombiChem with respect to a Collaboration Compound, Active Compound, Lead Compound, Development Compound or Product, all of ImClone's rights pursuant to Sections 3.1, 3.2, 5.2, 5.3, 9.1, 9.3 and 9.5 shall be retained by ImClone. ImClone may make, use, sell or import Active Compounds, Lead Compounds, Development Compounds and Products with respect to which ImClone is not in material breach under rights retained by ImClone pursuant to this Section 10.3(b) so long as ImClone continues to satisfy all of its royalty, milestone, and Payment obligations in accordance with Sections 8.3, 8.4, 9.3 and 9.4, except that ImClone shall not be required to satisfy such obligations with respect to any Collaboration Compound, Active Compound, Lead Compound, Development Compound or Product with respect to which CombiChem is in material breach. (c) If ImClone materially breaches this Agreement following the Research Period with respect to an Active Compound, Lead Compound, Development Compound or Product for any reason including, but not limited to, failing to satisfy its royalty, milestone and Payment obligations pursuant to Sections 8.3, 8.4, 9.3 and 9.4, ImClone shall not make, use, sell or import Active Compounds, Lead Compounds, Development Compounds or Products with respect to which ImClone is in material breach. ImClone shall retain the right to make, use, sell and import Active Compounds, Lead Compounds, Development Compounds or Products with respect to which ImClone is not in material breach so long as ImClone continues to satisfy all of its royalty, milestone, and Payment obligations in accordance with Sections 8.3, 8.4, 9.3 and 9.4. 16 18 (d) If CombiChem materially breaches this Agreement following the Research Period for any reason including, but not limited to, failing to satisfy its confidentiality and warranty obligations under Articles 11 and 19, ImClone shall have the right to make, use, sell or import Active Compounds, Lead Compounds, Development Compounds and Products with respect to which ImClone is not in material breach so long as ImClone continues to satisfy all of its royalty, milestone, and Payment obligations in accordance with Sections 8.3, 8.4, 9.3 and 9.4. (e) Upon any expiration or earlier termination of this Agreement for any reason, ImClone shall not be entitled to any refund of any payments made to CombiChem hereunder except as provided in Section 7.2(c). 10.4 Effect of Termination on Licensees. In the event of any termination of this Agreement pursuant to this Article 10 where such termination shall not have been caused by the action or inaction on the part of any respective licensee of ImClone or CombiChem, or by any breach by such licensee of its obligations under its licensee from ImClone or CombiChem, as appropriate, such termination of this Agreement shall be without prejudice to the rights of each non-breaching licensee and such licensee shall be deemed to be a direct licensee hereunder. 11. CONFIDENTIAL INFORMATION 11.1 Nondisclosure. During the term of the Collaboration and for a period of five (5) years after termination thereof, each Party will maintain all Confidential Information in trust and confidence and will not disclose any Confidential Information to any third party for any purpose except (i) as expressly authorized by this Agreement, or (ii) as required by law or court order, or (iii) to its consultants, subcontractors or agents who need to know to accomplish the purposes of this Agreement. Each Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its Affiliates, employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information. Confidential Information is understood to include, but not necessarily to be limited to, the structures of chemical compounds and the identification of chemical compounds as Collaboration Compounds, Active Compounds, Inactive Compounds, Lead Compounds, Development Compounds, or Products. 11.2 Exceptions. Confidential Information shall not include any information which the receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available; (b) is known by the receiving Party at the time of receiving such information, as evidenced by its records; (c) is hereafter disclosed to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; (d) is independently developed by the receiving Party without the aid, application or use of Confidential Information; (e) is the subject of a written permission to disclose provided by the disclosing Party; or (f) is necessary to obtain regulatory approval for a Product, or 17 19 patent protection with respect to Active Compounds, Lead Compounds, Development Compounds, or Products, and the uses and methods of manufacturing thereof. 12. PUBLICATIONS AND PUBLIC STATEMENTS 12.1 Publications. Each Party shall be permitted to publish any information, except Confidential Information, relating to the Research Program as long as the Party has the prior written permission of the other Party. Such permission shall be approved or disapproved within twenty-one (21) days of written request for permission. Such permission shall not be unreasonably withheld. 12.2 Public Statements. Neither Party shall use the name of the other Party in any public statement, prospectus, annual report or press release or other public communication (collectively "Public Statements") without the prior written approval of the other Party, which may not be unreasonably withheld or delayed; provided, however, that both Parties shall endeavor in good faith to give the other Party a minimum of two (2) business days to review such Public Statements; provided, further, that, upon approval of any such Public Statement, both Parties may disclose to third parties the information contained in such Public Statement without the further approval of the other; and provided, further, that if a Party does not approve such Public Statement, either Party may still use the name of the other Party in any Public Statement without the prior written approval of the other Party, if such Party is advised by counsel that such disclosure is required to comply with applicable law. 13. INDEMNIFICATION 13.1 EACH PARTY HEREBY AGREES TO SAVE, DEFEND AND HOLD THE OTHER PARTY AND ITS OFFICERS, DIRECTORS, EMPLOYEES, CONSULTANTS AND AGENTS HARMLESS FROM AND AGAINST ANY AND ALL SUITS, CLAIMS, ACTIONS, DEMANDS, LIABILITIES, EXPENSES AND LOSSES, INCLUDING REASONABLE LEGAL EXPENSES AND ATTORNEYS' FEES ("LOSSES") RESULTING DIRECTLY OR INDIRECTLY FROM ANY ACTIVITY PERFORMED BY THE INDEMNIFYING PARTY PURSUANT TO THIS AGREEMENT, INCLUDING BUT NOT NECESSARILY LIMITED TO THE MANUFACTURE, DEVELOPMENT, USE, HANDLING, STORAGE, SALE OR OTHER DISPOSITION OF CHEMICAL AGENTS, COLLABORATION COMPOUNDS, ACTIVE COMPOUNDS, LEAD COMPOUNDS, DEVELOPMENT COMPOUNDS OR PRODUCTS BY SUCH PARTY, ITS AFFILIATES OR LICENSEES except to the extent such Losses result from the gross negligence or willful misconduct of the Party claiming a right of indemnification under this Article 13. 13.2 Indemnification. (a) Subject to Section 13.2(c) below, ImClone shall hold CombiChem and its officers, directors, employees, consultants, and agents harmless from and against any and all losses resulting from the infringement of any Patent of a Third Party due to the performance by 18 20 ImClone of any activity contemplated hereunder, including, but not necessarily limited to, ImClone's responsibilities under Section 2.2 above, developing Products, and selling Products. (b) Subject to Section 13.2(c) below, CombiChem shall hold ImClone and its officers, directors, employees, consultants, and agents harmless from and against any and all losses resulting from the infringement of any Patent of a Third Party due to the performance by CombiChem of any activity contemplated hereunder, including, but not necessarily limited to, CombiChem's responsibilities under Section 2.1 above. (c) The indemnity provided in Sections 13.2(a) and 13.2(b) above shall not apply where the loss is due to the breach by the indemnified Party of a warranty made in Article 19. 13.3 Procedures. If either Party seeks indemnification under this Article 13, it shall inform the other Party of a claim as soon as reasonable practicable after it receives notice of the claim, shall permit the other Party to assume direction and control of the defense of the claim (including the right to settle me claim solely of the other Party), and shall give reasonable cooperation (at the expense of the other Party) in the defense of the claim. 14. ASSIGNABILITY This Agreement may not be assigned by either Party without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement, in whole or in part, to an Affiliate or to a successor of a Party in connection with the merger, consolidation or sale of all or substantially all of such Party's assets or that portion of its business pertaining to the subject matter of this Agreement. 15. DISPUTE RESOLUTION PROCEDURES 15.1 Senior Executives Discussions. If a decision is not reached by the RMC, the dispute will be resolved as set forth in Article 6 above. If a dispute arises between CombiChem and ImClone with respect to matters other than the management of the Research Program, either during or after the Research Period, such dispute will be referred to the appropriate senior management in the area of the dispute. If such senior management are unable to resolve such dispute, such dispute will be referred to the Chief Executive Officers of CombiChem and ImClone. If such officers are unable to reach an agreement within thirty (30) days following the initiation of discussions between them, such dispute shall be settled by arbitration as described in Section 15.2 below. 15.2 Binding Arbitration. If the parties have not been able to resolve the dispute as provided in Section 15.1 above, the dispute shall be finally settled by binding arbitration. Any arbitration hereunder shall be conducted under rules of the American Arbitration Association. The arbitration shall be conducted before one (1) arbitrator chosen by mutual agreement of the Parties. If the Parties cannot agree on the choice of the arbitrator within a period of thirty (30) days after 19 21 submission, then the arbitrator shall be appointed by the Court of Arbitration of the American Arbitration Association. Any such arbitration shall be held in a mutually agreeable location; provided, however that if the parties cannot so agree, the location(s) for such arbitration(s) shall alternate between San Diego, California and New York, New York, with the first such arbitration to be located in San Diego, California. The arbitrators shall have the authority to grant specific performance, and to allocate between the parties the costs of arbitration in such equitable manner as he or she may determine. The arbitral award (i) shall be final and binding upon the parties; and (ii) may be entered in any court of competent jurisdiction. 15.3 Injunctive Relief. Nothing contained in this Article 15 or any other provisions of this Agreement shall be construed to limit or preclude a Party from bringing any action in any court of competent jurisdiction for injunctive or other provisional relief to compel the other Party to comply with its obligations hereunder before or during the pendency of arbitration proceedings. 16. NOTICES Any notice required or permitted to be given hereunder shall be deemed sufficient if sent by facsimile letter or overnight courier, or delivered by hand to ImClone or CombiChem at the respective addresses and facsimile numbers as set forth below or at such other address and facsimile number as either Party hereto may designate. If sent by facsimile letter, notice shall be deemed given when the transmission is completed if the sender has a confirmed transmission report. If a confirmed transmission report does not exist, then the notice will be deemed given when the notice is actually received by the person to whom it is sent. If delivered by overnight courier, notice shall be deemed given when it has been signed for. If delivered by hand, notice shall be deemed given when received. if to CombiChem, to: CombiChem, Inc. 9050 Camino Santa Fe San Diego, California 92121 Attention: President Fax number: (619) 530-9998 with a copy to: Brobeck, Phleger & Harrison LLP 550 South Hope Street, 21st Floor Los Angeles, California 90071 Attention: Laurie A. Allen, Esq. Fax number: (213) 239-1324 if to ImClone, to: ImClone Systems Incorporated 180 Varick Street New York, New York 10014 Attn: Vice President, Business Development Fax number: (212) 645-2054 20 22 with a copy to: Hoffmann and Baron 350 Jericho Turnpike Jericho, New York 11753 Attn: Irving N. Feit, Esq. Fax number: (516) 822-3582 17. SURVIVAL The provisions of Sections 2.5, 5.1, 5.2, 7.2(c),10.3, 10.4, and Articles 1, 3, 8, 9, 11, 12, 13, 14, 15, 16, 18 and this Article 17 shall survive termination of this Agreement in addition to those provisions which by their terms survive. 18. ADDITIONAL TERMS 18.1 Entire Agreement. This Agreement and the Common Stock Purchase Agreement constitute the entire understanding between the Parties with respect to the subject matter hereto and supersedes and replaces all previous negotiations, understandings, representations, writings and contract provisions and rights relating hereof. The Parties agree that all services provided hereunder shall be subject to and governed by the terms and provisions set forth herein, and none of the terms and conditions contained on any proposal, purchase order, invoice or other writing shall have any effect or change the provisions of this Agreement. 18.2 Amendment; No Waiver. No provision of this Agreement may be amended, revoked or waived except by a writing signed and delivered by an authorized officer of each Party. Any waiver on the part of either Party of any breach or any fight or interest hereunder shall not imply the waiver of any subsequent breach or waiver of any other right or interest. 18.3 Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, each of which shall remain in full force and effect. In addition, should the invalidity or unenforceability of any provision of this Agreement cause an unintended result or result in any unfairness to either Party, then ImClone and CombiChem shall promptly meet and negotiate in good faith to modify or amend this Agreement to change such result or to eliminate such unfairness. 18.4 Headings. The descriptive headings are inserted for convenience of reference only and are not intended to be part of or to affect the meaning of or interpretation of this Agreement. 18.5 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument. 21 23 18.6 Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of California, without regard to conflicts of laws principles. 19. WARRANTY Each Party warrants that it has the power to grant all of the rights granted and make such required assignments, and to assume all of the obligations required, under this Agreement. If, at the time a Patent application is to be filed by ImClone with respect to any Active Compound, Lead Compound, Development Compound or Products, CombiChem informs ImClone that CombiChem has the power to grant the exclusive rights to such Active Compound, Lead Compound, Development Compound or Products, and to assign such Patents related thereto, to ImClone in accordance with Sections 3.2 and 5.2 above, CombiChem further warrants that, in fact, as of such date, it has such power subject to the proviso that under no circumstances does CombiChem warrant to ImClone that its rights in any Active Compound, Lead Compound, Development Compound or Products are exclusive to the extent such Active Compound, Lead Compound, Development Compound or Products may be covered under the patent claims of Third Parties wherein such claims are not the direct result of a collaboration between the Third Party and CombiChem. IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the Effective Date. COMBICHEM, INC. IMCLONE SYSTEMS INCORPORATED By: /s/ Vicente Anido By: /s/ Carl S. Goldfischer --------------------- --------------------------- Its: President and CEO Its: CFO 22 24 Appendix A *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 25 Appendix B Milestone Payments (Triggered by Activities of ImClone or Its Licensees) Development Milestone Milestone Payment *** *** U.S. *** *** U.S. *** *** *** U.S. *** *** *** U.S. *** *** *** __________________ Total U.S. *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. EX-10.58 3 EXHIBIT 10.58 1 EXHIBIT 10.58 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN COMBICHEM, INC. AND ICOS CORPORATION MARCH 30, 1998 ***Certain confidential portions of this Exhibit were omitted by means of blackout of the text (the "Mark"). This Exhibit has been filed separately with the Secretary of the Commission without the Mark pursuant to the Company's Application Requesting Confidential Treatment under Rule 406 of Regulation C of the Securities Act of 1933. 2 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the "Agreement") is entered into and made effective as of March 30, 1998 (the "Effective Date"), by and between COMBICHEM, INC., a Delaware corporation having its principal offices at 9050 Camino Santa Fe, San Diego, California 92121 ("CombiChem") and ICOS CORPORATION, a Delaware corporation having its principal offices located at 22021 20th Avenue S.E., Bothell, Washington 98021 ("ICOS"). WHEREAS, CombiChem has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry (collectively, "CombiChem Technology"); WHEREAS, as of the Effective Date, ICOS and its Affiliates have developed and own certain drug discovery and intellectual property rights, including certain assays, methods and know how regarding the Initial Target and any Alternative Target(s), among other things (collectively "ICOS Technology"); WHEREAS, ICOS desires to utilize CombiChem Technology for its drug discovery activities under ICOS know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of *** and other diseases in humans; WHEREAS, the parties wish to collaborate in a chemical lead and drug discovery program, commencing on the Effective Date against a Collaboration Target ("Collaboration"); WHEREAS, during the Collaboration, the Parties intend to initially focus on one (1) Initial Target, and thereafter on any Alternative Target(s) as determined by ICOS; NOW, THEREFORE, the Parties agree as follows: 1. DEFINITIONS 1.1 "Active Compound(s)" means a compound (or compounds) or its Derivatives which (a) (i) is selected by the RMC under the Research Program from Collaboration Compounds under Section 4.2, or (ii) is a Derivative of a Collaboration Compound which has been so selected by the RMC to be an Active Compound; and *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 1 - 3 (b) shows In Vitro Activity satisfactory to the requirements of the Research Plan. 1.2 "Affiliate" of a Party means any corporation or other business entity controlled by, controlling or under common control with, such Party. For this purpose "control" shall mean direct or indirect beneficial ownership of more than fifty percent (50%) of the voting securities or income interest in such corporation or other business, or if not meeting the preceding requirements, any company owned or controlled by or owning or controlling such Party at the maximum control or ownership right permitted in the country where such company exists. 1.3 "Alternative Target" shall have the meaning set forth in Section 3.2 hereof. 1.4 "Collaboration" has the meaning set forth in the preamble. 1.5 "Collaboration Compound(s)" means a compound (or compounds) which (a) is synthesized following the Effective Date for screening against a Collaboration Target under the Research Program, (b) is a pre-existing or hereafter acquired CombiChem compound which CombiChem desires to designate as a Collaboration Compound, or (iii) is a pre-existing or hereafter acquired ICOS compound which ICOS desires to designate as a Collaboration Compound. 1.6 "Collaboration Patent" means a Patent to which CombiChem has made an inventive contribution arising out of the Collaboration, as determined under U.S. Patent law. 1.7 "Collaboration Target" means (a) the Initial Target beginning on the Effective Date or (b) an Alternative Target substituted for the Initial Target under Section 3.2(b) or (c) any other target by mutual agreement of the Parties. 1.8 "CombiChem Compound" means a chemical compound that is proprietary to CombiChem, or whose use or manufacture is proprietary to CombiChem. 1.9 "CombiChem Technology" has the meaning set forth in the preamble. 1.10 "Confidential Information" includes, but is not limited to, (a) all information and materials received by either Party from the other Party pursuant to this Agreement which is confidential under Article 11 hereof; (b) all information and materials by either Party arising out of the Collaboration during the Research Period including, without limitation, information directly and specifically deduced from Confidential Information such as information regarding compounds that were not active against the Targets in the screening or secondary selective assays; and - 2 - 4 (c) the terms and conditions of this Agreement. 1.11 "CPI" means the Consumer Price Index, All Urban Consumers, as published by the U.S. Bureau of Labor Statistics. 1.12 "Daughter Libraries" shall mean the compound libraries which are designed and synthesized as a part of the Collaboration either by CombiChem or under the direction of the RMC. 1.13 "Derivative" shall mean a compound (or compounds) which has resulted (a) (i) from chemical synthesis, during the Exclusivity Period, to generate an Active Compound or Development Compound in support of the Research Program or (ii) from chemical synthesis on an Active Compound or Development Compound in support of the Research Program; and (b) is covered under claims of any Collaboration Patent. 1.14 "Development Compound(s)" means a Collaboration Compound (or compounds) which (a) (i) is an Active Compound or (ii) is a Derivative of an Active Compound; and (b) is determined by ICOS to be appropriate for the purpose of IND filing by ICOS either before preclinical studies or from the results of preclinical studies to determine without limitation, data on efficacy, potency, toxicity, bioavailability and other pharmacokinetics related parameters. 1.15 "Due Diligence" means the use of by a Party of its resources in the Collaboration in a manner which is consistent with the exercise of reasonable and prudent scientific and business judgment as applied to other programs of ICOS or CombiChem, as the case may be, targeting products aimed at markets or patient groups of similar sizes and of similar scientific and commercial potential. With respect to any Development Compound, "Due Diligence" shall also require ICOS or its Affiliates, partners or licensees to use commercially reasonable efforts to conduct all necessary preclinical studies and to file an IND for such Development Compound within a commercially reasonable period from the date upon which ICOS has designated such Development Compound from any Active Compound or its Derivatives. For purposes of this Agreement, failure to exercise Due Diligence by any Party may be alleged by written notice to such Party describing such failure with specificity and describing the actions necessary to cure such failure with specificity (the "Due Diligence Notice"). Sixty (60) days after delivery of a Due Diligence Notice, if the Party receiving such Due Diligence Notice has not completed the actions necessary to cure such failure as specified in such Due - 3 - 5 Diligence Notice to the reasonable satisfaction of the other Party, the Parties shall immediately be subject to the dispute resolution provisions set forth in Article 15 hereof starting at the discussions between the Parties' Chief Executive Officers described in Section 15.1 hereof. 1.16 "Exclusivity Period" means the Research Period plus *** as may be extended or reduced pursuant to Article 4 hereof. 1.17 "Field" means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed. 1.18 "First Commercial Sale" of a Product shall mean the first sale for use or consumption of such Product in a country after required marketing and pricing approval has been granted by the governing health regulatory authority of such country. Sale to an Affiliate shall not constitute a First Commercial Sale unless the Affiliate is the end user of the Product. 1.19 "FTE" shall mean a full-time equivalent employee of CombiChem having the requisite skills to fulfill CombiChem's obligations under this Agreement. For purposes of this Agreement, the FTEs shall include synthetic and analytical chemists, compound control scientists and computational scientists. 1.20 "Inactive Compound(s)" means a Collaboration Compound(s) which is not an Active Compound or an Active Compound that is reclassified as described in Section 4.2 hereof. 1.21 "ICOS Compound" means a chemical compound that is proprietary to ICOS or whose use or manufacture is proprietary to ICOS or its Affiliates. 1.22 "ICOS Technology" shall have the meaning set forth in the preamble of this Agreement. 1.23 "In Vitro Activity" shall mean during the Research Term, the observation of *** in assays as described by ICOS in the Research Plan for each Collaboration Target. 1.24 "Initial Target" shall have the meaning set forth in Section 3.1 hereof. 1.25 "Net Sales" means the gross sales invoiced by ICOS, its Affiliates or its sublicensees for Products to non-Affiliated Third Parties (and to Affiliates who are the end users of such Products) less actual deductions or returns (including withdrawals and recalls), rebates (price reductions, including formulary or Medicaid and similar types of rebates, e.g. chargebacks), cash, trade or volume (quantity) discounts, discounts granted at the time of invoicing, the cost of transport, insurance, delivery, sales taxes and use, tariff, excise or other taxes (other than income taxes) directly linked to and included in the gross sales amount as computed on a product-by-product basis for the countries concerned, whereby the amount of such sales in foreign *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 4 - 6 currencies is converted into United States dollars at the exchange rate of the last business day for each calendar month as reported in The Wall Street Journal. 1.26 "Patent" means (a) valid and enforceable U.S. or non U.S. Patent, and any non-U.S. equivalent, including any extension (including Supplemental Protection Certificates), registration, confirmation, reissue, continuation, divisionals, continuation-in-part, reexamination or renewal thereof, or (b) pending applications for any of the foregoing, whether filed or issued before or after the Effective Date. 1.27 "Party" means CombiChem or ICOS, as the case may be, including their respective Affiliates, permitted successors and assigns. 1.28 "Product(s)" means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field. 1.29 "Project Team" shall have the meaning set forth in Section 2.1(c). 1.30 "Research Management Committee" or "RMC" has the meaning set forth in Article 6 below. 1.31 "Research Period" means that part of the Collaboration commencing *** or sooner by mutual agreement *** unless earlier terminated, and which can be extended in accordance with Section 7.1 below for the Initial Target or an Alternative Target substituted therefore under Section 3.2(b) herein. 1.32 "Research Plan" means the research plan to be agreed in writing between the Parties, which describes in mutually agreed upon detail the research activities to be performed for each Collaboration Target. 1.33 "Research Program" means the research and activities to be conducted for the Collaboration during the Research Period including, without limitation, the activities described in the Research Plan and set forth in Sections 2.1 and 2.2 of this Agreement. 1.34 "Returned Compound" shall have the meaning set forth in Section 9.2. 1.35 "Royalty Term" means, in the case of any Product, in any country, the period of time commencing on the First Commercial Sale and ending upon the later of (a) *** or (b) the expiration of the last-to-expire Patent resulting from the Research Program filed in the Field during the Exclusivity Period with claims covering that Product in the relevant country. In the event such *** period shall extend beyond the end of the term or terms of the last to expire Patents resulting from the Research Program containing a valid claim in such country, the earned royalties *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 5 - 7 hereunder in such country shall be *** for the remainder of such *** period so long as *** as the Product exists and is sold in competition with the Product. 1.36 "Target" means a biomolecular entity that a Collaboration Compound is synthesized against wherein the small molecule demonstrates relevant activity and unless otherwise specified may include both Initial and Alternative Targets. 1.37 "Target Exclusivity Obligations" shall have that meaning set forth in subsection 4.1(a) hereof. 1.38 "Territory" means the entire world. 1.39 "Third Party" means an entity other than CombiChem or ICOS or their respective Affiliates or assigns. 1.40 "UIL" means CombiChem's proprietary Universal Informer Library(TM). 2. RESEARCH COLLABORATION 2.1 CombiChem Responsibilities. CombiChem shall with Due Diligence provide the following resources to ICOS and conduct the following activities under the Research Program and as more fully described in the Research Plan: (a) Within thirty (30) days of the Effective Date, CombiChem will deliver to ICOS its UIL sufficient in quantity for ICOS to screen against the Initial Target and any Target contained in Appendix B at the time of such shipment. (b) At any time following the Effective Date, CombiChem shall provide to ICOS data analysis and evaluations for results from the screening of the UIL against the Initial Target and any substituted Alternative Target under Section 3.2(b) herein within *** of CombiChem's receipt of the relevant screening data from ICOS. (c) During the Research Period, CombiChem shall (i) review data and information regarding the Collaboration Target provided by ICOS and derived from the UIL by CombiChem; (ii) based on such data and information and using the CombiChem Technology, design Daughter Libraries; and (iii) supply all lead chemistries and synthesize compounds as provided in Section 5.4 hereof. (d) During the Research Period, CombiChem shall keep ICOS informed of its activities performed in connection with the Collaboration, *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 6 - 8 including, without limitation, providing ICOS with data and information (and, upon ICOS's request, reasonable quantities of samples pursuant to Section 5.4) regarding the status of all Collaboration Compounds prior to the meetings of the Research Management Committee. (e) Subject to Section 2.3, Article 3 and Section 8.3 hereof, and at all times during the Research Period, CombiChem shall dedicate, in separate laboratory facilities as to its chemistry efforts *** to conduct all of CombiChem's activities in connection with the Collaboration at a per annum rate of U.S. *** per FTE to be paid by ICOS. The *** unless the RMC recommends otherwise and ICOS and CombiChem agree in writing to alter the size of *** . 2.2 ICOS Responsibilities. ICOS shall with Due Diligence provide the following resources to CombiChem and conduct the following activities under the Research Program as more fully described in the Research Plan: (a) ICOS shall make payment to CombiChem for the Collaboration as set forth in Article 8 hereof, provide screening, biological and structural data and information (including leads and/or screening hits and any assay methods relating to Collaboration Compounds) to CombiChem necessary for CombiChem to perform its duties under this Agreement, and will assume scientific, financial and administrative responsibility for screening and biological support activities, drug development and regulatory filings during and after the term of the Collaboration on the terms set forth below. (b) During the Research Period, ICOS shall provide CombiChem with data and information regarding Collaboration Compounds and the Collaboration Target assays developed by ICOS under the Research Program prior to the meetings of the Research Management Committee. (c) During the Exclusivity Period, ICOS shall screen Collaboration Compounds for *** and, where ICOS reasonably deems it to be appropriate, *** against the Collaboration Target. (d) During the Exclusivity Period, with respect to any Collaboration Target against which an Active Compound has been designated by the RMC, ICOS shall (i) screen Active Compounds, (ii) determine Development Compounds, and (iii) endeavor to develop Products. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 7 - 9 At any time during the Collaboration, ICOS may apply chemistry effort, including synthesis, to any Collaboration Compound as agreed and directed by the RMC. (e) Following the first IND filing through First Commercial Sale, ICOS shall provide CombiChem with an annual report similar to that which would be provided in the usage of the trade or business, by a licensee to a licensor summarizing ICOS's activities in developing Development Compounds that shall include, without limitation, all material information with respect to the following: (i) status of both regulatory filings and communications with the United States Food and Drug Administration or any foreign equivalent ("FDA"); (ii) status of Patents within and outside of the United States; (iii) status of current and planned clinical trials; (iv) occurrence of any milestone events; and (v) any permitted sublicensing under this Agreement. (f) During the Research Period and in connection with CombiChem providing the services in Section 2.1(c) hereof, ICOS shall, at its option, send *** to conduct ICOS' activities at CombiChem's facilities under the Research Program. ICOS shall have sole responsibility for the expenses associated with its visiting chemists, including, without limitation, salary, travel, living and other associated expenses of such chemists. 2.3 Conduct of Research Program. The Parties hereby agree that the Research Programs shall be carried out in accordance with the Research Plan and this Agreement, as each may be amended from time to time. The Research Management Committee shall review the Research Plan on a regular and ongoing basis and may make written changes to the Research Plan so long as such changes are mutually agreed to in writing by CombiChem and ICOS. 2.4 Third Party Licenses. Each Party shall be solely responsible for any Third Party license fees required to perform its obligations under this Agreement. 3. TARGETS 3.1 Initial Target. ***. 3.2 Alternative Target. (a) An Alternative Target is any of those alternative targets selected from Appendix B attached hereto, as amended in writing by mutual agreement of the Parties hereto from time to time, and for which ICOS has identified such selection in a written notice to CombiChem. Unless otherwise agreed by the Parties in writing or as set forth in this Section 3.2, ICOS shall have the right to screen the UIL against any target contained in Appendix B, as *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 8 - 10 amended, but shall *** in accordance with Section 8.1(b) hereof. (b) At any time prior to *** , ICOS may decide, or may accept a recommendation by the RMC, to pursue any Alternative Target in substitution for the Initial Target and thereafter the Alternative Target shall be deemed to be a Collaboration Target for all purposes under this Agreement. Such substitution by ICOS shall be effective upon the date of a written notice provided to CombiChem by ICOS expressly stating that such substitution shall be made and identifying the Alternative Target from Appendix B to be substituted. 3.3 Substitute Target. After the commencement of a Research Program with respect to the Collaboration Target, the Parties, by mutual agreement, may substitute another target for such Collaboration Target. 4. EXCLUSIVITY 4.1 Collaboration Target Exclusivity. (a) Following the Effective Date, so long as ICOS or its Affiliates are proceeding with Due Diligence for that Collaboration Target, CombiChem shall not work on, or provide services, or advise, either independently, or with any Third Parties (except where CombiChem is providing its UIL to Third Parties without knowledge of such Third Parties' target) (the "Target Exclusivity Obligations"), except (a) as provided for in Section 12.2 hereof with regard to any Public Statements, (b) with respect to any Third Parties who are collaborators or proposed collaborators of CombiChem, CombiChem shall have the right, consistent with its corporate policy (but without identifying any Collaboration Target), to notify any such Third Party of its decision and/or inability to work on such Collaboration Target with that Third Party or (c) if CombiChem's Target Exclusivity Obligations have terminated pursuant to subsection 4.1 (b) below. (b) Upon the commencement of the Research Period and following synthesis of a Daughter Library by CombiChem for the Collaboration Target, the Target Exclusivity Obligations with respect to such Collaboration Target shall continue until (1) ICOS has provided CombiChem with a notice and release of Target Exclusivity Obligations, effective in sixty (60) days, that, because of business and scientific reasons, ICOS has decided to cease research and/or development activities for the Initial Target, or (2) ICOS has provided CombiChem with a notice and release of Target Exclusivity Obligations, effective *** from the date of such notice and release, that ICOS has decided to cease research *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 9 - 11 and/or development activities for a specific Collaboration Target except the Initial Target, or (3) *** after the date of the written notice provided by ICOS under Section 3.2(b) herein, or (4) (A) ICOS has failed to exercise Due Diligence with respect to that Collaboration Target and (B) has not transferred or assigned its control of the development of its program for that Collaboration Target to a Third Party with due diligence requirements no less stringent than those set forth in this Agreement. In the event of such transfer or assignment to a Third Party, the Target Exclusivity Obligations with respect to such Collaboration Target shall continue until the earlier of (a) receipt by CombiChem of a written release from such Third Party, or (b) the failure of such Third Party to exercise Due Diligence with respect to that Target. Any notice under this subsection 4.1(b) shall be provided by ICOS to CombiChem promptly following the relevant decision under subsections (1), (2) or (3) above or failure under subsection (4) above. 4.2 Alternative Target Exclusivity. From the Effective Date through *** CombiChem shall not work on, or provide services or advise, either independently, or with any Third Parties (except where CombiChem is providing its UIL to Third Parties without knowledge of such Third Parties' target), except as provided for in Section 12.2 hereof with regard to any Public Statements or (b) with respect to any Third Parties who are collaborators or proposed collaborators of CombiChem, CombiChem shall have the right, consistent with its corporate policy (but without identifying any Alternative Target), to notify any such Third Party of its decision and/or inability to work on such Alternative Target with that Third Party. 4.3 Active Compound Exclusivity. Any Active Compound shall be exclusively available to ICOS for research or application within or outside the Collaboration, during the Research Period, and CombiChem shall not work on or provide information regarding such Active Compound to any Third Party, except to take any steps necessary to protect ICOS's exclusivity hereunder. Following the expiration of the Research Period, Active Compounds for which a Patent has not been filed within ninety (90) days following the Research Period shall be deemed to be Inactive Compounds for all purposes hereunder; provided, that any Active Compound which is the subject of claim(s) under a pending Collaboration Patent shall continue to be treated as Active Compounds until a Collaboration Patent is issued with respect to one or more of such claims; or until all of such Patent claims have been denied and all appeals and refiling procedures have been exhausted, at which time the compounds which are the subject of those claims shall be Inactive Compounds hereunder. 4.4 Inactive and Returned Compounds. Any Inactive Compounds and Returned Compounds (subject to Section 9.2 hereof) shall be available to CombiChem (except for any pre-existing ICOS Compound) and ICOS for any purpose. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 10 - 12 4.5 Survival. This Article 4 shall survive termination or expiration of this Agreement. 5. COLLABORATION COMPOUNDS 5.1 Pre-Existing Compounds or Other Pre-Existing Rights. Neither Party shall have any rights then existing in the other Party to any pre-existing compound of the other Party unless and until such compound is designated as a Collaboration Compound by such Party. Additionally, CombiChem may decline (after informing ICOS) to synthesize a particular compound or library of compounds by written notice to ICOS of existing Patents, Patent Applications and/or contractual obligations with Third Parties restricting CombiChem's performance of such activities and such notice shall contain a statement of warranty that such Patents, Patent Applications and/or contractual obligations exist and that their existence and the obligations of CombiChem predate an ICOS request of CombiChem to synthesize such compound or library of compounds. 5.2 Intellectual Property Rights; License to ICOS. Subject to Section 9.2 hereof, and except as set forth in this Section 5.2, ICOS shall have *** relating to Active Compounds, Development Compounds and Products and the subject matter contained therein and resulting from the Research Program *** . ICOS shall be responsible for filing, maintaining and prosecuting all Collaboration Patents at its sole expense and CombiChem shall use commercially reasonable efforts to assist ICOS in filing such Collaboration Patent applications. Prior to the filing of any such Collaboration Patent applications, CombiChem shall assign to ICOS or its designee all intellectual property rights it may have in *** and the subject matter claimed therein which are necessary for the development and commercialization by ICOS or its designee; provided under no circumstances does *** in any Active Compound, Development Compound or Products are *** to the extent such Active Compound, Development Compound or Products may be *** . If ICOS fails to so file, maintain or prosecute such Collaboration Patent, CombiChem shall have the right to request ICOS to do so. If ICOS elects not to file, maintain or prosecute such Collaboration Patent, on a country-by-country basis, ICOS shall provide CombiChem with a fully-paid up license so that CombiChem can take over such filing, maintenance or prosecution of such Collaboration Patent, at its sole expense. 5.3 Structural Information. Neither Party shall disclose the structure of the other Party's compound, any Active Compound, Development Compound or Product to any Third Party without the other Party's written permission, unless required to do so by law, in which case such Party shall promptly notify the other Party of such required disclosure. If a subpoena or other legal process concerning the same is served upon either Party, the other Party shall *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 11 - 13 cooperate with the Party served in any effort to contest the validity of such subpoena or other legal process. 5.4 Supply of Collaboration Compounds. Aliquots of *** of any Collaboration Compound that has been synthesized will be prepared and given to ICOS. CombiChem shall replenish that amount upon ICOS's reasonable request. CombiChem shall maintain aliquots of any Collaboration Compound that has been synthesized by CombiChem. CombiChem shall also provide ICOS with additional requirements of samples at CombiChem's cost. To the extent that Collaboration Compounds are not available in a timely and sufficient quantity to allow the earliest start of necessary large scale preclinical or other studies such unavailability of Collaboration Compounds shall not be cited as a lack of Due Diligence provided that the Parties have made commercially reasonable attempts, and continue such attempts, to provide such unavailable Collaboration Compounds in required quantities in the most expedient manner. 6. RESEARCH MANAGEMENT COMMITTEE The design, review and conduct of the Research Program will be coordinated by the Research Management Committee, which will meet regularly on a mutually-agreeable schedule. Each Party shall bear its own expenses related to such meetings. The Research Management Committee may establish and amend or revise the Research Plan as reasonable and necessary to reflect the scientific progress and work performed under the Research Program, such amendments to be mutually agreed to in writing by ICOS and CombiChem. The Research Management Committee will consist of an equal number of members from ICOS and CombiChem and will include appropriate representatives from ICOS and CombiChem as mutually agreed. The co-chairs of the Research Management Committee will initially be *** and subsequently may change as each Party determines for its co-chair. Decisions of the Research Management Committee shall be by consensus. If a decision is not reached by the RMC with respect to management of the Research Program, the dispute will be referred to the co-chairs of the RMC. If the co-chairs of the RMC are unable to resolve the dispute, the dispute will be referred to the Chief Executive Officer of CombiChem and the Chief Executive Officer of ICOS for resolution. If those officers are unable to resolve the dispute, after good faith discussions, the dispute shall be resolved first by a process of mediation and then in the case of a failure to resolve the dispute, as determined per Section 15.2 hereof. Any decisions, recommendations, amendments or performance criteria agreed by consensus of the RMC which could, or may, materially affect any obligations concerning consideration or ownership of intellectual property shall be consistent with the terms of this Agreement and shall be ratified in writing by both CombiChem and ICOS prior to it being binding on either party and any performance or partial performance of an unratified agreement shall not be construed as a waiver or acquiescence of the right of ratification. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 12 - 14 7. RESEARCH PERIOD; TERMINATION OF RESEARCH PROGRAM 7.1 Research Period: Option to Extend the Research Period. The initial term of the Collaboration shall commence on the Effective Date and conclude at the end of the Research Period, subject to extension upon mutual agreement. To extend the Research Period, ICOS must notify CombiChem no later than ninety (90) days prior to the then-current expiration date and the Parties shall negotiate in good faith the terms and conditions of any such extension. 7.2 Termination of Research Program Upon Breach. The Research Program and/or this Agreement may be terminated by a Party for the material breach by the other Party as provided by Section 10.2 hereof. 8. CONSIDERATION 8.1 Fees. (a) As of the Effective Date, ICOS shall be obligated to pay CombiChem a non-refundable, noncontingent project initiation fee of U.S. *** in cash, by registered check or wire transfer, to initiate the Research Program for the Initial Target within fifteen (15) days of the Effective Date. Such initiation fee shall include payment for the *** made for the Initial Target. Should ICOS request in writing a *** for any *** ICOS shall pay CombiChem an additional U.S. *** for the *** and *** for *** for a total of up to *** such *** . If any such request occurs after *** such *** shall only be upon the mutual agreement of the Parties. The action of replacing an *** for an *** pursuant to Section *** hereof shall not obligate ICOS to an additional *** for such *** . 8.2 Research Program Funding. (a) Research Support for Project Team. Beginning *** ,or earlier if mutually agreed by the Parties, and continuing throughout the Research Period, ICOS shall make payments to CombiChem for direct research support for its Project Team, which shall initially consist of *** full time employees ("FTEs") of CombiChem, as modified by the RMC pursuant to Section 8.2(b) below. The total amount per FTE payable shall be U.S. *** per FTE per annum, which amount shall be upwardly adjusted annually based on cumulative changes in the CPI, using 1998 as the base year. All payments for direct research support shall be paid by ICOS to CombiChem, quarterly in advance, and adjusted as necessary in subsequent quarters, of such amounts as are equal to the product of (i) the number of CombiChem FTEs allocated to the Research Program by the RMC for the calendar quarter to which each such payment applies, multiplied by (ii) U.S. *** (i.e., the quarterly amount per CombiChem FTE on the basis of U.S. *** per annum). *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 13 - 15 (b) Expansion or Contraction of Project Team. Notwithstanding Section 2.1(e) herein, either Party may request that CombiChem expand or contract its Project Team during the Research Period in order to properly regulate the work-flow on a Collaboration Target. In such event, the RMC shall promptly confer as to the appropriate number of FTEs to be added to the Project Team, at a cost to ICOS of U.S. *** per FTE as upwardly adjusted annually based upon cumulative changes in the CPI, using 1998 as the base year, to be paid as specified in Section 8.2(a) hereof and make a recommendation to such expansion or contraction of the Project Team which recommendation may be adopted by mutual written agreement of ICOS and CombiChem. 8.3 Milestone Payments. Within thirty (30) days of the occurrence of a development milestone triggered by the activities of ICOS or its Affiliates as shown on Appendix A attached hereto, ICOS shall pay CombiChem the related milestone payment in U.S. dollars as set forth on Appendix A attached hereto. Such payments shall apply to any milestone reached by an Active Compound, Development Compound or Product, for a Target within the Collaboration. 8.4 Royalties. During the Royalty Term, ICOS will pay CombiChem an earned royalty of (i) *** of Net Sales of Products sold by ICOS, its Affiliates or its sublicensees on the first *** of Net Sales made per calendar year in *** and (ii) *** on any Net Sales of Products sold by ICOS, its Affiliates or its sublicensees over *** made per calendar year in *** (iii) *** of Net Sales of Products sold by ICOS, its Affiliates or its sublicensees on the first *** of Net Sales made per calendar year *** and (iv) *** on any Net Sales of Products sold by ICOS, its Affiliates or its sublicensees over *** made per calendar year *** . Each payment of royalties shall be accompanied by a report of Net Sales of Products in sufficient detail to permit confirmation of the accuracy of the royalty payment made. (a) ICOS may reduce the percentage amount of earned royalties payable for a Product under this Agreement by *** the amount in excess of *** that ICOS decides, in its reasonable business judgment, to pay to third parties who are not Affiliates or sublicensees of ICOS (not including any royalties payable to CombiChem hereunder) in order to sell the Product to avoid or settle a patent infringement action relating to *** under a Collaboration Patent; provided however, that the royalties payable by ICOS to CombiChem for the sale of Product shall not be reduced to less than *** the amount that ICOS would otherwise be obligated to pay to CombiChem. (b) For any Product which is sold in combination with any other active ingredient which other ingredient is not royalty bearing hereunder (a "Combination Product"), Net Sales, for purposes of calculating royalties, as defined in this Section 8.4, on a Combination Product, shall be calculated by multiplying the net sales with respect to the Combination Product determined in the same manner as Net Sales for a Product by the fraction A/B where A is the gross selling price of the Product sold separately (i.e., without the other active ingredients) and B is the gross selling price of the Combination Product. In the event that no such separate sales *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 14 - 16 are made, net sales value shall be calculated by multiplying net sales of the Combination Product by the fraction C/(C + D), where C and D shall be negotiated by the Parties in good faith prior to such sales. (c) Earned royalty shall be paid in the manner provided herein on a country-by-country basis. 8.5 Manner and Place of Payment. Royalty payments and reports for Net Sales of Products shall be calculated in local currencies and reported for each calendar quarter. All royalty payments owed under this Agreement shall be made by wire transfer to the bank account to be designated by CombiChem within sixty (60) days following the end of each such calendar quarter. 8.6 Records and Audit. During the term of this Agreement and for a period of three (3) years thereafter, ICOS shall keep complete and accurate records pertaining to the sale or other disposition of Products in sufficient detail to permit CombiChem to confirm the accuracy of all payments due hereunder. CombiChem shall have the right to cause an independent certified public accounting firm reasonably acceptable to ICOS to audit such records to confirm ICOS's Net Sales for the preceding year. Any information obtained during such audit shall be treated as Confidential Information. Such audits may be exercised after reasonable notice during normal business hours of ICOS no more than once each year. CombiChem shall bear the full cost of such audit unless such audit discloses a deficiency of the greater of U.S. $100,000 or more than five percent (5%) from the amount of the Net Sales reported by ICOS for such audited period. In such case, ICOS shall bear the reasonable cost of such audit. 8.7 Taxes. All income and other taxes levied on account of the royalties and other payments accruing to CombiChem under this Agreement shall be paid by CombiChem, including taxes levied thereon as income to CombiChem. If provision is made in law or regulation for withholding, such tax shall be deducted from the royalty or other payment made by ICOS to the proper taxing authority and a receipt of payment of the tax secured and promptly delivered to CombiChem. Each Party agrees to assist the other Party reasonably in claiming exemption from such deductions or withholdings under any double taxation or similar agreement or treaty from time to time in force. 9. LICENSE GRANTS; SUBLICENSE 9.1 CombiChem License Grant to ICOS. In addition to ICOS's non-exclusive right to use CombiChem Technology as necessary to conduct activities under the Research Program as described in Section 2.2 hereof, subject to the terms and conditions of this Agreement, CombiChem hereby grants to ICOS an exclusive, royalty-free, worldwide license, with the right to sublicense to use such CombiChem Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory. Such license shall remain exclusive (including as to CombiChem) in relation to an Active Compound, Development Compound and/or Product so - 15 - 17 long as ICOS or its licensee continues to develop and commercialize such Active Compound, Development Compound and/or Product against a Collaboration Target with Due Diligence. 9.2 ICOS License Grant to CombiChem. Subject to Article 4 hereof and following the decision of ICOS or its licensee to not develop and commercialize with Due Diligence an Active Compound, a Development Compound or Product, as the case may be (collectively, "Returned Compounds"), ICOS shall grant to CombiChem a royalty-bearing license, with the right to sublicense, under those Collaboration Patents and know-how which are resulting from the Research Program and related exclusively to the Returned Compound, to make, have made, use, have used, sell, have sold, import and export such Returned Compound in the Territory. The royalty payments payable to ICOS for the license granted to CombiChem pursuant to this Section 9.2 shall be identical to the royalty payments provided for in Section 8.4 hereof (including the Royalty Term in Section 1.35 hereof) substituting CombiChem for ICOS and ICOS for CombiChem. No additional payments shall be due ICOS in consideration of the license grant under this Section 9.2. 9.3 ICOS Sublicense. ICOS shall have the right to transfer, assign or sublicense to a Third Party the Products or Collaboration Patents covering the Products, subject to CombiChem's right to receive all royalties and milestone payments as provided in Sections 8.4 and 8.5 hereof. All payments payable hereunder shall be made to CombiChem by wire transfer to such bank account designated by CombiChem within five (5) business days after receipt by ICOS or its Affiliates of such payments from a Third Party. As an express condition of any such sublicense, any such licensee shall be required to agree in writing (a) to be bound by due diligence, royalty reporting and recordkeeping and inspection provisions no less stringent than those contained in this Agreement and (b) to allow CombiChem to institute or join legal actions against any ICOS sublicensee who fails to satisfy any obligations provided pursuant to this Section 9.3. ICOS shall remain responsible to CombiChem for all milestone and royalty payments actually received by ICOS from its sublicensees. In addition, CombiChem shall have the right to receive all audit reports relating to sales of Products of ICOS's sublicensees, and to cause ICOS or its Affiliates or assigns to have an independent certified public accounting firm (reasonably acceptable to ICOS) audit such sublicensee's records on the same terms as those specified in Section 8.6 hereof. 9.4 Rights to Inactive Compounds. Each Party shall be free to screen Inactive Compounds against any target other than a Collaboration Target. In the event that either ICOS or CombiChem shall develop, market and/or sell, or enter into a binding agreement with a Third Party to develop, market and/or sell, any product containing the Inactive Compound as an active ingredient, then except to the extent that such Inactive Compound is subject of a valid claim in a Patent or Collaboration Patent giving rights to the Party, the other Party hereto shall not be entitled to any payments, milestones, royalties, fees or compensation of any kind. - 16 - 18 10. TERM AND TERMINATION OF THE AGREEMENT 10.1 Term. The term of this Agreement shall commence upon the Effective Date and unless earlier terminated as provided in this Agreement, shall expire at the end of the Research Period. 10.2 Termination by ICOS or CombiChem. If either Party materially breaches this Agreement and fails to remedy that breach within ninety (90) days of receiving written notice thereof from the other Party, or enters into any arrangement of compromise with its creditors or goes into liquidation, insolvency, bankruptcy, receivership or reorganization proceedings, whether voluntarily or compulsorily which is not dismissed by a court of competent jurisdiction within ninety (90) days, then the other Party may at any time, by notice in writing or by facsimile transmission, terminate this Agreement. Within ninety (90) days following termination for any Research Program and/or research related to any Target under this Agreement, the RMC shall prepare a detailed, final written report to each Party, and provide any remaining supply of compounds in synthesis to date, for each Target or Research Program being terminated. 10.3 Termination by ICOS. ICOS may terminate this Agreement effective at any time after one hundred eighty (180) days from the Effective Date, in its sole discretion, upon ninety (90) days' prior written notice. 10.4 Termination by CombiChem. CombiChem may terminate this Agreement effective at any time after one hundred eighty (180) days from the Effective Date, in its sole discretion, upon ninety (90) days' prior written notice. In the event that CombiChem elects to terminate under this Section 10.4, CombiChem shall not work on or provide services, or advice, either independently or with any Third Party on any Collaboration Target for a period of eighteen (18) months from the date that the termination is effective. No termination of this Agreement pursuant to this Section 10.4 shall extend the Target Exclusivity Obligations set forth in Section 4.1 hereof. 10.5 After Termination. Any termination of this Agreement or the Research Program shall be without prejudice to the accrued rights of either Party prior to the termination. In case of termination of this Agreement or the Research Program pursuant to Sections 10.2, 10.3 or 10.4 above, all royalty, milestone, payment and confidentiality obligations set forth in Sections 8.1, 8.4, 8.5, 9.3, 9.4 hereof and Articles 11 and 12 hereof shall survive any such termination. Moreover, ICOS shall not be entitled to any refund of any payments made to CombiChem hereunder upon the expiration of the term of this Agreement or earlier termination pursuant to this Article 10. 10.6 Effect of Termination on Licensees. In the event of any termination of this Agreement pursuant to this Article 10 where such termination shall not have been caused by the action or inaction on the part of any respective licensee of ICOS or CombiChem, or by any breach by such licensee of its obligations under its license from ICOS or CombiChem, as appropriate, such termination of this Agreement shall be without prejudice to the rights of each non-breaching licensee and such licensee shall be deemed to be a direct licensee hereunder. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 17 - 19 11. CONFIDENTIAL INFORMATION 11.1 Nondisclosure. During the term of this Agreement and for a period of *** years after termination or expiration thereof, each Party will maintain all Confidential Information in trust and confidence and will not disclose any Confidential Information to any third party or use any Confidential Information for any purpose except (i) as expressly authorized by this Agreement, (ii) as required by law or court order, after as much advance notice as is practical to the other Party, (iii) to its consultants, subcontractors or agents who need to know to accomplish the purposes of this Agreement and who are bound by equivalent written confidentiality obligations. Each Party may use the other Party's Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its Affiliates, employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information. 11.2 Exceptions. Confidential Information shall not include any information which the receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available; (b) is known by the receiving Party at the time of receiving such information, as evidenced by its written records; (c) is hereafter disclosed to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; (d) is independently developed by the receiving Party without the aid, application or use of Confidential Information; or (e) is the subject of a written permission to disclose provided by the disclosing Party. 12. PUBLICATIONS AND PUBLIC STATEMENTS 12.1 Publications. Without affecting obligations under Article 11 above, neither Party shall publish any information with respect to Collaboration Compounds or Development Compound during the Exclusivity Period without the prior written permission of the other Party. Such permission shall be approved or disapproved within thirty (30) days of written request for permission unless the other Party requests additional time (not to exceed ninety (90) days) for the purpose of protecting its intellectual property position. Such permission shall not be unreasonably withheld. The Party proposing to publish such information shall give the other Party ninety (90) days prior written notice and an opportunity to review such manuscript in order to determine the patentability of the information contained therein. 12.2 Public Statements. Neither Party shall use the name of the other Party in any public statement, prospectus, annual report or press release or other public communication (collectively "Public Statements") (except to the extent that use of the name is required for disclosure by the Securities and Exchange Commission or other governmental rules or regulations) without the prior written approval of the other Party, which may not be unreasonably withheld or delayed; provided, however, that both Parties shall endeavor in good faith to give the other Party a minimum of two (2) business days to review such Public Statements; provided, *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. - 18 - 20 further, that, upon approval of any such Public Statement, both Parties may disclose to Third Parties the information contained in such Public Statement without the further approval of the other; and provided, further, that if a Party does not approve such Public Statement, either Party may still use the name of the other Party in any Public Statement without the prior written approval of the other Party, if such Party is advised by counsel that such disclosure is required to comply with applicable law. 13. INDEMNIFICATION 13.1 EACH PARTY HEREBY AGREES TO SAVE, DEFEND AND HOLD THE OTHER PARTY AND ITS OFFICERS, DIRECTORS, EMPLOYEES, CONSULTANTS AND AGENTS HARMLESS FROM AND AGAINST ANY AND ALL SUITS, CLAIMS, ACTIONS, DEMANDS, LIABILITIES, EXPENSES AND LOSSES, INCLUDING REASONABLE LEGAL EXPENSES AND ATTORNEYS' FEES ("LOSSES") RESULTING DIRECTLY OR INDIRECTLY FROM THE INDEMNIFYING PARTY'S ACTS OR OMISSIONS IN CONNECTION WITH THE MANUFACTURE, DEVELOPMENT, USE, HANDLING, STORAGE, SALE OR OTHER DISPOSITION OF CHEMICAL AGENTS, COLLABORATION COMPOUNDS, ACTIVE COMPOUNDS, DEVELOPMENT COMPOUNDS OR PRODUCTS BY SUCH PARTY, ITS AFFILIATES OR LICENSEES except to the extent such Losses result from the negligence (whether active, passive or imputed), breach of this Agreement or willful misconduct of the Party claiming a right of indemnification under this Article 13. 13.2 Infringement (a) Subject to Section 13.2(c) below, ICOS shall hold CombiChem and its officers, directors, employees, consultants, and agents harmless from and against any and all losses resulting from the infringement of any Third Party's Patent issued as of the Effective Date due to the performance by ICOS or its Affiliates of any activity contemplated hereunder, including, but not necessarily limited to, ICOS's responsibilities under Section 2.2 above, developing Products, and selling Products. (b) Subject to Section 13.2(c) below, CombiChem shall hold ICOS and its officers, directors, employees, consultants, and agents harmless from and against any and all losses resulting from the infringement of any Third Party's Patent issued as of the Effective Date due to the performance by CombiChem of any activity contemplated hereunder, including, but not necessarily limited to, CombiChem's responsibilities under Section 2.1 above. (c) The indemnity provided in Sections 13.2(a) and 13.2(b) above shall not apply where the loss is due to the breach by the indemnified Party of a warranty made in Article 19. 13.3 Procedures. If either Party (the "Indemnified Party") seeks indemnification under this Article 13, it shall inform the other Party (the "Indemnifying Party") of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle any claim - 19 - 21 brought against the Indemnified Party upon prior written consent, which shall not be unreasonably withheld), and shall give reasonable cooperation (at the expense of the Indemnifying Party) in the defense of such claim. 14. ASSIGNABILITY This Agreement may not be assigned by either Party without the prior written consent of the other Party, not to be unreasonably withheld; provided, however, that either Party may assign this Agreement, in whole or in part, to an Affiliate or to a successor of a Party in connection with the merger, consolidation or sale of all or substantially all of such Party's assets or that portion of its business pertaining to the subject matter of this Agreement (and upon doing so will promptly notify the other Party in writing); provided that the assigning Party remains fully liable as obligated hereunder. 15. DISPUTE RESOLUTION PROCEDURES 15.1 Senior Executives Discussions. If a decision on a matter regarding the management of the Research Program as provided herein is not reached by the RMC, the dispute will be resolved as set forth in Article 6 above. If a dispute arises between CombiChem and ICOS with respect to matters other than the management of the Research Program, either during or after the Research Period, such dispute will be referred to the appropriate senior management in the area of the dispute. If such senior management are unable to resolve such dispute, such dispute will be referred to the Chief Executive Officer of ICOS and the Chief Executive Officer of CombiChem. If such officers are unable to reach an agreement within thirty (30) days following the initiation of discussions between them, such dispute shall be submitted to mediation and if there is no settlement of the dispute within sixty (60) days following the commencement of such mediation process, such dispute may, at the Party's mutual written agreement, be settled by arbitration as described in Section 15.2 below. 15.2 Binding Arbitration. If the Parties have not been able to resolve the dispute as provided in Section 15.1 above and the Parties mutually agree in writing, the dispute shall be finally settled by binding arbitration. Any arbitration hereunder shall be conducted under rules of the American Arbitration Association. The arbitration shall be conducted before three arbitrators chosen according to the following procedure: each of the parties shall appoint one arbitrator and the two so nominated shall choose the third. If the arbitrators chosen by the parties cannot agree on the choice of the third arbitrator within a period of thirty (30) days after their appointment, then the third arbitrator shall be appointed by the Court of Arbitration of the American Arbitration Association. If CombiChem brings an arbitration action, such arbitration shall occur in Seattle, Washington. If ICOS brings an arbitration action, such arbitration shall occur in San Diego, California. The arbitrators shall have the authority to grant specific performance, and to allocate between the parties the costs of arbitration in such equitable manner as they determine. The arbitral award (i) shall be final and binding upon the parties; and (ii) may be entered in any court of competent jurisdiction. - 20 - 22 15.3 Injunctive and Other Relief. Nothing contained in this Article 15 or any other provisions of this Agreement shall be construed to limit or preclude a Party from bringing any action in any court of competent jurisdiction for injunctive or other provisional relief to compel the other Party to comply with its obligations hereunder before or during the pendency of arbitration proceedings. In the event that the Parties do not mutually agree to enter binding arbitration as provided in Section 15.2 hereof, the Parties may pursue all available legal remedies. 16. NOTICES Any notice required or permitted to be given hereunder shall be deemed sufficient if sent by facsimile letter or overnight courier, or delivered by hand to ICOS or CombiChem at the respective addresses and facsimile numbers as set forth below or at such other address and facsimile number as either Party hereto may designate. If sent by facsimile letter, notice shall be deemed given when the transmission is completed if the sender has a confirmed transmission report. If a confirmed transmission report does not exist, then the notice will be deemed given when the notice is actually received by the person to whom it is sent. If delivered by overnight courier, notice shall be deemed given when it has been signed for. If delivered by hand, notice shall be deemed given when received. if to CombiChem, to: CombiChem, Inc. 9050 Camino Santa Fe San Diego, California 92121 Attention: President Fax number: (619) 530-9998 with a copy to: Brobeck, Phleger & Harrison LLP 550 West C Street, Suite 1200 San Diego, California 92101 Attention: Faye H. Russell, Esq. Fax number: (619) 234-1966 - 21 - 23 if to ICOS to: ICOS Corporation 22021 20th Avenue, S.E. Bothell, Washington 98021 Attention: Legal Department Fax number: (425) 489-0356 17. SURVIVAL The provisions of Sections 2.4, 5.1, 5.2, 5.3, 10.5, 10.6 and Articles 4, 8, 9, 11, 12, 13, 15, and this Article 17 shall survive termination of this Agreement in addition to those provisions which by their terms survive. 18. ADDITIONAL TERMS 18.1 Entire Agreement. This Agreement constitutes the entire understanding between the Parties with respect to the subject matter hereto and supersedes and replaces all previous negotiations, understandings, representations, writings and contract provisions and rights relating hereof. 18.2 Amendment; No Waiver. No provision of this Agreement may be amended, revoked or waived except by a writing signed and delivered by an authorized officer of each Party. Any waiver on the part of either Party of any breach or any fight or interest hereunder shall not imply the waiver of any subsequent breach or waiver of any other right or interest. 18.3 Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, each of which shall remain in full force and effect. 18.4 Headings. The descriptive headings are inserted for convenience of reference only and are not intended to be part of or to affect the meaning of or interpretation of this Agreement. 18.5 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument. 18.6 Further Assurances. At any time and from time to time after the Effective Date, the Parties shall each do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, transfers, conveyances, or assignments as may be reasonably required to carry out the transactions contemplated by this Agreement. 19. REPRESENTATIONS AND WARRANTIES 19.1 Authorization. All action on the part of each of CombiChem, ICOS and their respective officers, and directors necessary for the authorization, execution and delivery of this - 22 - 24 Agreement and the performance of all obligations of CombiChem, ICOS and ICOS, respectively, hereunder has been taken. 19.2 Rights to Intellectual Property. Each Party warrants that it has the power to grant all of the rights granted and make such required assignments, and to assume all of the obligations required, under this Agreement. Under no circumstances does CombiChem warrant to ICOS that its rights in any Active Compound, Development Compound or Products are exclusive to the extent such Active Compound, Development Compound or Products may be covered under the patent claims of Third Parties wherein such claims are not the direct result of a collaboration between the Third Party and CombiChem. [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] - 23 - 25 IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the Effective Date. COMBICHEM, INC. ICOS CORPORATION By: /s/ Illegible By: /s/ Illegible ---------------------------- -------------------------------- Its: Illegible Its: Illegible --------------------------- ------------------------------- [SIGNATURE PAGE TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT] - 24 - 26 Appendix A Milestones and Payments(1) (in U.S. Dollars) Milestone Milestone Payment(2) - --------- -------------------- *** *** Total *** (1) Paid in U.S. Dollars *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Appendix A-1 27 Appendix B Targets ------- Initial Target: *** Alternative Targets: *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Appendix B-1 EX-23.2 4 EXHIBIT 23.2 1 EXHIBIT 23.2 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS We consent to the reference to our firm under the captions "Selected Financial Data" and "Experts" and to the use of our report dated January 13, 1998, except for Note 10, as to which the date is March 31, 1998, in Amendment No. 9 to the Registration Statement (Form S-1) and related Prospectus of CombiChem, Inc. for the registration of its common stock. San Diego, California /s/ Ernst & Young LLP May 5, 1998 -----END PRIVACY-ENHANCED MESSAGE-----